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ABSTRACT 
 
 
The Cost of Dying on Medicare:  
 
An Analysis of Expenditure Data. (August 2005) 
 
Donald Reed House, Jr., B.S., Texas A&M University 
 
Chair of Advisory Committee: Dr. Thomas Saving 
 
 
 Roughly one third of Medicare expenditures are made on behalf of beneficiaries in 
their terminal year, though only five percent of the Medicare-covered population dies 
annually.  Per-capita spending on decedents is as much as six times the level of spending 
on survivors.  The demographic, technological and political trends that will determine the 
future path of spending on terminal-year beneficiaries have important implications for the 
fiscal well-being of the Medicare program, and by extension, the American taxpayer.  
Coming to an understanding of the moving parts that will control the path of the cost of 
dying on Medicare is vital for careful consideration of Medicare’s future, and for any 
discussions about further reform of the program. Analysis of expenditures in the terminal 
year must be made while keeping in mind the fact that major expenditures are often made 
in surviving years.  The spike in spending in the terminal period rightly focuses attention to 
expenditures near death, but also we should proceed in its analysis keeping in mind that it 
is not the only spell of elevated medical spending for a typical individual. Given those 
cautions, however, the cost of dying on Medicare stands as an important area of economic 
inquiry and policy consideration.  As total Medicare expenditures top a quarter trillion 
dollars, the third of that spending which covers treatments in beneficiaries’ terminal years 
ought to be understood more fully than it is currently. 
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CHAPTER I 
 
 
INTRODUCTION 
 
Roughly one third of annual Medicare expenditures are made on behalf of 
beneficiaries in their terminal year, though only five percent of the Medicare-covered 
population dies annually. Per-capita spending on decedents is as much as six times the level 
of spending on survivors. The demographic, technological and political trends that 
determine the path of spending on terminal-year beneficiaries have important implications 
for the fiscal well-being of the Medicare program and, by extension, the American taxpayer. 
Understanding the parts that will control the path of the costs of dying on Medicare is vital 
for careful consideration of Medicare’s future, and for any discussions on further reform of 
the program.
Because Medicare covers recipients through death, the program can expect to make 
expenditures for every enrollee related to his or her death. Given current life expectancies, 
92% of all American decedents who die after the age of 65 have some of their death related 
expenditures covered by the program. Expenditures for beneficiaries in their terminal year 
stand out as a subject for investigation in part, because there is almost always a significant 
increase in expenditure at that time. If one averages the expenditure paths of a death-cohort 
together and examines the mean profile, the sole period of significantly elevated spending 
occurs at or near death. Death is related to high levels of spending for a death-cohort for the 
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simple reason that it is the only event where the spending of the entire cohort “stacks.” All 
other major events in representative individuals’ medical histories are distributed prior to 
death, and thus average out, losing salience. An unknown, but no doubt significant, portion 
of intensive medical procedures are done with the expectation that the person will survive 
and recover. Analysis of expenditures in the terminal year must be made while keeping in 
mind that major expenditures are often made in surviving years. The spike in spending in the 
terminal period rightly focuses attention to expenditures near death, but we should proceed 
in analysis keeping in mind that is not the only spike in typical spending. 
Concerns over the cost of dying on Medicare and the quality of end of life care those 
expenditures secure is not new. Probably the most familiar effort to control costs for 
beneficiaries in their terminal year was the provision in the Tax Equity and Fiscal 
Responsibility Act of 1982 for a Medicare hospice benefit. The program was intended to 
reduce Medicare costs by providing a means for elderly individuals with terminal illnesses 
to spend their final days receiving palliative care in a lower-cost hospice facility or at home 
with the aid of home-health personnel. A further discussion of the hospice benefit will come 
later, but it serves as an illustration of the level of attention drawn by terminal period 
medical costs.  
One aspect of terminal year spending that has conceptual bearing on the economics 
of terminal period benefits is considering the counterfactual to all but palliative efforts. If 
one pauses to consider the “but for” scenario if the expenditures were withheld, the outcome 
would not be expected to be much different. There is a sense in which expenditures around 
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the time of death that are not purely palliative in nature are wasted, at least ex post, as they 
obviously failed to extend the life of the beneficiary. This impression fails to consider the 
uncertainty under which medical care for the elderly is provided. Many of the procedures 
which necessitate Medicare expenditures are provided in an attempt to extend life, as 
standard treatments for morbidities not distinctly related to death. Most people who receive 
expensive care survive (W.A. Knaus, et al.. 1993).  It is a different matter to discuss the 
cost-effectiveness of extending life than it is to address expenditures in the terminal year, 
and policy makers must tread carefully around these matters.  However, there is evidence 
that Medicare expenditures on end of life care are not being spent in a manner that 
maximizes beneficiaries’ quality of life near death. This paper will address some of that 
evidence and the history of those concerns. 
The cost of dying on Medicare is an important area of economic inquiry and policy 
consideration. As total Medicare expenditures top a quarter trillion dollars, the third of that 
which covers treatments in beneficiaries’ terminal years should be understood more fully. 
One must consider the intensive dimensions of Medicare usage in the terminal year, 
controlled by medical standards, technological advances, increases in health and longevity, 
and reimbursement policy as well as the extensive dimensions driven primarily by 
demographic and generational population changes. Demographic changes will steer the 
solvency of the program but a better handle is needed on the individual experience. This 
work will focus on the health drivers of terminal period expenditures at the individual level. 
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Health and death are necessarily related, and an analysis of death which ignores health 
would be severely limited in its application.
At the level of an individual’s experience on Medicare, several factors contribute to 
shaping the path of their expenditures. A beneficiary’s initial health on entering the program 
and their health habits while on the program will have enormous consequences for their 
expected Medicare expenditures. Expenditure paths can reasonably be expected to be 
sensitive to medical technological advances. As technology advances, the standards of care 
for specific health conditions change. The ability of medical science to allow the elderly to 
survive into more advanced ages impacts the bottom line of the Medicare program in a 
number of dimensions, both positively and negatively. A key determinate of the cost of the 
terminal year of a given beneficiary to Medicare is their age at death. Older people die less 
expensively, but there are maintenance costs associated with getting a beneficiary to an 
advanced age. The net effect on expenditure paths is ambiguous. For example, if many more 
beneficiaries survived into extreme old age death-related expenses would be dramatically 
reduced as a matter of economic interest. The expenditures related to getting that number of 
beneficiaries to advanced ages would no doubt attract our attention, however. As medical 
science pushes forward and people survive to older ages, the consequences for Medicare 
could be significant.  
The dimensions of a typical individual’s experience on Medicare that are primarily 
concerned to this present work are as follows: 
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• Health at age 
• Probability of disease onset at age 
• Standard of care at age of disease 
• Effectiveness of care toward improving health and extending longevity 
• Impact of health on expenditures 
• Impact of longevity on expenditures 
• “Death experience” 
• Impact of alternatives in palliative care on death related expenditures 
• Impact of care on quality of life 
 
Outline 
 The remainder of the current chapter will cover many relevant features of the 
Medicare program and give an overview of several of the analytical issues investigated in 
this work.
 The second chapter will provide a discussion of the relevant literature. Medicare is 
politically significant and an economic issue in this country and as such has already attracted 
a huge amount of analysis. As medical, economic and political situations have changed, 
different concerns take priority in emphasis, but there seems to be no single dimension of the 
program or its future not addressed somewhere. As economic and econometric science has 
advanced, our ability to glean important relationships in the path of Medicare spending has 
increased. The second chapter will attempt to establish the foundation in the literature on 
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which the current analysis builds. 
 Chapter III will present the data used to estimate the empirical models to be 
discussed in the fourth chapter. It is customary to precede a discussion of the data with an 
outline of the models, but a reverse order is more appealing in this case. The structure of the 
models (and the contribution of this work) is, to a great degree, controlled by the data used. 
Because the data is the star, it gets higher billing.  
 As mentioned, Chapter IV will contain the empirical models estimated using the data 
discussed in Chapter III. There are three areas of focus on which the models will seek to 
provide insight. They are the persistence of Medicare reimbursed expenditures and terminal 
period expenditures by specific disease under the ICD-9 disease categorization; the impact 
of utilizing quarterly versus annual data in estimating expenditure persistence; and the 
relationship between total spending and disease-specific expenditures across disease 
categories. The results of the models for each disease will be presented and briefly 
discussed.  
 The fifth chapter will present a consideration of further steps for the research and the 
challenges they present. 
 
Issues for Analysis 
 The specific study of the composition of death-related expenditures made by 
Medicare on the behalf of individuals for medical services has been fairly limited in the past 
few years. There was a significant level of interest around the time of the institution of 
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hospice benefits in 1983, but the focus has moved away from specifically death-related 
expenditures. As befits analysis that is concerned with the overall viability of the program, 
most recent work that includes death-related expenditures have as their focus the entire 
expenditure profile, if not simply the expected total lifetime expenditures, e. g. James D. 
Lubitz, et al.. (2003).  From a policy standpoint, it is the total “bill” the government can 
expect to receive that is the primary issue. One limitation of studies directed at lifetime 
expenditures is that they cannot directly incorporate the impact on expenditures from 
changes in the standards of care for people at various stages of their lives and in specific 
health circumstances. Strengthening that aspect of analysis, and focusing specifically on the 
most expensive period of a beneficiaries’ career on Medicare is an important goal which this 
work seeks to further explore. The data available to utilize the investigational approach 
pursued in this work is limited in time, so the primary goal of this research is to investigate 
and establish the existent relationships between Medicare beneficiaries’ medical 
expenditures during the period proceeding their terminal quarter and the expenditures 
related to their death. The first step in developing policies that could contribute to control the 
cost of dying on Medicare is to establish a way of predicting those costs under the current 
policy. The question investigated in this work is: To what degree and under what 
circumstances can Medicare-reimbursed death related expenditures be predicted by a 
beneficiary’s medical experiences while enrolled in the program?  
 To answer this question, a series of econometric models of varying and generally 
increasing econometric complexity will be estimated. One goal of the modeling strategy is 
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to discover the most efficient level at which to model Medicare expenditures to predict 
death-related expenditures. The models will be estimated using individual data that cover an 
eight year span of Medicare reimbursement histories, which include specific diagnoses, 
treatments and levels of expenditure. 
One weakness of the data used compared to other studies is that little is known about 
the individuals other than their medical histories. The self-reported health and ADL and 
IADL disability levels which make up a large part of the information in related studies are 
not available here. Their absence constrains the questions that can directly address, but do 
not limit the achievement of the goal of this work. One consequence in lacking such 
information is the difficulty it causes in linking this investigation with others that have made 
use of them. Lubitz, et al.. (2003), for example, exclusively used disability scores as the 
measure of health state in predicting total Medicare expenditures. With no bridge between 
that study and this one, it is difficult to single out the cause of disparities in predictions. 
 
Background 
To die of old age is a death rare, extraordinary, and singular and so much 
less natural than others. It is the last and extremist kind of dying ... a 
privilege rarely seen. - Montaigne, 1575 
 Death from old age is entirely different in nature and frequency now than it was in 
the 16th century. Even since the beginning of the last century, life expectancy has gone from 
50 years to over 75. The death rate in 1900 was around 1720 per 100,000 population. It was 
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half that in 1990. Adjusting for age, the death rate has fallen by 63% in the past fifty years. 
The typical American can now expect to live a long life and die at an advanced age, 
historically speaking.
 The radical changes in life expectancy have, to a large degree, come from medical 
advances against communicable diseases. In 1900, respiratory, infectious, parasitic, and 
gastrointestinal diseases and disorders accounted for about 40% of all deaths in the US. 
Today the number is much lower. For example, tuberculosis caused 11% of all deaths a 
century ago. Today it represents a fraction of a percent. With fewer deaths from 
communicable diseases, disorders associated with old age have become more common as 
causes of death. Heart disease now kills more than three times the rate it did 100 years ago.  
The implication of medical successes against the killers of prior history is that people are 
now living to an advanced age. A woman surviving until age 75 can expect almost twelve 
more years of life, while a man in the same circumstance is expected to live almost ten 
additional years.  The typical decedent, then, is far older than has historically been common. 
The change in life expectancy has also changed the nature of death. Today, the typical 
decedent is quite elderly and death frequently comes when they succumb to a chronic illness 
which they battled for some period prior to death.
 The changing nature of death is also evident when one considers where people die. 
Less than 50 percent of deaths (49.6%) occurred in hospitals or institutions in 1949.  U.S. 
mortality statistics for 1992 indicate that the proportion of people who pass away in 
hospitals or institutions had risen to 74 percent. The increased rate of death in hospitals as 
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opposed to death at home reflects the changed nature of death in recent history. In addition, 
many more people experience disability prior to death. Death comes later and slower than it 
used to.  
 A large part of the costs of the typical later, slower deaths in America are borne by 
the Medicare program. Over 60 percent of all costs of enrolled decedents in their final year 
are covered by Medicare. A significant portion of Medicare-enrolled decedents are also 
covered by Medicaid; especially those decedents who spend their final days in a nursing 
home or other institution.  Medicare enrollees who die in the hospital incur roughly twice the 
costs of those who die at home, and death in a hospital setting is much more typical than in 
the recent past. Table 1-1 from Marilyn J. Field and Christine K. Cassel (1997) makes clear  
TABLE 1.1- A CENTURY OF CHANGE   
A Century of Change   
 
  
1900 
  
2000   
Life Expectancy 
  
47 years 
  
75 years   
Usual place of death 
  
home 
  
hospital   
Most medical expenses 
  
paid by family 
  
paid by Medicare   
Disability before death 
  
usually not much 
  
2 years on average   
Source: Field and Cassel, eds  Approaching Death: Improving Care at the End of Life, 
IOM (1997) 
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the triumph of modern medicine over many forms of disease has vastly improved the active 
life expectancy of Americans. In doing so, it has changed the nature of death experienced by 
the average American.  
 Many in the medical community are concerned that the American medical society in 
general and the Medicare program in specific have adopted attitudes and polices which harm 
the quality of life people experience near death. It is argued that we as a society have been 
so intent on saving and extending life that we are ill equipped to provide care and support to 
those people nearing death. Daniel Callahan decried the unwillingness to let nature take its 
course resulting in a needlessly cruel and entirely impersonal death “in a technologic 
cocoon.” A study of medical professionals indicated that at least half feel they have at some 
time delivered burdensome and useless medical procedures against their own conscience 
(M.Z. Solomon et al., 1993). The RAND corporation issued a white paper in 2003 entitled 
Living Well at the End of Life: Adapting Heath Care to Serious Chronic Illness in Old Age. 
In it, authors Joanne Lynn and David Adamson are highly critical of the medical 
communities approach to the dying.  
 Chronically ill elderly people and families living through the end of life of a 
family member deserve a better system than the one currently available. They 
depend on the health care system to serve their needs and certainly not to add to the 
burden of their or a loved one’s final days.
 The Medicare program has a hard time with terminally ill Americans. Despite the 
provision in 1983 (eighteen years after the program began) of hospice benefits under 
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Medicare, the program is still seen as inadequately handling beneficiaries near the end of 
their lives. In a report from the Medicare Payment Advisory Commission produced in 1998,  
There is widespread agreement that the quality of care provided at the end 
of life is poor. Many studies have found that people do not get the care they 
want and that many suffer from high levels of pain due to miscommunication. 
Studies also suggest that current payment policies fail to provide adequate 
incentives for the provision of palliative care. 
 The hospice benefit was intended to both care for the dying and hopefully 
limit death-related expenditures. In 1982, Senator Dole and Congressman Pannetta 
led a bipartisan effort to pass the Medicare Hospice Benefit. That was the 
culmination of burgeoning interests in developing alternatives to what was seen as 
the inhuman fate of the critically ill and elderly in modern acute care hospitals. 
Leaders in the Hospice movement in America drew inspiration from Dame Cicely 
Saunders in England who founded St. Christopher’s Hospice in 1964, the first in the 
modern era. As the Medicare Hospice Benefit has been instituted, beneficiaries are 
eligible to enroll in a Hospice program when, in the judgment of their physician, they 
can expect death within the next six months. Enrollees who survive that time period 
must be recertified at regular intervals by their physician. By enrolling in a Hospice 
program, Medicare beneficiaries waive their access to other Medicare services.  
 Because of the structure of Hospice regulation, the program has attracted a 
subset of the dying population because of its characteristics.  Hospice patients are 
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typically characterized as cancer patients given fewer than six months to live by their 
physicians, and in need of substantial ameliorative services while beyond the reach 
of life-saving measures. 
 Ordinarily, the failure to provide quality end-of-life care is blamed on the 
necessary orientation of the medical community for aggressively attacking acute 
illness with the intention to cure it. Most physicians are not trained to accept the 
coming of death, but fight it with all the means at their disposal. A related problem 
which surfaces in assigning critically ill patients to Hospice is the high level of 
uncertainty under which care is provided for chronic illnesses. This will be addressed 
in greater detail in the next chapter, but it is reasonable to assume that it is very 
difficult for doctors or patients to sign away their access to curative care if there is 
any hope remaining for extending the life of the patient.  
 Despite these concerns, Hospice has been reasonably successful at 
controlling costs for those critically ill persons who enroll in it. Estimates in some 
studies suggest that every dollar spent on the Hospice program can save up to $1.52 
in Part A and Part B benefits. This and similar estimates will be addressed in the next 
chapter.
 One remaining concern about the Hospice benefit and a general criticism of 
the medical system that can lead to poor end of life care is the discontinuity in 
services provided by having to formally enroll in a Hospice program to receive 
palliative care. Medicare hospice structure and other cost control measures that are 
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part of Medicare regulation are seen as impediments to quality end of life care 
because they cause care to be provided in manners contrary to the medical and 
personal realities at hand. The administrative requirements of the Medicare program 
often require choices to be made about the care a terminally ill patient receives at 
times and in conditions which are non-optimal. Patients often must remain in acute 
care hospitals and often receive invasive procedures which degrade quality of life 
with a low probability of extending longevity. One alternative can be to “give up” 
and enroll in Hospice and forgo further curative treatments.  
 The first step in matching treatments to patterns of disease and demise is to 
understand those patterns in the diseases and disorders which most significantly 
affect Medicare beneficiaries. Present work represents an effort to understand the 
trajectories of death inherent in modern “killer diseases” and econometrically model 
the path of those expenditures.  
 
Technical Points 
 It will be useful as this work continues to understand how Medicare pays for claims, 
no matter what type of care. Allowables are set specifically according to type of product or 
service and are categorized by acute or long-term care, by outpatient or inpatient services, 
but there is a general formula that is used as the basis for all types of services. In the typical 
Fee-For-Service (FFS) program which most Medicare beneficiaries use, providers’ 
reimbursement or payment from Medicare are based on predetermined rates and are not 
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affected by the provider’s costs or posted fee schedule. These providers have agreed to 
accept as payment in full, minus the patient’s cost sharing liability, the determined payment 
amounts that Medicare has set. Medicare policy makers determine these amounts by 
researching national base payment rates or conversion factors based on national average 
historical costs. There is an adjustment formula to reflect regional price levels, normally 
based on the local hospital wage index. Other adjustments can be factored in for unusual 
patient characteristics, unusual treatment, atypical market areas, or because policymakers 
wish to encourage certain activities, such as the need for medical professionals in a rural 
community.  
 Many technical aspects of the Medicare program and the history of its analysis 
intrude on the discussion of the cost of dying on Medicare. Some will be directly addressed, 
but others need to be acknowledged and answered. For example, the total unfunded liability 
of the Medicare program is forecasted to be $23.3 trillion, while the addition of Medicare 
Part D has raised the unfunded liability by an additional estimated $16.6 trillion. If the plan 
continues unchanged into the future and future generations participate in the program on the 
same terms as current generations, the total Medicare debt rises to $61.6 trillion.  It is 
beyond the scope of this work to remain sufficiently general such that certain measurement 
problems are resolved without notice. 
 First among the challenges of analyzing medical care over time is the measure of 
price, and to separate that from quantity. Those forces which influence the prices paid by 
Medicare for the various standard procedures directly influence Medicare expenditures. 
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Work by Joseph Newhouse (2001) has made clear that we have a poor handle on real price 
and quantity changes within medicine. The Medicare program controls the prices they pay 
for medical services, supplies, and equipment through a complicated process of base price 
ceilings with geographic adjustments along with erratic yearly percentage adjustments 
across expenditure categories. While it is beyond the scope of this work to tackle the 
problems inherent in medical price adjustments, it is necessary to keep them in mind as the 
analysis proceeds. Changes in reimbursement levels or reimbursement formulas can be 
expected to have significant effects, obviously on per-unit expenditures, but also on 
utilization levels. A rapid increase in the level of utilization of specific benefits could either 
reflect the evolution of best medical practices, or a change in the reimbursement formula that 
encourages the marketing and distribution of a product covered. One can currently see many 
advertisements on television for powered wheelchairs and scooters, and respiratory 
equipment and supplies covered by Medicare. Such publicity can be expected to increase the 
use of the products advertised independent of standards of care or best practices in the 
medical establishment.   
 
Conclusion 
 The work outlined thus far represents an effort to address some key elements of the 
experience of beneficiaries of the Medicare program and the impact of their health problems 
on Medicare finances. The data used to address the questions is vast and a bit unwieldy. The 
potential for insight into the relationships between health and expenditures that will shape 
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the future of Medicare is hard to overstate. The present work is intended as a first cut to 
consolidate some facts, develop insights into some basic relationships, reveal similarities 
and differences among diseases that may have bearing on financing decisions, and to 
highlight anomalous or interesting elements in the data. The results generated at this stage 
are in the main descriptive and risk becoming quite tedious. The work serves primarily to 
inform and motivate more targeted work within specific diseases or disease categories. By 
developing and implementing a standard template through which to assess the relationship 
between diseases and expenditures over time, the work has the potential to reveal as much 
when it works well at getting at the relationships as when it does not. The structure of the 
approach is useful, not because it perfectly defines or identifies at the distinct features of 
each disease (it does not), but because it processes an immense problem and an equally 
immense data resource and reveals many areas ripe for a closer look.  The promise of the 
present project is in what it makes possible more than in what is accomplished in the 
following pages. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
End-of-life medical care for Medicare beneficiaries has long been an area recognized 
as ripe for re-evaluation and reform.  There is a sense that significant waste and unnecessary 
suffering are hallmarks of the dying process caused in part by the regulations and economic 
incentives built into the Medicare program.  The Medicare program seems to have been 
designed to care for seniors with acute illnesses, and has significant trouble addressing 
chronic and/or terminal conditions through its standard reimbursement formula.  The 
institution of the Hospice benefit in 1982 was aimed at addressing this difficulty, but there is 
evidence the Hospice benefit is doing a poor job addressing the situation.  The challenges 
that Medicare faces in funding high quality end-of-life care for beneficiaries has generated 
a significant level of scholarly interest and discussion.  The following chapter presents a 
survey of the literature(s) which provide a foundation for the present work. 
A discussion and organization of the literature relevant to the cost of dying on 
Medicare has to contend with the fact that the subject is the confluence of several branches 
of literature that have developed in various fields of inquiry and with widely varying 
emphases.  The foundational question of this study of the determinates of terminal period 
Medicare expenditures, and the focus of the following review will remain on those issues 
addressed in the literature which have the most significant bearing on the question.  It is very 
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difficult, however, not to go somewhat a field if an interpretable picture is to be presented.  
The cost of dying on Medicare depends on the costs associated with the services determined 
to be necessary to care for individuals with often significant health challenges.  Decisions 
over the target quality of care and the evolution of effective treatments are central to the 
level of expenditures generated during the terminal period. As such, the literature which 
addresses standards of care and treatment is directly related to the question herein 
approached. The following literature review is intended to discuss and organize the relevant 
literature to a degree which facilitates a deeper understanding of the forces at work which 
impact the cost of dying on Medicare, and at the same time avoid excessive entanglement in 
the real and important questions which remain imperfectly answered in each branch of the 
literature. Given that the intent of the review that follows is to walk a fine line between 
insights into pertinent issues and overwhelming confusion from the many directions the 
review must take to accomplish its goal, it will become a bit wobbly in places.  The findings 
in the literature are organized by topic, and the relevance to the present question addressed 
within each topic. 
 
Disease Specific Studies 
 
To understand what death on Medicare means, one must understand the patterns of 
demise that lead to a death for which Medicare is financially responsible. As technologies in 
medicine advance, the way in which we die and from which ailments we die have changed. 
 One attempt of outlining the patterns of demise is RAND’s White Paper. In it the authors 
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outlined three patterns of functional decline differentiated by the diseases from which 
people ultimately die. The first of the three patterns is a short period of evident decline, 
typical of most types of cancer. This pattern shows an ability to be comfortable for most of 
the duration of the illness and then as the disease worsens, the pattern shows a rapid decline. 
 This is the pattern for which Hospice as we know it is most commonly used and where it 
seems most appropriate. This first pattern is how one-fifth of Medicare claims are 
categorized. 
The second pattern, which represents 20% of the Medicare claims, is described as 
one that shows “long-term limitations” that include “intermittent exacerbations and sudden 
dying.”  These circumstances are typical of organ system failure.  Patients seen following 
this pattern live relatively longer with their ailment, and are only moderately limited by the 
disease.  If the disease is managed well, a patient can live comfortably for an extended 
period and only dies, somewhat suddenly, after a series of complications from which the 
body could no longer rebound.   
The third is a pattern of prolonged dwindling, typical of dementia or Alzheimer’s 
disease, a disabling stroke, or general frailty.  This pattern makes up 40% of Medicare 
claims. The last 20% of Medicare deaths are categorized as completely unexpected and 
sudden deaths or are simply not yet able to be categorized. 
To further breakdown our question, Mark C. McClellan, et al. (2000) took specific 
disease codes and looked specifically at expenditures at those times, focusing on home 
health and use of Hospice services.  McClellan uses four types of illnesses to see how a death 
  
21
 
by this disease is foreseen and managed. The first disease is an AMI or acute myocardial 
infarction, more commonly known as a heart attack. Heart attacks are usually quite 
unexpected and do not allow much time to plan for palliative care.  It is no surprise that AMI 
sufferers are not typical Hospice care users and are not likely to die at home with Hospice 
care.  The second ailment McClellan uses is the hemorrhagic stroke.  This is again an acute 
ailment that leaves little time for proactive measures in palliative care.  The place of death 
and circumstance of care statistics for the stroke victims are very similar to those if the AMI 
sufferers.   
In contrast, the third disease pattern is for lung cancer.  Lung cancer is often used as 
the prototypical terminal illness.  Prognoses are more accurate, and there is often at least 3 to 
6 months of time to offer palliative care. The time of death is therefore more predictable, and 
lung cancer patients are very common users of Hospice care.  Lung cancer deaths in a 
hospital have come down from 52% to 36% in the last fifteen years.  In 1988, 2 % of lung 
cancer deaths occurred at home with Hospice care, whereas in 1995 that number was up to 
30%.  The last disease McClellan used for his research was COPD or chronic obstructive 
pulmonary disease.  This is a type of chronic respiratory illness such as serious asthma, 
bronchitis, and emphysema.  It is also a good example of long term chronic and terminal 
disease like ling cancer, but one that is substantially less painful and more easily managed. 
With the use of certain durable medical goods and regular doctor visits, a COPD patient is 
able to maintain relative comfort without feeling the need for serious intervention like 
Hospice, unlike cancer sufferers.  From 1988 to 1995, COPD deaths in hospitals hovered 
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consistently just above 35%.  COPD patients reached out to Hospice care at 1% in 1988 and 
that number rose to only 10% in 1995.   
Looking at the issue from another prospective, Jay Bhattacharya, et al. (1996) looks 
to demographic group and specific disease expenditure patterns to estimate life expectancy 
curves.  The Bhattacharya paper further gleans meaning from the Medicare claims files as a 
basis for analyses of patterns of a cause-specific demise. They note that the Medicare claims 
form is not the most accurate in explanation of cause of death as having a more 
comprehensive description for each claimant in hand, but that it is more thorough and 
accurate than the limited death certificate data that has been used in previous 
population-based studies.   
  This paper wishes to dive somewhere in between RAND and McClellan by looking 
at patterns of demise by disease code using both studies.  At the same time, we will borrow 
much of the structure of Bhattacharya’s analysis to investigate the issues at hand.   
 
Parallel Research 
Since Medicare is such an important political topic and has such an influence on 
America’s governmental budget, it is natural that a significant part of the literature on 
Medicare focuses on estimating total program liabilities.  This literature has as its focus 
forecasting the impact on Medicare’s bottom line from demographic, technological, and 
policy changes.  As a result, several facts and methodologies have been developed which 
have a bearing on the present question. Chief among these is the treatment of increasing 
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longevity on expected total lifetime Medicare expenditures for individuals.  Most studies in 
the branch of the literature focus on the individual only to better understand impacts on 
entire cohort expenditures and then total program liabilities.  Nevertheless, several of their 
findings are important and relevant to the present work.   
 An example is Tim Miller’s research on increasing longevity and Medicare 
expenditures (2000).  His theme is to argue for the use of expected time until death rather 
than age as health state variables in official Medicare funding projections.  He argues 
conclusively that in a world of improving health and increasing longevity, use of age as a 
predictor of expenditure will necessarily bias expenditure forecasts upward.  As the health 
of people in their seventieth year improves, estimates of the cost of care required for them 
should fall.  Depending on age as a predictor will mask improvements in health at age for a 
considerable period.  Miller argues that since expenditures are more closely related to health 
than age and the linkage between age and health has weakened. Age has become an 
inefficient proxy for health state.  He recommends the use of life expectancy in its place for 
Medicare predictions.  The present research seeks to offer an alternative but follows in the 
spirit of Miller’s argument.   
The pertinent findings in Miller (2000) that help provide context for the research that 
follows include the following:   
• Decline in age specific mortality lead to decline in age specific costs because 
declining mortality reduces the proportion of high cost users. 
• Average medical costs rise both with age and with time until death, primarily 
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because time until death is generally related to age. 
• Medical technological advances serve to de-link age and time until death. 
• Death related expenditures fall with age, because fewer invasive procedures are 
recommended for the oldest old.  
 With a similar goal, Lubitz, et al. (2003) issued a much publicized study in the New 
England Journal of Medicine which surprisingly found increases in the life expectancy of 
the elderly had a neutral effect on total lifetime Medicare expenditures.  Lubitz’s work 
stands as different as one can get in approach as the study here, while still seeking to answer 
some of the same questions.  Lubitz sets up a first order Markov chain transition matrix 
across disability states based on longitudinal reports of individual’s ADL, IADL, and Naki 
Disability scores.  Through this he treats health state as entirely embodied in current 
disability level.  The methodology employed follows Sarah B. Laditka and Douglas A.Wolf 
(1998).  They find that individuals who remain free of disability into advanced old age put 
less of a burden than beneficiaries who spend many fewer years on the program but live with 
disability during the period.  They find a seventy-year-old who has no functional limitation 
can expect 14.3 more years of life and will cost the Medicare program roughly $136,000.  In 
contrast, a seventy-year-old with at least one ADL limitation is expected to live 11.6 years 
with expenditures of approximately $145, 000.  Thus the consequence of improving health 
at age will offset the added anticipated costs of increasing longevity. 
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What Are Expenditures Buying? 
 One of the strongest criticisms of end of life care in America and of Medicare 
program’s treatment of the dying come not from a unwillingness to spend sufficient 
resources to ease suffering at the end of life, but the misuse and misapplication of effort and 
resources in ways that can even cause further suffering for beneficiaries facing the end of life. 
 Concern over the quality of life of people near death and of the “quality” of death arose 
significantly in this country in the last seventies.  Congress instituted the hospice benefit 
under Medicare in 1983 to provide some alternative sources of care near death.  For reasons 
addressed below, Hospice may have been an incomplete solution and if anything concern 
over the quality of end of life care had increased since its inception.
 The magnitude of the problem was made clear through two studies funded by the 
Robert Wood Johnson Foundation in the 1990s.  The Study to Understand Prognoses and 
Preferences for Outcomes and Risks of Treatment (SUPPORT) collected data from patients 
in teaching hospitals from 1989 to 1994 to understand their care, treatment, preferences, and 
patterns of decision-making among critically ill patients.  The study focused on hospital 
admitted patients suffering from nine specific disease categories: acute respiratory failure, 
COPD, congestive heart failure, liver disease, coma, colon cancer, lung cancer, multiple 
organ system failure with malignancy, and multiple organ system failure with sepsis.  The 
data used covered roughly five thousand patients over a five year period. 
 The project aimed at collecting data useful in answering a host of important 
questions related to dying.  Most salient of these for the present research is the investigators 
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interest in the ability of physicians to accurately anticipate the time of a patient’s death.  
Addressing concerns about care of the dying demands a strong ability to distinguish the 
dying from those people who are likely to survive.  The SUPPORT study indicates that 
physicians are particularly poor at judging (or at least expressing) when a person with a 
serious chronic illness has “crossed the line.”   If one looks at a death cohort of people the 
day before they pass away, on average they would be given a 17% chance of living another 
two months.  A week prior to death, they would be given a 50% of surviving two months.  
As investigator Joanne Lynn (2003) points out, the inability to distinguish probable 
decedents from probable survivors calls into to question the use of the term end-ofBlife care, 
at least from any sort of prospective approach. A separate but equally important outcome of 
the study has been a better understanding of the preferences of terminally ill people about 
their deaths and care near the end of life.  How the services provided match the preferences 
of the dying gets at the question of what the Medicare program is really buying for its 
expenditures on behalf of the dying. 
 The SUPPORT study indicates that the medical community is doing a particularly 
poor job in providing care that matches terminal ill patient’s preferences.  The investigators 
suggest that primary reason for this important failure is the reluctance of physicians to 
“admit failure” by shifting a patient’s care to a palliative approach and abandoning hopefully 
curative interventions. 
 A recent study in the Journal of General Internal Medicine (Amy Sullivan, Michael 
Lakoma, and Susan Block 2003) used a telephone survey of roughly 1500 medical students 
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to investigate their attitudes towards and training related to patient death.  More than 40% 
of respondents reported that dying patients were not considered good teaching cases and that 
quality of life concerns for dying patients was not considered a core competency.  Fewer 
than 18% had received any formal training concerning end-of-life care.  Nearly half felt 
unprepared to manage their own feelings about patients’ deaths or help bereaved families.  
Virtually every serious investigation into end-of-life care done within the medical 
community has come away making strong recommendations for revamping the education 
and training medical students receive for dealing with terminally ill patients.  In the past few 
years, efforts have been made to train physicians in palliative care procedures and to 
encourage rational and quality-of-life focused care decisions (E.H. Wagner et al., 2001).   
 In addition to the typical doctor’s reluctance to discuss death, the SUPPORT study 
found significant evidence of ignorance of the patients references regarding end-of-life care. 
 Fewer than 50% of physicians were aware of patient’s unwillingness to submit to invasive 
procedure with a low probability of success.
 The medical literature is equally critical of America’s health care system in its 
almost exclusive focus on acute care.  The Institute of Medicine’s Committee on Care at the 
End of Life make an issue of the fact that health insurers often restrict care to people with 
ongoing medical problems or terminal illnesses out of fear that they will disproportionately 
attract sicker that average people. Carol F. Capello, Diane E. Meier, and Christine K. Cassel 
(1998) find that while a large percentage of deaths occur in hospitals, hospitals are not 
explicitly reimbursed for providing palliative care provided there.  As will be discussed in 
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Chapter III, Medicare reimbursements make use of specific codes for treatments.  There is 
a diagnostic code under Medicare that identifies patients receiving inpatient palliative care 
at an acute care facility, but there is no reimbursement associated with the code, and it is not 
surprising that the code is rarely used (Christine K. Cassel and Bruce C. Vladeck, 1996).   
 To further question what Medicare is getting for the expenditures the program makes 
on behalf of beneficiaries, studies have made use of regional differences in Medicare usage 
rates among the critically ill.  One such investigation by Elliott S. Fisher, et al. (2003) found 
that despite usage rates that can vary as much as 60%, there was little difference in mortality 
rates, in changes to functional status, or in reported patient satisfaction levels.  Jon Skinner 
and John E. Wennberg (1998) similarly found no evidence that increased per capita 
spending in the last six months of life lowered mortality rates.   
 
Proportions of Total Medicare Spending in Terminal Year 
 One question that serves to give an impression of the magnitude of the issue is the 
proportion of total Medicare spending which is accounted for by medical care provided to 
beneficiaries in their final years of life.  The first notable inquiry came in 1984 by James 
Lubitz and Ronald Prihoda in Health Care Financing Review.  Making use of cross-sectional 
data about the Medicare expenditures made on the 1978 death cohort during the cohorts final 
two years, the authors found that the total expenditures on decedents represented roughly 
28% of total Medicare expenditures while the group studied accounted for only 6% of the 
beneficiaries of the program in that year.     
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 Lubitz and Prihoda’s estimates were partially confirmed by S. H. Long, et al. (1984) 
work in the same year which specifically considered beneficiaries who died of cancer.  Other 
concurrent studies include N. McCall and one by W. D. Spector and V. Mor, both papers 
from 1984.  Essentially the same question was addressed more recently using a panel of 
decedents from the year 1993-1998.  Christopher Hogan, et al. (2001) used data similar to 
that employed in the present research to estimate the proportion of Medicare expenditures 
going to decedents in their final year in Health Affairs in 2001.  They determine that 27.4% 
of all expenditures were associated with the care of the 5% of the beneficiary population 
which were in their terminal year.  It seems the proportion has held up over the past twenty 
years.  Studies which arrived at similar estimates include G. L. Gaumer and J. Stavins (1992), 
and James D. Lubitz & Gerald F. Riley (1993). 
Hospice 
 The U.S. Congress instituted a Hospice benefit for Medicare beneficiaries in 1983.  
The intent of the benefit was to provide a funding mechanism through which terminally ill 
patients could face their final days in their own homes or in specialized institutions free of 
invasive medial care.  As the consistency of the estimates across time shows, the Hospice 
benefit has done little to reduce the proportion of Medicare expenditures associated with 
services for the dying.  Concerning absolute expenditures in hospice those studies which 
have tried to establish direct cost savings have been troubled by methodological issues.  It is 
known that Medicare Hospice rates reflect historic patterns of treatment, such as the 
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population of those beneficiaries dying of cancer in the early 80s, a matter which affects not 
just the Hospice issue but all Medicare expenditures.  H.A. Huskamp, et al. (2001) suggest 
several ways in which this program can be updated to better reflect technological advances 
in the treatment of prototypical terminal illnesses like cancer, and the usefulness of Hospice 
care for other disease patterns.  
 Reduction in that proportion was not the only significant intent of the program, 
however. A major intent of providing hospice services to the terminally ill was to improve 
the quality of life of the dying.   The Medicare hospice benefit came out of the rise in interest 
in hospice services generally.  There was substantial concern that not only was the Medicare 
program spending a significant level of funds on the dying, but also that the services it was 
purchasing were not entirely appropriate.  
 One final area of the literature relevant to contribution the present work is aimed at 
making is that on persistence.  The question addressed can be roughly expressed as the 
following: What does a high level of expenditure in one period predict for the next period?  
Are there high-cost and low-cost individuals?  The answer is particularly important to 
discussion of alternatives to Medicare funding and the practicality of private insurance 
replacing or augmenting Medicare.  Andrew Rettenmaier and Zijun Wang’s work of 2002 
and 2003 represent the apex of technical precision and brute econometric force being 
brought to bear on the subject.  The present work has a bit easier a time than do those authors 
in that medical expenditures in the run-up to death are strongly increasing across most 
diseases.  As people near death, their medical expenses rise each quarter.  The problem that 
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plagues the persistence literature of many periods with zero costs and the econometric 
challenges that result are less of a problem near death. 
 The literature presented above serves as a foundation for the work which will unfold 
in the following two chapters.  The data and methods used hereafter are distinct from any of 
the papers sighted, but they together establish the motivation for the work and inform the 
decisions made explicitly and behind the scenes that allow for the results obtained.  The 
existing literature on Medicare comprises a breadth and depth that serve to indicate the 
importance and complexity of the subject for the taxpayer, the researcher and the beneficiary 
of the Medicare program.  The work to be presented in the next two chapters does not 
promise to either or extend or contract the complexity of the issues or the literature, but 
hopes to contribute to a clearer understanding of the existing relationships between health, 
finances, and diseases under the present system. 
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CHAPTER III 
 
DATA 
 
The data used to estimate the models in this work come from the 5% Sample 
Standard Analytical Files from the Centers for Medicare and Medicaid Services.  The 
Standard Analytical Files are a set of annual files covering the Medicare reimbursements 
made at the individual level. They consist of complete Medicare claims information of a 5% 
sample of Medicare enrollees determined by using the last digits of the Social Security 
Number or equivalent Railroad Retirement Board number. The seven files which comprise 
the information relevant to this work are broken down by class of Medicare expenditure.  
Durable medical equipment, home health services, skilled nursing facilities, inpatient 
services, outpatient services, and hospice services are itemized in distinct files. Claims for 
physician services are held in the carrier file. Finally, the denominator file contains 
demographic information about the beneficiary including age, race, gender, Medicare 
enrollment history and zip code. These files are linked together through the use of 
non-identifiable beneficiary numbers.  The information in the data comes from billing 
records for individuals. The records include the principle diagnosis code which motivated 
the claim (ICD-9 classification), secondary supporting codes, the level of expenditure, and 
a host of supportive information. The files are publicly available, but are subject to stringent 
use restrictions which include proscriptions on merging in outside data.  Some work has 
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been done with the data by groups not constrained by usage restrictions (inside CMS, for 
example), so some things are known about the sample that are not legally reproducible here.  
It is common for the Standard Analytical files to be used in cross section.  Each year 
of observation contains roughly two million individuals.  Each individual is assigned a 
unique identifier (hic hereafter).  The hospice file for a given year, for example, contains 
hospice claims data for each person who had any covered treatment in a hospice setting.  A 
full record of any individual’s Medicare expenditure in a year requires that each of the seven 
files for that be merged together.  Each claim record contains the hic, information of the 
disease code requiring treatment, the treatment administered, unique codes for the hospital 
or medical professional administering the treatment, supplemental disease codes in cases of 
multiple causes or co-morbidity, and the level of claim in dollars with the necessary 
information about geographic adjustments in allowables.   Across two million individuals 
and seven files, it is easy to see why computational limitations quickly become relevant, and 
thus why cross-sectional analysis is the usual choice of researchers. 
One special feature of the data used herein is the fact that it contains eight years of 
data on the sample of individuals, provided they lived throughout the window.  The data 
covers the time period from the first quarter of 1994 to the final quarter of 2001.  For 
modeling tractability, the current data set has been collapsed into quarters.  Thus, it entails 
thirty-two quarters worth of full claims information on a 5% sample of the Medicare 
population.   
It is important to note what is not in the data.  The files contain all the billing 
information for procedures covered by Medicare.  Thus, those medical services not covered 
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under Medicare which are administered to the population in our data set are entirely missing. 
 The fact that significant portions of medical expenditures are absent, significantly limits the 
interpretation that can be taken from the data.  For example, little can be said about 
pharmaceuticals and institutional care.  This stands in contrast to survey data such as the 
National Long-Term Care Survey, the standard venue in which to investigate the questions 
here explored.  One key areas of information that are not in this data but that are foundational 
for most of the literature in the area are disability scores.  In prior literature, disability scores 
such as IADL and NAGI have formed the basic (health state) variables.  One novel aspect 
of the present research is the attempt to define health state on the basis of prior medical 
expenditures, both generally and in-disease.  
 It should be emphasized that to whatever degree the present effort proves acceptable, 
the resulting measures are likely far weaker than disability measures, for example, for 
quality of life inquiries. Perhaps however, it may prove more relevant for budget impact 
analysis. Thus, the data used in the present study is quite different than the data used in the 
existing literature, both in its content and its potential use.  It is hoped that this work will 
prove complementary to those studies based on survey data.  Also, to make a virtue of 
necessity, it is interesting to consider how this essentially administrative data can be more 
easily monitored than the standard survey data.  Claims information is necessarily messier 
than survey data, but it is free, it is available and it is current.   
The subset of the data used to estimate the model outlined in the next chapter is more 
limited than the 5% sample.  It consists of the decedents among a 10% sample of the 5% 
sample of Medicare enrollees.  The reason for working with a subset rather than the entire 
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available sample is simple computational constraints.  The models in the next chapter are 
estimated using machines which are fairly powerful by the current desktop standards, but no 
more observations could be used than are currently in the subset. A similar study done three 
years ago was limited to a sample 20% the size of the one used here for the same reasons.  
 
Comparison of Data to Earlier Studies 
The primary concern about data that has been as “processed” as this has been the 
degree to which it is representative of the population it is intending to describe.  For that 
purpose, what follows are a series of tables containing descriptive statistics of the sample 
along with those of comparable studies.   
As is evident Table 3-1 above, samples are not identical.  The differences are not 
necessarily intuitive.  The Hogan sample is smaller and covers an earlier period.  The 
perception that people are dying at older ages coupled with the fact that the present sample 
encompasses Hogan’s time frame plus three later years makes the age distribution 
differences a concern.   
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TABLE 3-1-SUMMARY STATISTICS OF DECEDENTS 
       
            Hogan  House    
Demographic 
Characteristics 
Survivor
s Decedents 
Decedent
s    
        
Average Age in Years 70.6 78.3 * 78.5    
Percent Under 65 17 7 * 6    
Percent 65 to 74 47 26  31    
Percent 75 to 84 27 37 * 34    
Percent 85 and older 9 29 * 29    
        
Percent Female 57 53  53.69    
Percent race non-Caucasian 14 13 * 13    
        
Percent with Some HMO 
Enrollment in Year 13 10 * 7.25    
        
        
Source : Analysis of Medicare enrollment data for a 0.1 percent sample of 
beneficiaries, 1994 through 1998  
Taken from Hogan : Table 3-3: Demographics of Decedents vs. Survivors, Pooled Annual 
Rates 1994 through 1998 
*Signifies statistically significant difference between decedents and 
survivors, p. <.05, two-tailed t-test   
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 Cause of Death Determination 
One set of variables generated from the raw information in the claims files concerned 
the cause of death.  The data used in the present study contained no official cause of death 
of the sort that would appear on a death certificate.  The cause of death used in the analysis 
in the next chapter is generated by a simple algorithm from the medical claims files.  The 
following Table (3-2) from D. Hoyert, et al. (1999) shows the distribution of the leading 
causes of death in persons age 65 and older in 1997. 
 
TABLE 3-2: LEADING CAUSES OF DEATH FOR PERSONS AGE 65 AND OLDER, 
1997 
   
Rank Disease (ICD-9 code range) 
Decedent
s 
Rate per 
100,000 
Percent of 
Decedents 
 All causes 1,728,872 5,074 100%
     
1 
Diseases of heart (390-398, 
402,404-429) 606,913 1781 35%
2 Malignant neoplasms (140-208) 382913 1124 22%
3 Cerebrovascular diseases (430-438) 140,366 412 8%
4 
Chronic obstructive  pulmonary diseases 
(490-496) 94411 277 5%
5 Pneumonia and influenza (480-487) 77,561 228 4%
6 Diabetes mellitus (250) 47289 139 3%
7 
Accidents and adverse effects 
E800-E949) 31,386 92 2%
8 Alzheimer's disease (331.0) 22154 65 1%
9 
Nephritis, nephrotic syndrome, 
Nephrosis (580-589) 21,787 64 1%
10 Septicemia (038) 18079 53 1%
 All other causes (Residual) 286,013 839 17%
     
     
 
Source: Taken from Hoyert et al.. 1999, 
Table 8    
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The current study focuses on a group of disease categories which together account 
for over 80% of all causes of death on official death certificates for the beneficiary 
population.  Beneficiaries, for whom the plurality of expenditures in their last year of life 
were attributed to a single disease category in the list, are designated to have died from that 
disease.  Those decedents for whom no single disease accounts for more than 50% of their 
expenditures are designated in the “other” category.  Also, decedents whose primary disease 
is not one of the ones on which the study focuses are included in the “other” category.  The 
procedure described has significant drawbacks when it comes to interpreting results, but it is 
common in the literature.  The adopted procedure already hits the limit of computational 
power available, and all sensible refinements of it considered to date would require even 
more power.   At present, it seems best to explicitly identify the limitations of the adopted 
procedure and await refinements and expansions in future work. 
The majority of elderly decedents suffer from several chronic conditions at the time 
of death.  The records used in this study have a primary ICD-9 code assigned to each 
procedure, but up to three secondary codes may also be assigned to any treatment.  For many 
conditions, the procedure adopted yields a plausible and straight-forward assignment of 
cause of death.  Treatments of terminal cancer, for example, are concentrated and specific.  
The same is true of kidney disease, for example.  Other conditions, however, are associated 
with significant levels of varied complications.  Treatments specifically motivated by 
complications may well cloud the picture of the primary cause of death for a beneficiary.  If 
the cost of treating a complication were to exceed the cost of treating the underlying cause 
of death, the decedent would be presumed to have died of the co-morbidity, and not the 
  
 
39
 
disease which truly caused death.  Heart disease and diabetes are commonly co-morbid.  A 
beneficiary may be equally likely to die of one or the other according to the adopted 
procedure.   
 
Competing Risk Determination  
The adopted methodology has the inherent weakness that the assigned cause of death 
may have cost only slightly more than another, possibly the “real” cause of death.  There 
have been extensive investigations on the impact of various medical technological advances 
and general medical scientific advances on the rate at which people die of various diseases. 
 The standard data used in such studies is the Census Bureau’s Multiple Cause of Death 
Mortality files from 1970, 1980, 1990 and 2000.  Much of the refinement that has taken 
place in that literature has involved overcoming the competing risk problem.  The basic 
difficulty in that data is that all that is available to researchers is cause of death and age at 
death.  Since everyone eventually dies of something, the prevention of a death by cancer will 
“cause” a death by something else.  If longevity is increased, it is difficult in that setting to 
assign which field of progress is responsible.  Various innovative ways have been developed 
to put bounds on the impact of life-extending interventions. The methodology adopted here 
has the same conceptual problem as the mortality files, but the sin is perhaps worse because 
much more information is available. One potential avenue of refining the present method 
would be to consider ratios of expenditure and denote those individuals where the cause of 
death is not as clear because competing causes were near the same level.  For the present, the 
interpretation of the results should be considered with the understanding that the 
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competing-causes problem has been left uncorrected.  It is believed that the problem should 
weaken the results sought in the modeling section. Thus, the decision to use the 
methodology adopted should come at the cost of efficiency and precision, but the results 
should not be biased as a result of the problem. 
To further emphasize the gravity of this reservation, it is useful to consider evidence 
on the prevalence of chronic conditions among the elderly. A study of 1999 Medicare 
beneficiaries suggested that 82% had one or more chronic conditions and 65% had multiple 
chronic conditions (Jennifer Wolff, Barbara Starfield and Gerard Anderson, 2002).  
Treatment for such conditions as diabetes, heart disease and the care needed after a stroke 
are all quite expensive, but may well not be the cause of death for many people. The adopted 
procedure will however pick up any of these as the cause of death for the purposes of the 
analysis rather than the medically valid one.   
 
Selection of Causes of Death 
 What follows is a detailed analysis of the death-related expenditure profiles for 
several diseases under Medicare. There are potentially 3,492 specific disease codes by 
which someone could conceivably die. The analysis focuses on 34 disease codes grouped 
into 25 “diseases”.  The reasoning behind the selection of diseases is rather straightforward. 
 The primary motivation was to capture those diseases from which the majority of Medicare 
recipients die.  Heart disease, common cancers, and strokes are obvious choices.  In addition, 
several diseases that are considered of interest to CMS, CDC or (possibly) the Census 
Bureau have been included because they feature in popular statistical reports on changes in 
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the rate of death.  Finally, one disease code, hip fracture, was included because it was 
convenient and relevant to a particular subset of spending that will feature prominently in 
future work. Due to the constraints of processing power, the diseases reported are not 
complete representations of the true mortality of those diseases.  Many diseases can be 
categorized under several ICD-9 codes. By definition, heart disease consists of ICD-9 codes 
410-414.  Of these, the most common codes assigned for morbidity are 401, 402, 410, and 
414.  It is only these that are included in this analysis.  Thus, the disease categories are not 
complete but are intended to be representative and capture the majority of decedents.   
 
Death-related Expenditure Profiles  
Heart Disease (ICD-9 codes 401,402,410,414) 
Heart Failure (ICD-9 code 428) 
Breast Cancer (ICD-9 code 174) 
Skin Cancer (ICD-9 code 172) 
Cancer of the Larynx (ICD-9 code 161) 
Cervical Cancer (ICD-9 code 180) 
Prostate Cancer (ICD-9 code 185) 
Bladder Cancer (ICD-9 code 188) 
Lung Cancer (ICD-9 code 162) 
Colorectal Cancer (ICD-9 codes 153-154) 
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Leukemia (ICD-9 codes 204-205) 
Non-Hodgkin's Lymphoma (ICD-9 code 202) 
Cerebrovascular Disease (ICD-9 codes 436-443) 
Stroke (ICD-9 codes 431-432) 
COPD (ICD-9 codes 490-491, 492, 494, 496)  
Pneumonia (ICD-9 codes 480-487) 
Diabetes Mellitus (ICD-9 code 250) 
Alzheimer’s disease (ICD-9 code 331) 
Kidney Failure (ICD-9 codes 580, 582, 583, 585, 590, 592) 
Septicemia (ICD-9 code 38) 
Parkinson’s disease (ICD-9 code 332) 
Multiple Sclerosis (ICD-9 code 340)   
Muscular Dystrophy (ICD-9 code 359) 
Hip Fracture (ICD-9 code 820) 
Other  
 
One significant omission from the list is the general section for frailty.  While frailty 
is a recognized medical condition from which significant numbers of elderly persons die, it 
is rarely, if ever, used for Medicare billing.  The reason for this is the fact that the Medicare 
system has not implemented any payment for procedures motivated exclusively by frailty.   
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Heart Disease (ICD-9 codes 401,402,410,414) 
  Heart disease is the leading cause of hospitalization among the elderly. In 1996, 
acute myocardial infarction or AMI accounted was the cause of hospitalization of 394,850 
Medicare beneficiaries. Medicare spent nearly $3.6 billion, or about $9,780 per discharge.  
Heart disease is composed of a few significantly different medical conditions.  Chronic 
hypertensive disease (ICD-9 401) is a manageable long-term chronic condition that can be 
associated with ongoing medical costs. Acute myocardial infarction (ICD-9 code 410), on 
the other hand, is probably the most common example of an acute condition that causes rapid 
death.  Combining these two conditions which have inherently very different expenditure 
profiles, is an unfortunate consequence of the way the data was available.  An early 
opportunity for future investigation will be to parse out these particular codes to get a clearer 
picture of this costly disease. The pattern of total expenditures and those expenditures 
specific to heart disease are illustrated in Figure 3.1 and listed in Table 3.3. In addition, the 
difference between the total and in-disease expenditures is provided to serve as an 
illustration of out of disease spending.  
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FIGURE 3.1.  HEART DISEASE: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
 
 
TABLE 3.3-HEART DISEASE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 951.4927 279.3621 7006
6 1066.415 303.4583 7093
5 1083.861 286.399 7067
4 1207.184 344.376 7146
3 1341.537 355.6126 7207
2 1776.156 500.9474 7253
1 2915.603 879.7377 7394
0 5637.623 2376.977 7658
    
Male 47.87   
Black 9.26   
Hispanic 0.8   
Age at death 78.16949   
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Heart Failure (ICD-9 code 428) 
Heart failure is listed as the reason for more than 700,000 hospitalizations among 
Medicare recipients every year, and is linked with high rates of mortality and morbidity. 
For patients over 65 years of age, there is no disease more commonly noted as cause for 
hospitalization.  It is estimated that national annual It is a common disease in the older 
population, accounting for more hospital admissions than any other diagnosis in patients 
over the age of 65.  Estimates of Medical expenditures paid out for the treatment of heart 
failure in the United States range from $10 billion to $40 billion. The pattern of total 
expenditures and those expenditures specific to heart failure are illustrated in Figure 3.2 and 
listed in Table 3.4. 
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FIGURE 3.2. HEART FAILURE: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
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TABLE 3.4- HEART FAILURE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 1036.519 241.3204 7982
6 1137.897 278.9559 7993
5 1252.406 326.7693 8031
4 1435.035 389.5881 8092
3 1613.112 465.7726 8160
2 2055.903 590.2862 8226
1 3110.718 985.9734 8467
0 4479.006 1389.854 8543
    
Male 43.27   
Black 9.51   
Hispanic 0.82   
Age at death 79.85465  Heart F 
 
 
 
Breast Cancer (ICD-9 code 174) 
It is estimated that almost 75 percent of all breast cancers are found in women over 
the age of 50.  Conditional on having reached the age of 60, a woman has a 1 in 13 chance 
of developing breast cancer before age 79. Between 1996 and 2000, 96% of breast cancer 
deaths occurred in women aged 40 and older (SEER Cancer Statistics).  The pattern of total 
expenditures and those expenditures specific to breast cancer are illustrated in Figure 3.3 
and listed in Table 3.5. 
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Breast Cancer: Medicare Expenditures in Final Eight 
Quarters
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FIGURE 3.3. BREAST CANCER: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
 
 
 
TABLE 3.5-BREAST CANCER: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 877.2484 246.0202 801
6 916.7862 311.01 805
5 1333.195 467.2803 835
4 1278.143 397.7901 836
3 1574.421 524.7276 855
2 2119.177 631.6492 868
1 3211.752 1057.458 917
0 3398.279 1016.284 930
    
Male 0.93   
Black 10.31   
Hispanic 0.42   
Age at death 75.28874  Breast 
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Skin Cancer (ICD-9 code 172) 
Over one-half of all cancers diagnosed in 2002 were categorized under the broad 
heading of skin cancer (American Cancer Society, Cancer Facts & Figures, 2002).  It has 
been estimated that roughly half of all Americans who live beyond age 65 will develop skin 
cancer at least once.  The heading of skin cancer includes both the generally non 
life-threatening non-melanoma conditions (i.e. basal cell carcinoma and squamous cell 
carcinoma) and the more serious melanoma version that can quickly metastasize. Melanoma 
accounts for about 4% of skin cancer cases, but it causes about 79% of skin cancer deaths 
(American Cancer Society, Overview of Skin Cancer). The pattern of total expenditures and 
those expenditures specific to skin cancer are illustrated in Figure 3.4 and listed in Table 3.6. 
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FIGURE 3.4. SKIN CANCER: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
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TABLE 3.6-SKIN CANCER: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 786.8785 181.0224 105
6 514.0691 133.5749 112
5 1044.231 174.3489 112
4 1241.635 148.1614 115
3 1453.553 289.0154 114
2 2276.613 455.0162 120
1 2748.598 698.8285 127
0 3003.966 752.3239 131
    
Male 64.93   
Black 0.75   
Hispanic 0   
Age at death 75.39179  skin 
   
 
 
Cancer of the Larynx (ICD-9 code161) 
Laryngeal cancer or cancer of the larynx is primarily a disease that affects persons 
over age 55. It is a disease often occurring in tobacco users and heavy drinkers. The 
American Cancer Society estimates that 9,880 new cases of laryngeal cancer (7,920 in men 
and 1,960 in women) will be diagnosed, and 3,770 people (2,960 men and 810 women) will 
die from the disease in the United States in 2005. There are approximately 2,500 cases of 
“hypopharyngeal” cancer are diagnosed each year. The pattern of total expenditures and 
those expenditures specific to cancer of the larynx are illustrated in Figure 3.5 and listed in 
Table 3.7. 
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Cancer of the Larynx: Medicare Expenditures in Final 
Eight Quarters
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FIGURE 3.5. CANCER OF THE LARYNX: MEDICARE EXPENDITURES  
IN FINAL EIGHT QUARTERS 
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TABLE 3.7-CANCER OF THE LARYNX: SUMMARY STATISTICS 
 
Quarters 
Prior to Death Total 
Disease 
Specific 
Observation
s    
        
 7 854.6842 233.1253 108    
 6 2089.813 495.0283 113    
 5 2047.804 425.4714 112    
 4 2475.038 721.9085 110    
 3 2856.756 736.7877 112    
 2 3465.025 1020.419 120    
 1 3908.873 1184.609 125    
 0 5126.641 1641.788 130    
        
 Male 84.85%      
 Black 13.74%      
 Hispanic 1.53%      
 
Mean Age at 
Death 71.94      
        
        
 
      
 
 
 
 
Cervical Cancer (ICD-9 code 180) 
 
Women over the age of 65 have a cervical cancer incidence rate of 16.8 per 100,000, 
contrasted against 7.4 for women younger than 65. This age group also accounts for 
forty-one percent of cervical cancer deaths in the United States as they have a cervical 
cancer mortality rate that is nearly three times greater than for women younger than 65 
(National Cancer Institute Cancer Statistics Branch and NIH Consensus Panel 1996). The 
pattern of total expenditures and those expenditures specific to cervical cancer are illustrated 
in Figure 3.6 and listed in Table 3.8. 
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Cervical Cancer: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.6. CERVICAL CANCER: MEDICARE EXPENDITURES 
IN FINAL EIGHT QUARTERS 
 
 
 
TABLE 3.8-CERVICAL CANCER: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 505.8303 132.1593 66
6 496.214 25.97666 66
5 852.4665 171.2725 62
4 1267.511 270.0361 67
3 1920.335 315.124 70
2 2317.213 553.3955 74
1 3704.867 1053.112 85
0 3935.283 719.8556 89
    
Male 3.3   
Black 13.33   
Hispanic 2.22   
Mean Age at 
Death 73.95604  Cervical 
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 Prostate Cancer (ICD-9 code 185) 
  
 In 2003, prostate cancer accounted for more than a quarter of the cancer cases in 
men and 11% of the deaths. Men over the age of 60 have a 1 in 7 chance of developing 
prostate cancer. The average age at diagnosis is 72 years of age, so many patients with 
prostate cancer, especially those whose disease does not spread, may die of other illnesses 
or mere frailty without ever having suffered significantly from their cancer (American 
Cancer Society, Cancer Facts and Figures 1998). The pattern of total expenditures and 
those expenditures specific to prostate cancer are illustrated in Figure 3.7 and listed in Table 
3.9. 
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FIGURE 3.7. PROSTATE CANCER: MEDICARE EXPENDITURES  
IN FINAL EIGHT QUARTERS 
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TABLE 3.9-PROSTATE CANCER: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 748.7248 252.8714 1212
6 829.4112 294.0032 1216
5 917.683 293.3112 1223
4 1081.395 339.2733 1240
3 1355.522 444.3537 1258
2 1790.12 599.8556 1280
1 2743.175 850.1349 1322
0 3311.276 865.747 1345
    
Male 99.86   
Black 13.4   
Hispanic 0.86   
Mean Age at 
Death 78.91566  Prostate 
 
 
Bladder Cancer (ICD-9 code 188) 
Bladder cancer is the development of tumors inside the transitional cell lining of the 
urinary tract.  It is estimated by the American Cancer Society that in 2004 there were 60,240 
new cases of Bladder Cancer and that from those 12,710 deaths occurred. Bladder cancer is 
2 to 3 times more common in men and those persons 70 and older have 2 to 3 times greater 
incidence of developing the disease than those aged 55–69 and 15 to 20 times more often 
than those aged 30–54 (Urology Channel Website, 2004). The pattern of total expenditures 
and those expenditures specific to bladder cancer are illustrated in Figure 3.8 and listed in 
Table 3.10. 
  
 
55
 
 
Bladder Cancer: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.8. BLADDER CANCER: MEDICARE EXPENDITURES 
 IN FINAL EIGHT QUARTERS 
 
 
TABLE 3.10-BLADDER CANCER: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 1033.082 320.8533 414
6 1141.168 323.853 421
5 1175.858 407.5471 428
4 1494.566 469.5311 438
3 2000.183 724.8035 444
2 2192.207 746.2583 454
1 4102.955 1574.352 475
0 4379.005 1404.624 481
    
Male 68.74   
Black 5.65   
Hispanic 0.6   
Mean Age at 
Death 78.7014  Bladder 
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Lung Cancer (ICD-9 code 162) 
The American Cancer Society estimates that there will be 172,570 new cases of lung 
cancer in 2005, accounting for approximately 13% of cancers detected this year. Of those 
there will be 163,510 deaths.  Lung cancer is consistently the leading cause of cancer-related 
deaths among both men and women.  Men aged 60 to 79 have a 1 in 17 chance of developing 
the disease, whereas women in the same age range face a 1 in 26 chance of having lung 
cancer (American Cancer Society, Cancer Facts and Figures, 2005). The pattern of total 
expenditures and those expenditures specific to lung cancer are illustrated in Figure 3.9 and 
listed in Table 3.11. 
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FIGURE 3.9. LUNG CANCER: MEDICARE EXPENDITURES 
IN FINAL EIGHT QUARTERS 
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TABLE 3.11-LUNG CANCER: SUMMARY STATISTICS 
Quarters Prior to 
Death Total 
Disease 
Specific 
Observation
s 
7 645.7616 164.5728 2792
6 831.6551 227.6184 2837
5 984.1343 289.9235 2877
4 1194.429 363.8389 2903
3 1595.704 534.2246 2990
2 2126.567 860.5966 3185
1 3537.425 1547.575 3438
0 4230.202 2154.693 3633
    
Male 59.42   
Black 8.9   
Hispanic 0.3   
Mean Age at Death 74.0033  lung 
 
 
Colorectal Cancer (ICD-9 codes 153-154) 
In 2005, it is estimated that Americans will face almost 145,000 new cases of 
colorectal cancer, with about 56,290 deaths from the disease, accounting for 10% of the 
cancer-related deaths this year. The biggest risk factor with this disease is simply age, as 
90% of the cases diagnosed are those found in patients over the age of 50 (American Cancer 
Society, Cancer Facts and Figures, 2005). The pattern of total expenditures and those 
expenditures specific to colorectal cancer are illustrated in Figure 3.10 and listed in Table 
3.12. 
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Colorectal Cancer: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.10. COLORECTAL CANCER: MEDICARE EXPENDITURES  
IN FINAL EIGHT QUARTERS 
 
 
TABLE 3.12-COLORECTAL CANCER: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 998.7629 326.1158 1536
6 1318.251 415.7167 1541
5 1201.579 387.9865 1570
4 1651.881 574.394 1613
3 1926.45 676.6422 1631
2 2583.112 997.1344 1698
1 4038.49 1732.164 1807
0 5161.01 2330.305 1877
    
Male 46.37   
Black 8.88   
Hispanic 1.05   
Age at death 77.34333  colo 
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Leukemia (ICD-9 codes 204-205) 
Leukemia is a malignant disease or a cancer of the bone marrow and blood. It is 
characterized by the unrestrained accumulation of blood cells (Leukemia and Lymphoma 
Society, Leukemia, Lymphoma, Myeloma, Facts 2004, In Press). The American Cancer 
Society projects there will be 34,810 new cases of leukemia in 2005 and from that, 22,570 
deaths.  Leukemia is often thought to be a primarily childhood disease, but it is in fact ten 
times more likely to be diagnosed in adults. The pattern of total expenditures and those 
expenditures specific to leukemia are illustrated in Figure 3.11 and listed in Table 3.13. 
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FIGURE 3.11. LEUKEMIA: MEDICARE EXPENDITURES 
IN FINAL EIGHT QUARTERS 
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TABLE 3.13-LEUKEMIA: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 966.4444 256.8718 344
6 794.4889 157.6479 354
5 1283.782 330.7558 356
4 1508.1 240.9146 365
3 2026.317 499.0542 379
2 2625.835 983.2448 377
1 4528.256 1836.537 399
0 8159.386 4554.312 412
    
Male 58.95   
Black 7.67   
Hispanic 0.48   
Age at death 75.5358  Leuk 
 
 
Non-Hodgkin’s Lymphoma (ICD-9 code 202) 
Non-Hodgkin’s Lymphoma is cancer of the lymph nodes, and it is a cancer that is 
unpredictable and one easily spreads beyond the lymphatic system.  Non-Hodgkin’s 
Lymphoma will account for 8% of new cancer diagnoses in 2005 or 56,390 cases.  Of these, 
Non-Hodgkin’s Lymphoma is expected to claim the lives of 19,200 Americans.  A little 
more than 1% of Americans between the ages of 60 and 79 will develop the cancer.  One 
year survival rate is 77% and the five year survival rates is 59% (American Cancer Society, 
Cancer Facts and Figures, 2005). The pattern of total expenditures and those expenditures 
specific to non-Hodgkin’s lymphoma are illustrated in Figure 3.12 and listed in Table 3.14. 
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Non-Hodgkin's Lymphoma: Medicare Expenditures in 
Final Eight Quarters
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FIGURE 3.12. NON-HOGKIN’S LYMPHOMA: MEDICARE EXPENDITURES IN 
FINAL EIGHT QUARTERS 
 
 
TABLE 3.14-NON-HOGKIN’S LYMPHOMA: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 988.8598 236.493 519
6 966.6587 237.884 523
5 1107.328 301.1254 526
4 1364.971 365.8223 536
3 1979.254 517.7737 549
2 2807.915 916.0848 565
1 4719.498 1594.711 602
0 5877.8 2298.997 621
    
Male 49.6   
Black 5.44   
Hispanic 0.16   
Mean Age at Death 74.85063  Non Hopkins 
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Cerebrovascular Disease (ICD-9 codes 436-443) 
This category of disease is “ill-defined” as cerebrovascular disease that may or may 
not be acute and does not include an intracranial or intra-cerebral hemorrhage, commonly 
known as a stroke, but does include an aneurysm or the bulging of a blood vessel wall.  
Cerebrovascular disease is much more life-threatening in patients over the age of 70. The 
pattern of total expenditures and those expenditures specific to cerebrovascular disease are 
illustrated in Figure 3.13 and listed in Table 3.15. 
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FIGURE 3.13. CEREBROVASCULAR DISEASE: MEDICARE EXPENDITURES IN 
FINAL EIGHT QUARTERS 
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TABLE 3.15-CEREBROVASCULAR DISEASE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 946.6813 196.4355 4861
6 1015.734 250.0618 4893
5 1027.689 242.8582 4917
4 1251.504 295.4154 4915
3 1358.954 295.4213 4927
2 1807.41 419.4126 4995
1 2640.459 606.0752 5201
0 3512.287 647.6719 5295
    
Male 39.03   
Black 11.16   
Hispanic 0.66   
Age at death 80.52686  cere 
 
 
Stroke (ICD-9 codes 431-432) 
A stroke is when a blood vessel in the brain is blocked or is made narrower, reducing 
the blood flow in that vessel significantly.  A stroke encompasses the damage done to the 
brain when this vessel is blocked or bursts.  It was estimated that three-quarters of a million 
Americans would suffer a stroke in 2004, and of those, 160,000 would die. It is said to be the 
third leading cause of death in the US.  Sixty-two percent of people who suffer a stroke in 
any given year are over the age of 65 (The Internet Stroke Center). The pattern of total 
expenditures and those expenditures specific to stroke are illustrated in Figure 3.14 and 
listed in Table 3.16. 
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Stroke: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.14. STROKE: MEDICARE EXPENDITURES IN FINAL EIGHT QUARTERS  
 
 
TABLE 3.16-STROKE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 537.0868 68.17584 798
6 808.5765 129.2901 788
5 767.147 67.68327 798
4 911.4004 166.667 813
3 1031.52 149.9741 810
2 1333.275 260.3714 827
1 2656.37 645.7846 855
0 5473.204 3033.411 983
    
Male 46.64   
Black 11.34   
Hispanic 0.91   
Age at death 78.48571  Stroke 
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COPD (ICD-9 codes 490-492, 494, 496) 
Chronic Obstructive Pulmonary Disease or COPD includes two conditions. The first 
is chronic bronchitis, which is the inflammation and subsequent scarring of the airway 
structure.  Emphysema is the enlargement and degradation of the air sacs within the lungs 
which are called the alveoli.  Almost 90% of the cases of COPD occur as a result of smoking, 
as a smoker has a tenfold risk to acquiring the disease as does as a non-smoker (JAMA web 
site, Information on COPD, 2004). COPD is the fourth leading cause of death for persons 
aged of 65 to 84, claiming the lives 120,000 American in 2002 (National Center for Health 
Statistics, Report of Final Mortality Statistics, 2002).  Females are now twice as likely to be 
diagnosed with COPD as males. Quality of life diminishes significantly as the disease 
worsens, and a patient can require mechanical respiratory assistance. The pattern of total 
expenditures and those expenditures specific to COPD are illustrated in Figure 3.15 and 
listed in Table 3.17. 
 
 
  
 
66
 
COPD: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.15. COPD: MEDICARE EXPENDITURES IN FINAL EIGHT QUARTERS 
 
 
TABLE 3.17-COPD: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 1217.557 359.0775 4470
6 1248.877 393.1828 4531
5 1350.321 424.5832 4545
4 1606.012 472.7045 4567
3 1708.227 548.0693 4607
2 2068.93 677.9129 4682
1 3104.336 1001.868 4791
0 4850.652 1491.567 4847
    
Male 51.91   
Black 5.96   
Hispanic 0.75   
Age at death 75.44517  COPD 
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Pneumonia (ICD-9 codes 480-487) 
In 2002, pneumonia claimed the lives of almost 60,000 Americans over the age of 65. 
 The elderly, who have weakened cough and gag reflexes and decreased immune ability, 
have much lower survival rates, especially those with other conditions (National Center for 
Health Statistics, 2002). The pattern of total expenditures and those expenditures specific to 
pneumonia are illustrated in Figure 3.16 and listed in Table 3.18.  
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FIGURE 3.16. PNEUMONIA: MEDICARE EXPENDITURES IN 
FINAL EIGHT QUARTERS 
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TABLE 3.18-PNEUMONIA: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 1018.034 175.9555 6090
6 1105.655 198.3878 6024
5 1185.596 216.0888 6090
4 1416.359 274.7908 6128
3 1637.202 346.4828 6178
2 2107.628 470.1097 6275
1 3465.062 927.2706 6507
0 5628.785 2372.38 6697
    
Male 50.25   
Black 9.09   
Hispanic 0.88   
Age at death 80.16489  pneu 
 
 
Diabetes Mellitus (ICD-9 codes 250) 
Diabetes mellitus is one of the more expensive causes of morbidity and mortality in 
older Americans.  In 1997, the condition accounted for 2.3 million hospital admissions, 14 
millions hospital days, and 70 million nursing home days with specific medical expenditures 
estimated at $44 million.  More than half a million new cases are diagnosed each year. Over 
10% of people over the age of 65 have clinical diabetes.  This condition increases an older 
adult’s likelihood of having myocardial infarction, stroke and kidney failure (Lebovitz, H.E., 
1997). The pattern of total expenditures and those expenditures specific to diabetes mellitus 
are illustrated in Figure 3.17 and listed in Table 3.19. 
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Diabetes Mellitus: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.17. DIABETES MELLITUS: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
 
 
TABLE 3.19-DIABETES MELLITUS: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 1164.872 277.0593 3446
6 1295.349 328.3004 3466
5 1347.708 317.8169 3467
4 1565.188 397.7791 3491
3 1796.613 450.9656 3506
2 2073.745 492.184 3558
1 3070.086 641.2895 3611
0 4192.373 638.2264 3593
    
Male 44.86   
Black 15.66   
Hispanic 1.59   
Mean Age at 
Death 75.12347  diabetes 
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Alzheimer’s Disease (ICD-9 code 331) 
It is estimated that 4.5 million people in the US have Alzheimer’s disease and the 
number is expected to grow significantly (L.E. Hebert, et al. 2003). Medicare spent $31.9 
billion on Alzheimer’s disease in 2000 (Lewin Group, 2001).  A person suffering from 
Alzheimer’s disease is expected to live an average of eight years from the diagnosis, but can 
live more than twenty.  Patients with the disease have half the survival rates as there 
unaffected counterparts, and that survival rate is also changed by age at onset and the 
severity of other medical conditions (E.B. Larson, et al. 2004). The pattern of total 
expenditures and those expenditures specific to Alzheimer’s disease are illustrated in Figure 
3.18 and listed in Table 3.20. 
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FIGURE 3.18. ALZHEIMER’S DISEASE: MEDICARE EXPENDITURES IN FINAL 
EIGHT QUARTERS 
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TABLE 3.20-ALZHEIMER’S DISEASE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 621.5586 145.5056 1239
6 576.8116 127.3169 1249
5 693.1146 182.6369 1252
4 809.1196 174.4844 1269
3 960.3822 257.0144 1301
2 1241.72 349.0617 1315
1 1625.684 493.1615 1349
0 2043.651 432.0051 1341
    
Male 35.01   
Black 6.58   
Hispanic 0.64   
Age at death 81.65196  alz 
 
 
Kidney Failure (ICD-9 codes 580, 582, 583, 585, 590, 592) 
The 1999 U.S. Renal Data System Annual Report, produced by the National Institute 
of Diabetes and Digestive and Kidney Diseases, showed that the number of Americans with 
kidney failure is increasing by 6% each year, with the US leading the word in number of new 
diagnoses per million population.  79,000 Americans suffered End Stage Renal Disease or 
total kidney failure in 1997.  These patients require kidney dialysis or transplants of the 
organ to survive the disease.  Sixty-two percent of the new cases reported in 1997 were 
patients aged 60 or more. The pattern of total expenditures and those expenditures specific 
to kidney failure are illustrated in Figure 3.19 and listed in Table 3.21. 
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Kidney Failure:Medicare Expenditures in Final Eight 
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FIGURE 3.19. KIDNEY FAILURE: MEDICARE EXPENDITURES IN 
FINAL EIGHT QUARTERS 
 
 
TABLE 3.21-KIDNEY FAILURE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 3406.887 1044.46 1832
6 3697.979 1132.208 1848
5 4035.811 1244.213 1883
4 4339.213 1426.178 1903
3 4823.353 1565.086 1927
2 5549.128 1763.32 1958
1 6749.506 1846.772 1992
0 7576.899 1133.665 2002
    
Male 52.11   
Black 25.05   
Hispanic 2.08   
Age at death 68.7358  Kidney 
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Septicemia (ICD-9 code 38) 
Septicemia is infection or poisoning of the blood and is often associated with severe 
disease.  The infection can begin in the lungs, urinary tract, or abdomen and can lead to 
septic shock and sometimes death.  Septic shock has a survival rate of slightly more than 
50%, depending on the organs of the body involved.  People over the age of 65 are at 
particular risk of developing septicemia and subsequently dying from it. During the last 
decade, there was a considerable, unexplained increase in the rate of elderly US who were 
hospitalized for septicemia, according to William B. Baine, M.D., of the Agency for 
Healthcare Research and Quality. Dr. Baine and his colleagues used Medicare claims data 
for hospital discharges from 1991 through 1998 to study over 75,000 hospitalizations for 
septicemia in patients aged 65 or older. 
From 1991 through 1997, the diagnosis codes for “unspecified septicemia" increased 
108 percent annually, and those for pneumococcal septicemia increased 310 percent. These 
increases exceeded the growth of the elderly Medicare population. In this period the 
morbidity associated with the disease hit males and African-American patients the hardest. 
The pattern of total expenditures and those expenditures specific to septicemia are illustrated 
in Figure 3.20 and listed in Table 3.22. 
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FIGURE 3.20. SEPTICEMIA: MEDICARE EXPENDITURES IN 
FINAL EIGHT QUARTERS 
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TABLE 3.22-SEPTICEMIA: SUMMARY STATISTICS 
Quarter Prior to 
Death Total 
Disease 
Specific 
Observation
s  
    
7 1285.47 128.1493 2481
6 1422.53 177.7643 2482
5 1455.66 177.5688 2490
4 1754.52 234.4857 2522
3 2172.74 301.3311 2538
2 2805.66 392.0569 2596
1 4501.33 924.2728 2686
0 7112.48 3152.251 2819
    
Male 43.02%   
Black 14.69%   
Hispanic 1.10%   
Mean Age at 
Death 78.34  sept 
 
 
Parkinson’s Disease (ICD-9 code 332) 
Parkinson’s disease is a chronic, progressive, and disabling neurological disorder of 
which 85% of cases are diagnosed in persons over the age of 60, with the average age of 
onset at 57.  In its later stages, it can be completely debilitating and cause some dementia. It 
is very common for older Parkinson’s disease sufferers to also suffer arthritis, broken bones, 
and diabetes. They are much more likely to use home-health care or skilled nursing facilities 
(Medicare Costs and Resource Use for Parkinson's Disease). In the United States, it is 
estimated that 1.5 million Americans suffer from the disease and that 60,000 new cases are 
diagnosed each year.  Parkinson’s disease can be difficult to diagnose and is usually a 
disease that is managed with therapy and pharmaceuticals, rather than being treated and/or 
cured (National Parkinson’s Foundation, 2004). The pattern of total expenditures and those 
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expenditures specific to Parkinson’s disease are illustrated in Figure 3.21 and listed in Table 
3.23. 
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FIGURE 3.21. PARKINSON’S DISEASE: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
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TABLE 3.23-PARKINSON’S DISEASE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 779.4796 171.8542 697
6 808.8793 215.6443 702
5 899.385 234.7422 700
4 876.6993 265.4056 693
3 1078.253 340.7946 701
2 1273.631 377.9488 709
1 1977.545 536.1833 705
0 2234.313 440.3613 689
    
Male 53.54   
Black 4.01   
Hispanic 0.4   
Age at death 79.41286  park 
 
 
Multiple Sclerosis (ICD-9 code 340) 
Multiple Sclerosis is an autoimmune disease affecting the central nervous system 
that is usually diagnosed between the ages of 20 and 50. It is a disruption or scarring on the 
myelin, the protective cover for the nerve fibers in the brain and spinal cord.  It currently 
afflicts between 350,000 and 500,000 Americans.  Only 10% of new diagnoses are made 
after age 65.  It is two to three times more common in women than in men.  The disease can 
be manageable at first, but as the patient ages the periods of remission decrease and the 
severity of the disability increases. Today, due to advancements in treatment options, this 
incurable disease still allows a patient a normal life expectancy pattern minus seven years 
(The Multiple Sclerosis Foundation, 2005). The pattern of total expenditures and those 
expenditures specific to multiple sclerosis are illustrated in Figure 3.22 and listed in Table 
3.24. 
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Multiple Sclerosis: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.22. MULTIPLE SCLEROSIS: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
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TABLE 3.24-MULTIPLE SCLEROSIS: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 1003.102 268.5977 109
6 1196.927 353.8864 107
5 1928.254 562.2959 101
4 1533.269 499.4747 106
3 1753.946 559.8756 110
2 1978.666 445.1169 106
1 2386.529 570.5417 112
0 3592.196 933.9864 110
    
Male 37.29   
Black 5.22   
Hispanic 1.74   
Age at death 63.03457  MS 
 
 
Muscular Dystrophy (ICD-9 code 359) 
Muscular dystrophy is a group of nine genetic, degenerative conditions that affect 
voluntary muscle control, although they are combined into one three-digit ICD-9 code and 
this work did not attempt to distinguish one from another. The nine types of muscular 
dystrophy have onset at different ages, from birth to late adulthood.  The majority of people 
affected by Muscular Dystrophy die before reaching the Medicare population age.  Specific 
variants more commonly affect individuals who could reach advanced age. Of particular 
interest to this research is the condition known as Distal Muscular Dystrophy which has an 
onset at 40 to 60 years of age or Amyotrophic Lateral Sclerosis (ALS) (Also known as Lou 
Gehrig's Disease) which usually affects adults.  As medical advance enables more of these 
people to reach older ages, the diagnosis will become more and more relevant to this 
research (Muscular Dystrophy Association website 2005). The pattern of total expenditures 
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and those expenditures specific to muscular dystrophy are illustrated in Figure 3.23 and 
listed in Table 3.25. 
 
 
Muscular Distrophy:Medicare Expenditures in Final 
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FIGURE 3.23. MUSCULAR DYSTROPHY: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
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TABLE 3.25-MUSCULAR DYSTROPHY: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 642.5296 73.9473 34
6 956.0851 180.2558 36
5 1697.59 355.0531 37
4 1681.079 144.2947 37
3 1740.884 116.1376 38
2 1554.309 345.6022 37
1 5617.672 1208.91 35
0 3927.507 413.1758 40
    
Male 66.67   
Black 2.22   
Hispanic 0   
Age at death 64.34028  MD 
 
 
 
Hip Fracture (ICD-9 code 820) 
 
Over one-third of older Americans age 65 or older fall each year and of those who 
fall, 20% to 30% suffer moderate to severe injuries such as hip fractures that reduce mobility 
and independence, and increase the risk of premature death (M.C. Hornbrook 1994; J.M. 
Hausdorff  2001; D.A. Sterling 2001). Among people ages 75 years and older, those who fall 
are nearly five times more likely to be placed in a long-term care facility for a stay of a year 
or more (I.P. Donald 1999).  Women sustain about 80% of all hip fractures (J.A. Stevens 
2000).  In 1999 in the United States, hip fractures resulted in approximately 338,000 hospital 
admissions (J.R. Popovic, 2001). The pattern of total expenditures and those expenditures 
specific to hip fracture are illustrated in Figure 3.24 and listed in Table 3.26. 
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Hip Fracture: Medicare Expenditures in Final Eight Quarters
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FIGURE 3.24. HIP FRACTURE: MEDICARE EXPENDITURES IN  
FINAL EIGHT QUARTERS 
 
 
 
TABLE 3.26-HIP FRACTURE: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 1227.312 403.2396 2544
6 1438.221 504.56 2568
5 1454.075 489.5794 2595
4 1557.56 523.9802 2609
3 1663.717 545.5047 2617
2 2055.197 678.7576 2660
1 3418.373 1286.431 2721
0 4272.15 1570.752 2758
    
Male 27.56   
Black 3.65   
Hispanic 0.35   
Age at death 83.28434  hip 
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Other  
Other consists of all ICD-9 codes net of the ones included above.  This was 
constructed by subtracting out expenditures for the codes above from an independent 
measure of total expenditures.  It is quite possible that some of the included spending was 
motivated by one the conditions above but that that condition was listed as a secondary 
diagnostic code for the covered procedure.  This category is not intended to be ripe for 
interpretation but to serve as a catch-all and perhaps a baseline or “average” profile. The 
pattern of total expenditures and those expenditures specific to other diseases are illustrated 
in Figure 3.25 and listed in Table 3.27. 
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FIGURE 3.25. OTHER: MEDICARE EXPENDITURES IN FINAL EIGHT QUARTERS 
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TABLE 3.27-OTHER: SUMMARY STATISTICS 
Quarter prior to 
death Total 
Disease 
Specific 
Observation
s 
7 841.5765 177.1004 8440
6 869.681 182.8368 8462
5 1015.42 222.2659 8393
4 1088.44 231.9564 8443
3 1261.917 276.1524 8403
2 1582.648 363.2562 8519
1 2297.092 487.8175 8775
0 3338.786 495.6446 9055
    
Male 40.48   
Black 9.99   
Hispanic 0.83   
Age at death 78.09937  other 
   
  
 
 The descriptive statistics on each disease represents the first contribution of the 
present work.  Only by stacking decedents on their time of death and then considering the 
expenditures path that got them to that point can useful analysis of the cost of dying begin.  
The patterns of expenditures for most diseases are quite similar in that they represent a 
person going from relatively good health up until their dying day.  The levels prior to death 
are in effect averaged across the experiences of all the decedents of each disease.  No one 
individual’s experience is likely to conform to the pattern presented.  They serve as an 
illustration of the path of expenditures both in disease and in total to give a visual impression 
of the cost of dying.  What can be observed from each is the relationship between in disease 
spending and in total spending and the changes in that relationship as death approaches.   
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 The underlying relationship between health and expenditure that these graphs and 
tables being to present are the subject of the econometric models in the chapters that follows. 
It is an open question whether the primary contribution of this work will come merely from 
the compilation of these statistics or from what econometric relationships can be revealed 
with the adopted procedure.  Taken together the statistics presented here and in the models 
developed in the next chapter serve as a reference for future targeted investigations on 
specific diseases or disease categories.  
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CHAPTER IV 
 
RESULTS 
 
 The design of the models undertaken in this work is intended to investigate several 
aspects of the costs of dying on Medicare. This section will be made up of three sets of 
models.  The goal of each model is to predict terminal period Medicare expenditures from 
expenditures made in prior periods. The models are designed to identify patterns that could 
potentially inform decisions about changes to the structure of Medicare repayment systems. 
The idea is that the models range from purely descriptive analyses of the data to 
specifications intended to establish whether or not the data can be used to forecast 
impending costs. It is hoped that these models can serve as a foundation for future work 
targeted at designing a repayment system that can efficiently provide ameliorative benefits 
as seniors enter their terminal periods. While the primary goal is simply to describe and 
further an understanding of the disease-specific cost profiles, the models are designed with 
particular forecasting thresholds in mind. The logic of the progression is directed at 
determining the level of detail which yields the most useful relationships.   
 The primary focus of the modeling in the work that follows is to establish the 
relationship between the path of expenditures leading up to death and the expenditures of the 
terminal period.  This is done at two levels. One set of models seeks to explain the 
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disease-specific expenditures, while the other focuses on the entire set of terminal period 
expenditures. While it is to be hoped that many models will reflect a tight and dependable 
relationship on which policy measures could be based, lack of a statistically significant 
relationship can be equally informative.   
 The initial descriptive model estimated for each disease focuses simply on the 
pattern of in-disease expenditure in the four quarters prior to the terminal period.  It is 
intended to focus on the period of time for which hospice services are presently available.  
Co-variates for each model include an indicator variable for sex, for race (black), as well as 
a discreet age variable assessed at the time of death.  It has been generally found that these 
demographic factors are strongly significant and they serve to ground the model in the prior 
literature. It is anticipated that the relationship between spending in these periods and the 
expenses in the terminal period will reflect the characteristic nature of the disease analyzed. 
For example, a disease such as septicemia is expected to show a strong relationship in the 
final period, but little earlier than that.  Chronic conditions such as diabetes are expected to 
be associated with a high level of persistence through out the terminal year.   
 The second set of models focus on in-disease spending in the final year averaged 
across four quarters prior to death.  Its unique characteristic is that it includes counts of 
specific treatments motivated by the disease which is ultimately estimated to cause death. 
Again, age at death, race and sex are included as co-variates. This specification is intended 
to investigate the relationship between major (expensive) interventions and total 
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expenditure versus the potential alternative of more frequent, less invasive procedures. It is 
naively expected that number of procedures will enter negatively in a model of terminal 
period expenditure after total in-disease expenditures are controlled.   
 The final model looks at total Medicare expenditures rather than disease-specific 
expenditures. A comparison of this set of models to the other sets will serve to suggest the 
relevance of the specific in-disease expenditure criterion used in the above models. It is 
expected that many diseases that ultimately cause the death of beneficiaries represent only 
the last straw in a long period of declining health. It is hoped the distinction between this set 
of models and the first set will differentiate diseases in an important manner. Given the fact 
that frailty is so poorly documented and many seniors lives with significant chronic illnesses 
for years prior to death, it is useful to distinguish between diseases that commonly “kill off” 
the frail, and those diseases which cause the death of people who otherwise have few claims. 
If it is the case that for a disease, total spending is a far more powerful predictor than 
in-disease spending that would argue that the disease in question could be associated with 
chronic poor health and that further specific study of its related expenditures would be of 
little use. If instead the in-disease spending is the primary driver of terminal period 
expenditures, it would seem to suggest that a stronger and clear picture can be defined.   
 For each disease the three models described above are estimated in the following 
manner.  The model of quarterly expenditure levels and the model of yearly averages with 
treatment counts are estimated with three distinct specifications. The need for the three 
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specifications comes from the nature of the death disease variables generated. In estimating 
the relationship between the pattern of expenditure prior to death and terminal period 
expenditure for colon cancer, the relevant population would of course be those people who 
die of colon cancer. Given the construction of the variables, it is unfortunately the case that 
many people who die at the time they do because they have colon cancer may well actually 
be flagged as having died of heart failure, stroke, or septicemia, etc. So many people who do 
not “die” of colon cancer will have positive levels of expenditure for colon cancer treatments 
(whether they survived it or not). In addition, the majority of individuals in the sample will 
have no expenditures for colon cancer in any particular quarter prior to death.  Thus, there 
are two problems with estimating the model.  The first problem is a muddy dependant 
variable and the second is a great many zeros in the independent variables.  The approach 
adopted to address these problems is to include three estimates of each model, OLS on the 
whole population, Tobit, and OLS only on decedents of the disease analyzed.  The third 
model uses total expenditures as a dependent variable.  The initial model in that set is 
common for all diseases and is presented first.  Within each disease, a Tobit model focusing 
on the expenditures in that disease and an OLS model on the decedents of that disease will 
be included.  
  The initial treatment is a simple OLS regression predicting terminal period 
expenditures using all persons in the sample. The OLS specification is not expected to be 
dependable due to the complication of a non-normal distribution in the independent 
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variables. It is likely that few men in the sample will have treatments for cervical cancer, for 
example. The fact that each disease will affect only a small segment of the sample generates 
a significant left-censoring of the expenditure distribution. OLS is included primarily as a 
baseline estimate.   
 Tobit analysis is intended to address the left-censoring problem. In most 
circumstances, this is probably the preferred estimator.  It has the property of correcting for 
the zero problem. A partial concern remains, however. It is possible for many diseases that 
small positive expenditures exist for people from testing, mislabeling, data errors or other 
reasons. It is also true that many people have net negative expenditures on their Medicare 
claims for particular diseases.  These represent rebates to correct for prior billing errors. It is 
a bit too strong to say that censoring exists at any expenditure level, because there are 
observations across the range, positive and negative. It is a drawback of the adopted 
approach that a blanket treatment for all diseases makes correcting for the problem 
unworkable at this level. In future work, diseases should be considered independently and 
the modeling procedure tailored to their particular characteristics. The intended contribution 
of the adopted methodology depends on a consistent approach across diseases, however. 
That said, the Tobit results are probably the most dependable but not without their problems. 
 A third set of estimates is a simple OLS on only those individuals who are flagged as 
having died of the disease in question. While this is likely to take care of the left-censoring 
problem in itself, it eliminates those people who have had positive levels of expenditure for 
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the disease, but are not listed as having died from it. As such, the conclusions drawn from the 
models must be very limited in application. It is certainly possible that a disease commonly 
co-morbid with other diseases with similar expenditure levels would suffer from such 
analysis. If it is largely a coin toss whether the decedent is classified as having died of a heart 
attack or a stroke, eliminating the expenditure profile of those who die of a heart attack from 
an understanding of the expenditure progression of victims of strokes will render the 
analysis biased and ineffective. 
 
Estimation Results 
 The following pages present and describe the results of the models outlined above in 
order of their prevalence in the data as a cause of death.  Given that many of the diseases 
have similar patterns of demise, in many cases emphasis will be placed on the differences 
between patterns rather than repeating the similarities. The focus of the analysis will be in 
comparing the results of the differing specifications to get a sense of the expenditure patterns 
within the disease and their correspondence to non-expenditure factors.   
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 One element at issues is the usefulness of adopted procedure for disaggregating 
expenditures into disease specific spending. For comparison, the first results presented cover 
total Medicare spending. The dependant variable in the initial model is total terminal period 
expenditures. The model seeks to explain variation in total terminal period expenditures 
with the path of total expenditures in the seven quarters prior, along with covariates. The 
results are assumed to be unique on their own, as no similar quarter-based modeling has 
been found in the existing literature. 
 The results in Table 4.1 confirm the general findings in the literature as well as the 
impression made by a casual inspection of the descriptive statistics. Total spending follows 
an upward trend up to the terminal period. Age at death is strongly negative. Increased age 
at death lowers terminal expenditures. Men incur higher levels of Medicare expenditure 
after controlling for age than women, and blacks have higher expenditures than whites. 
  
 
93
 
Full Sample 
 
 
TABLE 4.1-FULL SAMPLE HISTORY OF TOTAL SPENDING 
  
 Coeff Std. Err 
Total Spending t-1 0.166 0.0068
Total Spending t-2 -0.01 0.0092
Total Spending t-3 0.211 0.011
Total Spending t-4 0.348 0.0117
Total Spending t-5 0.258 0.13
Total Spending t-6 0.0341 0.0127
Total Spending t-7 0.0209 0.0126
Age at Death -61.65 3.37
Black 1323.2 123.5
Male 264.1 73
Cons 8713 285.4
   
Observations 62,829  
R^2 0.0385  
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 Heart Disease 
 
 
TABLE 4.2- HEART DISEASE: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
Heart disease OLS Tobit OLS on Decedents 
 Coeff Std. Err. Coeff 
Std. 
Err.  Coeff Std. Err.  
t-1 0.076 0.007 0.279 0.018 -0.04 0.019
t-2 0.029 0.001 0.169 0.025 -0.085 0.027
t-3 0.052 0.015 0.306 0.038 -0.13 0.041
t-4 0.016 0.014 0.192 0.035 -0.15 0.038
Age -5.65 0.951 2.26 2.95 -59.1 7.3
Black -24.33 35.15 267.16 105.7 32.9 250.6
Male 6.13 21.37 -22.52 65.38 -111.7 147.9
Cons 794.74 77.63 -5144.7 244.71 7233.1 598.4
       
Observations 58603  58603  7961  
Uncensored Obs 
(Tobit)   14459    
R^2 0.0032  0.0013  0.013  
LL   -162306    
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TABLE 4.3-HEART DISEASE: AVERAGE IN DISEASE SPENDING AND 
TREATMENT COUNTS IN FINAL YEAR 
Average In Disease Spending in Final Yr     
Heart disease       
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err
Expenditure Mean 0.0162 0.0033 0.143 0.0089 -0.084 0.014
Count Mean -9.87 1.28 -45.15 3.96 -69.38 8.98
Age Death -8.58 1.03 -9.57 3.2 -86.82 7.96
Black -26.99 35.14 265.68 105.82 -24.86 249.52
Male -6.99 21.43 -82.36 65.7     232.28 148.01
Cons 1181.96 92.78 -3563.2 290.18 10518.73 713.84
       
Observations 58676  58676  7961  
Uncensored Obs 
(Tobit)   14459    
R^2 0.0019  0.0011  0.0214  
LL   -162364    
  
 
 As shown in Table 4.2, more than one-third of the individuals in the sample had 
positive expenditures for heart disease as defined in this work during their final year of life, 
while only half as many are flagged as having died from it. The OLS model on all decedents 
finds a strong relationship between the in-disease expenditures leading up to death and the 
expenditures in the final period. The period four quarters prior to death is the only one 
without statistical significance. The Tobit model is similar in results but with much stronger 
statistical significance. Relative to many of the diseases that will be considered, the Tobit 
model for heart disease covers many more uncensored observations and thus has much more 
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foundation for the estimates. The OLS models run only on decedents of heart disease shows 
quite a different pattern. Contrary to the increasing pattern of expenditures found in the 
straight OLS and in the Tobit, it finds a negative relationship between past spending and 
terminal spending. This pattern would seem to suggest that individuals with a history of 
severe heart disease expire without significant medical interventions in the last quarter 
relative to individuals suffering from other conditions. This is reinforced by looking at the 
profile of individuals in the decedent regression. On average they are older and more likely 
to be male than the sample in the Tobit and OLS models.   
 The results of the model as shown in Table 4.3 for persistence in heart disease 
confirm the observation that those individuals that experience a high level of expenditure 
tend to persist at that high level.  The model finds that in the entire population, a high level 
of heart disease related expenditures in the year prior to the year of death is associated with 
increased expenditure in the terminal period.  The Tobit specification finds largely the same 
result. It would have been surprising to see this model contradict the model above in 
Tobit-OLS correspondence. OLS on decedents lends credence to the argument above that 
people with “terminal” heart disease may receive less invasive procedures in their last 
quarter. As with other models, the OLS on decedents specification is an exception to that 
finding, with decedents form heart diseases having lower terminal period costs.  It is  
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interesting to find that a reduction in the number of treatments for heart disease in quarters 
prior to the terminal period results in lower terminal period expenditures. This could simply 
be an indication that some individuals in the sample receive fewer medical services 
throughout their demise, and thus have lower costs. It would be plausible to suspect, 
however, that those receiving fewer treatments early on might need more invasive 
treatments later. The evidence suggests the prior explanation may carry more weight as 
regards heart disease. 
 In Table 4.4, the OLS specification finds a pattern for heart disease that is similar to 
that aggregated total spending, but the relationship is significantly weaker. By casual 
inspection, it seems logical that many people who die due to heart disease in later years may 
well have a long history of medical expenditures leading up to the terminal period.  For 
individuals who are very frail in later life, heart disease may well cause their death when few 
interventions are recommended.  Getting them to that point, though, could likely have 
required a significant level of total medical expenditures in prior years.   
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TABLE 4.4-HEART DISEASE: HISTORY OF TOTAL SPENDING 
 Tobit 
OLS on 
Decedents 
 Coeff 
Std 
Err Coeff 
Std. 
Err 
Total Spending t-1 0.235 0.028 0.192 0.02
Total Spending t-2 -0.047 0.040 -0.064 0.026
Total Spending t-3 0.068 0.049 -0.034 0.038
Total Spending t-4 0.11 0.051 -0.0084 0.039
Total Spending t-5 -0.06 0.051 -0.018 0.042
Total Spending t-6 0.023 0.054 0.05 0.036
Total Spending t-7 0.019 0.013 0.032 0.041
Age Death -53 3.5 -96.09 12.28
Black 1348.9 128.82 400.07 424.52
Male 315.37 75.82 122.49 242.95
Cons 7767.33 296.88 12601.92 1027.2
     
Observations 42581  5241  
Uncensored Obs 
(Tobit) 40648    
R^2 0.0018  0.0434  
LL -422917    
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Heart Failure 
 
TABLE 4.5-HEART FAILURE: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
Heart Failure  428       
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.15 0.006 0.42 0.013 0.017 0.0172 
t-2 0.09 0.0083 0.29 0.02 -0.04 0.025 
t-3 0.12 0.01 0.36 0.023 -0.04 0.03 
t-4 0.084 0.009 0.244 0.02 -0.012 0.03 
Age -0.21 0.52 17.63 1.53 -28.24 4.29 
Black -7.92 19.09 -117.2 55.87 122.48 151.93 
Male 15.74 11.60 -28.33 33.47 179.37 91.55 
Cons 197.46 42.13 -3887 127.8 3734.25 359.88 
       
Observations 58603  58603  6781  
Uncensored Obs (Tobit)  15685    
R^2 0.0267  0.0081  0.0089  
LL   -164227    
 
  
 As shown in Table 4.5, heart failure exhibits an expenditure pattern similar to that of 
heart disease. People who passed away from heart failure were a bit older than average, more 
likely to be white and less likely to be male. The sample used in the Tobit was one year older 
than the total sample on average, and those flagged as decedents were one year older still. 
The OLS model shows a steadily increasing level of expenditure to the terminal period.  
Interestingly, none of the demographic covariates are found to have statistical significance. 
The Tobit model, in contrast, finds a steeper expenditure slope as well as some strong results 
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for the age and racial indicator variables.  The age at death coefficient is strongly negative. 
The OLS model run only on decedents of heart failure shows little of interest other than a 
strong negative effect from age at death.   
 
TABLE 4.6-HEART FAILURE: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
Average In Disease Spending in Final Yr     
Heart Failure 
428       
 OLS Tobit 
OLS on 
Decedents 
 Coeff Std. Err Coeff Std Err Coeff Std. Err 
Expenditure 
Mean 0.056 0.0023 0.21 0.0055 -0.018 0.0085
Count Mean -5.97 0.7 -17.53 2.05 -44.19 5.46
Age at Death -1.60 0.56 14.54 1.68 -44.43 4.66
Black -9.39 19.23 -125.45 56.56 85.81 151.32
Male 11.20 11.73 -30.27 34.01 97.89 91.51
Cons 417.76 50.75 -3367.1 153.65 5749.58 427.59
       
Observations 58676  58676  6781  
Uncensored Obs (Tobit)  15685    
R^2 0.0109  0.0047  0.0191  
LL   -164809    
 
 
 
The results of the expenditure mean model shown in Table 4.6 require some 
consideration. There is a strong indication that patients who receive more treatments 
experience lower levels of terminal period expenditure.  In all other respects, there is 
contradiction between the findings. OLS and Tobit models find a positive relationship 
between pre-terminal and terminal expenditures, while the OLS on decedents model finds 
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the opposite. The most plausible reason for the disparity is the difference in mean age in the 
samples. The decedents group was the oldest, and the strong age at death result indicates that 
older people receive less expensive treatments in their terminal year.  If the pattern extends 
back to prior periods, a group of older heart failure patients would have lower expenditures 
both in the terminal and pre-terminal periods. 
 
 
TABLE 4.7-HEART FAILURE: HISTORY OF TOTAL SPENDING 
History of total spending    
428     
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err
Total Spending t-1 0.179 0.019 0.151 0.019
Total Spending t-2 0.02 0.02 -0.014 0.027
Total Spending t-3 0.03 0.034 0.077 0.032
Total Spending t-4 0.047 0.035 0.102 0.031
Total Spending t-5 -0.022 0.037 -0.005 0.036
Total Spending t-6 0.026 0.036 -0.013 0.034
Total Spending t-7 0.019 0.013 -0.014 0.035
Age at Death -52.99 3.5 -76.43 9.54
Black 1348.9 128.3 591.3 331.95
Male 315.37 75.82 196.34 195.04
Cons 7767.33 296.88 9995.1 822.11
     
Observations 42581  5241  
Uncensored Obs 
(Tobit) 40648    
R^2 0.0018  0.0434  
LL -422917    
  
 The path of total spending shown in Table 4.7 for heart failure patients is entirely 
similar to that of the full sample. There are no contradictions between the Tobit and OLS on 
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decedents model, though the decedents model is considerably better at explaining variations 
in terminal period expenditures. 
 
Breast Cancer 
 
 
TABLE 4.8-BREAST CANCER: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
174       
 OLS Tobit OLS on Decedents
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.379 0.004 1.236 0.048 0.242 0.035
t-2 0.068 0.008 0.513 0.088 -0.035 0.067
t-3 0.084 0.008 0.348 0.095 0.051 0.074
t-4 0.007 0.009 0.458 0.096 -0.105 0.072
Age -0.277 0.085 -18.735 2.758 -0.506 4.869
Black 2.249 3.168 -81.884 103.327 236.069 178.557
Male -18.817 1.930 -2905.832 166.287 -108.980 560.175
Cons 39.900 6.968 -2872.166 228.574 812.508 379.086
       
Observations 60214  60214  960  
Uncensored Obs 
(Tobit)   1195    
R^2 0.1907  0.1096  0.0552  
LL   13691.353    
 
 Breast cancer, as shown in Table 4.8, exhibits a significant upward trend in 
in-disease expenditures to the terminal period. The path increases steeply in the period just 
prior to the terminal period.  All three specifications concur in the relationship existing and 
generally agree in the slope of the path. The OLS model on decedents finds little, 
presumably due to the very low number of decedents.  It is probable that given the large 
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difference in strength between the Tobit and the OLS on decedents models that breast cancer 
is present for many individuals who are flagged as having died of something else. It is 
unclear at this point what diseases are commonly co-morbid with breast cancer.  Further 
research using the present data may well be warranted on the topic. 
 
 
 
TABLE 4.9-BREAST CANCER: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
Average In Disease Spending in 
Final Yr      
       
 OLS Tobit OLS on Decedents
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.046 0.001 0.288 0.014 0.001 0.009
Count Mean -1.114 0.124 -60.906 4.533 -15.253 6.647
Age Death -0.770 0.101 -46.670 3.447 -6.946 5.392
Black 2.139 3.460 -87.068 118.265 282.436 182.511
Male -33.022 2.111 -3982.717 209.687 -295.165 572.320
Cons 116.223 9.083 -482.486 287.071 1713.594 454.707
       
Observations 60265  60265  960  
Uncensored Obs 
(Tobit)   1195    
R^2 0.0335  0.0689  0.0089  
LL   -14318.018    
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As is the case with the quarterly observations as shown in Table 4.9, the annual means 
predict that higher than average expenditures prior to the terminal period predict higher than 
average terminal expenditures in the terminal disease. The OLS on the full sample and the 
Tobit model find particularly strong indications of the relationship.  The OLS on decedents 
specification finds no significant relationship between pre-terminal expenditures and 
terminal expenditures. In contrast to the pattern found in heart disease, the decedents from 
breast cancer are younger than the general sample.  The age at death variable is weak among 
decedents, most likely a result of the age distribution. Treatment counts are strongly 
negative in all specifications.  Race shows little relation to terminal period expenditures. The 
strength of the sex indicator variable is most likely not important for policy consideration. 
Less than one percent of breast cancer patients in the sample were men.   
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TABLE 4.10-BREAST CANCER: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.196 0.04 0.22 0.049 
Total Spending t-2 0.042 0.07 -0.102 0.07 
Total Spending t-3 -0.075 0.093 -0.09 0.9 
Total Spending t-4 -0.0005 0.098 0.014 0.1 
Total Spending t-5 0.004 0.105 -0.003 0.046 
Total Spending t-6 0.111 0.124 -0.023 0.107 
Total Spending t-7 -.0293 0.112 -0.056 0.097 
Age Death -48.28 14.46 -50.37 17.9 
Black 1344.98 534.44 -197.44 613.62 
Male -1073.31 394.67 2203.1 2098 
Cons 6638.88 1244.34 7001.781 1461.09 
     
Observations 42581  657  
Uncensored Obs (Tobit) 40648    
R^2 0.0018  0.0461  
LL -422916.71    
 
  
 The history of total spending, as distinct from in-disease spending, has no clear 
relationship with total terminal period expenditures, as shown in Table 4.10.  The common 
findings on age at death, sex, and race continue here.   
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Skin Cancer 
 
TABLE 4.11-SKIN CANCER: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
172       
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff Std. Err. 
t-1 0.341 0.003 1.378 0.121 0.258 0.075
t-2 0.015 0.005 0.749 0.175 -0.114 0.113
t-3 0.313 0.006 1.128 0.218 0.250 0.131
t-4 0.492 0.010 2.152 0.310 0.305 0.184
Age 0.023 0.020 -0.445 3.734 13.088 7.682
Black -0.209 0.742 -378.848 183.933 3175.887 976.289
Male 0.745 0.450 366.204 88.117 105.821 180.166
Cons -1.139 1.628 -4534.614 412.479 -572.665 625.626
       
Observations 60214  60214  134  
Uncensored Obs (Tobit)  195    
R^2 0.2983  0.1057  0.2077  
LL   -2489.7857    
 
  
 As evidenced by the paucity of observations in the OLS on decedents model as 
shown in Table 4.11, very few individuals were flagged as having died from skin cancer in 
the sample. The strength of the results in the OLS model indicate that positive levels of skin 
cancer-related spending are highly predictive of higher terminal period expenditures. Skin 
cancer decedents are younger than is average for the total sample, significantly less likely to 
be black, and more likely to be male.  Fully 65% of skin cancer decedents are men. The 
expenditure path leading up to the terminal period is consistent and well-defined. None of 
the demographic variables were found to have a significant impact on terminal year 
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expenditures. The OLS and the Tobit models exhibit strong results for the expenditure path 
while the OLS on decedent model does not. This is probably because if the fact that there are 
so few decedents from skin cancer in the sample. 
 
 
 
TABLE 4.12-SKIN CANCER: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
Average In Disease Spending 
in Final Yr      
Skin Cancer 172       
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.105 0.002 1.176 0.109 -0.008 0.047
Count Mean -0.106 0.031 -29.000 6.654 -15.918 10.444
Age Death -0.041 0.025 -15.480 5.052 4.829 8.507
Black -1.381 0.869 -743.143 262.175 2888.013 1037.648
Male 1.140 0.529 507.493 117.545 124.237 188.420
Cons 6.152 2.280 -4636.632 532.044 506.035 721.707
       
Observations 60265  60265  134  
Uncensored Obs 
(Tobit)   195    
R^2 0.0352  0.0429  0.094  
LL   -2664.7578    
 
 
  
 As shown in Table 4.12, early average expenditures are confirmed to have a strong 
positive influence on terminal in disease expenditure for skin cancer. The OLS and Tobit 
models agree while the OLS on decedents model is inconclusive. Treatment counts are 
found to be a strongly negative predictor of terminal period expenditures. The Tobit finds 
  
 
108
 
age at death to be significantly negative in its effect though both OLS models find no 
significance. The Tobit is unique in finding that blacks have lower terminal period 
expenditures for skin cancer. Men appear to incur higher costs.   
 
 
 
TABLE 4.13-SKIN CANCER: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 .01 .13 -.11 .123 
Total Spending t-2 .22 .16 .079 .093 
Total Spending t-3 .15 .18 .295 .189 
Total Spending t-4 -.19 .19 .024 .14 
Total Spending t-5 -.04 .19 .93 .116 
Total Spending t-6 .62 .29 -.17 .278 
Total Spending t-7 -.19 .33 -.083 .19 
Age Death -16.5 22.3 1.77 31.7 
Black 3362.8 855.4 7916 3072.7 
Male 271.6 503. -824.3 702.8 
Cons 2525.9 2032 2980.8 2609.8 
     
Observations 604  82  
Uncensored Obs 
(Tobit) 556    
R^2 .0029  .17  
LL -5643.1    
 
  
 Past observations of total Medicare expenditures have little predictive power for 
terminal period expenditures among skin cancer patients. In contradiction to the above 
model shown in Table 4.13, both the Tobit and OLS on decedents find that blacks with 
positive expenditures for skin cancer treatments have significantly higher terminal period 
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expenditures.  
 
Cancer of the Larynx 
 
 
 
TABLE 4.14-CANCER OF THE LARYNX: IN DISEASE EXPENDITURES  
IN YEAR OF DEATH 
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err.  Coeff Std. Err.  Coeff Std. Err. 
t-1 0.302 0.005 1.619 0.183 0.166 0.113
t-2 -0.059 0.005 0.638 0.163 -0.129 0.107
t-3 0.129 0.006 1.274 0.213 -0.010 0.134
t-4 -0.001 0.006 1.032 0.237 -0.175 0.137
Age -0.098 0.071 -47.491 14.150 -1.049 36.184
Black 0.340 2.646 760.131 474.730 -423.002 1031.475
Male 5.811 1.606 2838.139 438.868 1629.775 971.110
Cons 7.865 5.808 -14851.310 1505.290 476.911 2695.546
       
Observations 60214  60214  131  
Uncensored Obs 
(Tobit)   155    
R^2 0.06  0.712  0.0035  
LL   -2225.5909    
 
 
  
 Cancer of the larynx is typified by an unusual expenditure path relative to other 
cancers.  The OLS model as shown in Table 4.14 reveals a significant negative impact on 
terminal period expenditure from expenditures two quarter prior to death. The quarter 
immediately prior to death is found to be strongly positive. Men are found to have higher 
levels of expenditures and they make up almost 85 % of the population. Decedents are 
  
 
110
 
almost four years younger than the general sample, and significantly more likely to be black. 
There is no indication that race or age at death significantly changes the level of terminal 
period expenditures.   
 
 
TABLE 4.15-CANCER OF THE LARYNX: AVERAGE IN DISEASE SPENDING AND 
TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.042 0.002 1.167 0.114 -0.085 0.071
Count Mean -0.202 0.097 -102.637 22.100 4.041 43.404
Age Death -0.175 0.079 -72.260 15.864 -4.127 40.400
Black 1.273 2.720 1192.875 492.370 -561.450 1031.985
Male 6.378 1.656 3144.114 480.464 1401.511 977.063
Cons 16.985 7.137 -13062.260 1615.893 1027.836 3299.880
       
Observations 60265  60265  131  
Uncensored Obs 
(Tobit)   155    
R^2 0.0059  0.0614  0.0319  
LL   -2249.0396    
 
  
 Yearly average expenditures indicate higher levels of expenditure toward laryngeal 
cancer are associated with higher terminal period expenditures. This is consistent across the 
OLS and Tobit models, though the OLS model on decedents is inconclusive in this regard 
(as well as in all other things). Looking at Table 4.15, higher number of treatments for the 
disease led to lower terminal expenditures while age at death is also strongly negative. 
Blacks are found to have higher expenditures in the Tobit and men are found to have more 
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expenditures in both models.   
 
 
 
TABLE 4.16-CANCER OF THE LARYNX: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff 
Std 
Err Coeff Std. Err 
Total Spending t-1 .37 .12 .285 .166 
Total Spending t-2 -.04 .15 -.28 .22 
Total Spending t-3 -0.54 .245 -.095 .21 
Total Spending t-4 .068 .163 -.058 .16 
Total Spending t-5 .28 .242 .106 .20 
Total Spending t-6 -.14 .158 -.18 .17 
Total Spending t-7 .30 .242 .18 .40 
Age Death -28.82 26.01 -14.3 100.23 
Black 3042. 935.4 -357.3 3309.5 
Male 1000.9 579.7 3218.11 2313.3 
Cons 3347.8 2368.9 3025.5 7343 
     
Observations 582  84  
Uncensored Obs 
(Tobit) 534    
R^2 .0036  .078  
LL -5482.18    
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The history of total spending shown in Table 4.16 suggests little about terminal period 
expenditures for laryngeal cancer. High costs one quarter prior to the terminal period 
positively influence terminal period expenditures. Blacks are found to have higher 
expenditures than whites.  Little else can be deduced.  
 
 
 
Cervical Cancer 
 
 The results for the in disease expenditure path as shown in Table 4.17 are a bit of a 
puzzle. In general they suggest a strong level of persistence in treatment costs. The models 
are particularly strong relative to other cancers. The anomaly that stands out is the 
coefficient on expenditures in the OLS model three quarters prior to death. It suggests a 
statistically significant inverse relationship between expenditures in that period for cervical 
cancer and terminal expenses. This is opposed to the rest of the path and to the findings of 
the Tobit model. It is likely best not to speculate as to the cause of the unusual finding at this 
time. It may well prove interesting in future work. There is considerable evidence that men 
who die from cervical cancer do so cheaply. It is most likely the result of data error. 
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TABLE 4.17-CERVICAL CANCER: IN DISEASE EXPENDITURES 
 IN YEAR OF DEATH 
180       
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.114 0.003 0.873 0.136 0.046 0.066
t-2 0.323 0.004 0.300 0.165 0.360 0.090
t-3 -0.060 0.005 0.702 0.237 -0.176 0.164
t-4 0.228 0.006 0.691 0.244 0.207 0.144
Age -0.008 0.019 -15.715 6.395 2.258 8.429
Black 1.312 0.699 383.849 208.058 492.171 364.549
Male -1.168 0.424 -2115.235 409.187 647.616 672.670
Cons 1.770 1.535 -4809.839 647.258 195.827 641.581
       
Observations 60214  60214  90  
Uncensored Obs 
(Tobit)   98    
R^2 0.333  0.107  0.3356  
LL   -1327.7623    
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TABLE 4.18-CERVICAL CANCER: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
Average In Disease Spending 
in Final Yr      
180       
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff 
Std. 
Err 
Expenditure Mean 0.03 0.001 0.36 0.07 0.03 0.07
Count Mean -0.09 0.30 -51.37 12.51 8.95 17.45
Age Death -0.08 0.02 -39.22 9.05 -3.74 10.91
Black 0.92 0.85 415.54 277.54 328.04 422.31
Male -2.41 0.52 -3190.50 584.14 411.58 810.63
Cons 9.98 2.24 -4336.92 834.11 818.76 919.67
       
Observations 60265  60265  90  
Uncensored Obs 
(Tobit)   98    
R^2 0.0077  0.0544  0.0208  
LL   -1406.0242    
  
 
 Yearly averages indicate high level of persistence in cervical cancer expenditure. 
The findings, shown in Table 4.18, also demonstrate that a higher number of treatments 
results in lower levels of expenditure. Age at death enters in a strongly negative fashion.  
The results on race are inconclusive.  
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TABLE 4.19-CERVICAL CANCER: HISTORY OF TOTAL SPENDING  
History of total 
spending     
180     
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 .358 .14 .204 .143 
Total Spending t-2 .052 .19 -.101 .178 
Total Spending t-3 -.100 .27 -.056 .193 
Total Spending t-4 .15 .42 -.088 .263 
Total Spending t-5 .31 .64 -.66 .519 
Total Spending t-6 -.04 .44 -.200 .435 
Total Spending t-7 -.32 .58 .106 .599 
Age Death -31.3 23.62 -99.14 44.1 
Black 3145.6 854.4 1579.9 1485.1 
Male -65.63 548.6 -1181.1 3543.1 
Cons 3900.6 2146.1 11796 3608.4 
     
Observations 559  47  
Uncensored Obs 
(Tobit) 511    
R^2 .0032  .27  
LL -5206.7    
 
  
 As is the case with most cancers, history of total spending, as shown in Table 4.19, 
suggests little about terminal period expenditures. The OLS on decedents model seems to 
control well for the level of expenditure in terms of R-squared. It is most likely the result of 
little variance in those terminal expenditures.  
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Prostate Cancer 
 
 
 
TABLE 4.20-PROSTATE CANCER: IN DISEASE EXPENDITURES IN  
YEAR OF DEATH 
185       
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff Std. Err. 
t-1 0.462 0.005 1.329 0.045 0.344 0.037
t-2 0.118 0.007 0.384 0.056 0.068 0.047
t-3 0.075 0.008 0.428 0.064 -0.007 0.053
t-4 -0.027 0.009 0.521 0.072 -0.142 0.065
Age 0.195 0.094 26.351 2.448 -9.413 4.757
Black 19.110 3.479 510.179 72.165 340.712 121.347
Male 22.612 2.128 3362.047 184.621 71.501 1089.553
Cons -17.386 7.637 -8762.328 312.682 1215.620 1148.277
       
Observations 60324  60214  1396  
Uncensored Obs 
(Tobit)   1744    
R^2 0.2169  0.1243  0.0914  
LL   -18929.956    
 
  
 
 The path of expenditures for prostate cancer, as shown in Table 4.20, becomes 
significantly positive at least nine months prior to the terminal period. The specifications 
contradict each other in sign, though not in significance of costs a year prior. The typical age 
at death from prostate cancer is roughly a year older than the sample average and patients are 
more likely to be black. Blacks are found to have higher costs.  The older a prostate cancer 
patient is the fewer and less costly are the treatments they receive.  
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TABLE 4.21-PROSTATE CANCER: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
Average In Disease Spending 
in Final Yr      
185       
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.069 0.001 0.479 0.015 -0.002 0.012
Count Mean -0.783 0.137 -29.096 3.486 -13.209 5.589
Age Death 0.164 0.112 25.074 3.067 -18.237 5.563
Black 23.313 3.830 629.435 84.920 358.218 126.283
Male 36.786 2.355 4175.175 224.110 398.005 1133.564
Cons -3.702 10.060 -9650.175 392.850 2048.035 1222.417
       
Observations 60265  60265  1396  
Uncensored Obs 
(Tobit)   1744    
R^2 0.0492  0.0932  0.0009  
LL   -19601.583    
 
  
 The models at the level of yearly expenditures largely, shown in Table 4.21, confirm 
the findings done at the quarterly level. Blacks are confirmed as incurring distinctly high 
costs. A higher number of treatment counts appear to result in lower levels of terminal 
period expenditure. In total, the yearly observation do a much poorer job than do the 
quarterly ones which makes prostate cancer distinctly different than many other diseases.  
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TABLE 4.22-PROSTATE CANCER: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 .117 .037 .085 .043 
Total Spending t-2 .0317 .056 -.003 .054 
Total Spending t-3 .034 .065 .0675 .068 
Total Spending t-4 .182 .057 .205 .055 
Total Spending t-5 .130 .073 .031 .081 
Total Spending t-6 -.0759 .073 .002 .084 
Total Spending t-7 -.017 .074 -.04 .067 
Age Death -27.26 14.34 .538 16.8 
Black 1656.5 420.7 1222.4 453.7 
Male 1485.9 373.3 2203.9 3101.4 
Cons 3681.6 1313.13 450.9 3358.8 
     
Observations 1420  982  
Uncensored Obs (Tobit) 1372    
R^2 .0042  .0419  
LL -13667    
 
  
 As shown in Table 4.22, there appears to be a steady positive relationship between 
total expenditures in the quarters leading up to death and death-related costs among prostate 
cancer patients. The remainder of the results of these models simply confirms the picture 
outlined by other specifications and those of the general findings in other literature. 
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Bladder Cancer 
 
 
TABLE 4.23-BLADDER CANCER: IN DISEASE EXPENDITURES IN 
YEAR OF DEATH 
188       
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff Std. Err. 
t-1 0.172 0.003 0.882 0.056 0.091 0.038
t-2 0.098 0.007 1.274 0.116 -0.049 0.082
t-3 0.230 0.007 1.238 0.104 0.111 0.074
t-4 0.109 0.009 1.249 0.142 -0.061 0.099
Age 0.197 0.110 35.515 7.054 3.784 14.076
Black -2.865 4.076 -719.097 289.196 24.449 603.098
Male 8.890 2.474 1592.720 161.417 239.112 303.021
Cons -11.524 8.947 -13983.080 750.718 782.734 1180.637
       
Observations 60214  60214  496  
Uncensored Obs 
(Tobit)   591    
R^2 0.0922  0.0727  0.0173  
LL   -7665.0347    
 
  
 
 As shown in Table 4.23, bladder cancer appears to exhibit a steady positive path of 
persistence in expenditures with higher level of costs at any point in the year prior to death 
associated with higher terminal period expenditures. Age at death positively influences 
terminal period expenditures, contrary to the normal finding. Blacks are found to have 
normal expenditures in the Tobit model. Men make up the majority of cases and are 
associated with higher expenditures. 
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TABLE 4.24-BLADDER CANCER: AVERAGE IN DISEASE SPENDING AND 
TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.109 0.002 0.974 0.048 0.035 0.032
Count Mean -0.526 0.150 -44.198 9.267 -23.387 17.589
Age Death 0.002 0.122 17.335 7.841 -6.601 15.731
Black -4.207 4.194 -844.515 305.702 7.678 603.079
Male 8.629 2.555 1577.134 169.453 145.317 304.149
Cons 13.403 11.002 -12696.690 834.309 2046.392 1407.052
       
Observations 60265  60265  496  
Uncensored Obs 
(Tobit)   591    
R^2 0.038  0.0476  0.0061  
LL   -7873.0268    
 
  
 
 As is typical with other cancers, higher expenditures prior to death are related to 
higher terminal period expenditures, as shown in Table 4.24. In addition, the common 
finding that increased levels of treatment numbers are associated with lower expenditures 
holds for bladder cancer as well. There is evidence incur lower expenditures, while men 
generate higher costs.  
 
  
 
121
 
 TABLE 4.25-BLADDER CANCER: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 .33 .072 .153  
Total Spending t-2 .126 .12 -.031  
Total Spending t-3 -.024 .12 .007  
Total Spending t-4 .068 .13 -.217  
Total Spending t-5 .282 .16 .457  
Total Spending t-6 .023 .15 -.087  
Total Spending t-7 .332 .13 .262  
Age Death -40.6 22.6 -20.8  
Black 2006.7 850.7 145.9  
Male 876.1 491.9 1016  
Cons 4815.5 2042.6 4381.8  
     
Observations 820  335  
Uncensored Obs 
(Tobit) 772    
R^2 .0060  .076  
LL -7925.65    
 
  
 The profile of total expenditures prior to death, as shown in Table 4.25, bears little 
relation to in disease terminal spending. For decedents of bladder cancer, the demographic 
impacts are the same as for the general sample.    
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Lung Cancer  
 
 
TABLE 4.26-LUNG CANCER: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff Std. Err. Coeff Std. Err. Coeff 
Std. 
Err.  
t-1 0.265 0.006 1.37 0.03
     
-.055 0.02
t-2 0.13 0.009 0.99 0.05 -0.13 0.03
t-3 0.075 0.009 0.47 0.04 -0.05 0.03
t-4 0.056 0.012 0.71 0.06 -0.15 0.04
Age -2.474 0.038 -50.39 3.66 -0.76 7.23
Black -17.372 -14.12 -581.22 138.53 264.71 214.55
Male 43.585 8.57 896.22 81.00 8.94 123.94
Cons 279.524 31.1 -4494.07 295.45 2456.38 553.30
       
Observations 60214  60214  3675  
Uncensored Obs 
(Tobit)   4647    
R^2 0.05  0.0438  0.0124  
LL   -54,372.137    
  
 As shown in Table 4.26, lung cancer decedents follow an expenditure path that is 
similar to other cancers with a very strong increase in expenditures approaching death. Age 
at death is distinctly negative in its impact on in disease terminal expenditures. Men are over 
represented in decedents and have significantly higher costs. Blacks typically incur lower 
terminal expenditures for lung cancer contrary to the general finding in other diseases. The 
results for lung cancer should be viewed in the light that it is the disease that motivated a 
significant portion of hospice admissions. The expenditure pattern for lung cancer may well 
be atypical in the absence of hospice and only through hospice be brought down.   
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TABLE 4.27-LUNG CANCER: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit OLS on Decedents
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.098 0.004 0.764 0.023 -0.077 0.017
Count Mean -6.828 0.516 -109.060 5.009 -30.656 7.602
Age Death -5.461 0.421 -94.856 4.021 -16.300 8.267
Black -22.769
14.39
9 -629.654 140.614 242.571 
214.46
0
Male 45.072 8.767 933.452 83.038 -36.689 
124.19
2
Cons 
640.50
4
37.81
4 493.332 339.204
3878.20
3 
681.10
3
       
Observations 60265  60265  3675  
Uncensored Obs (Tobit)   4647    
R^2 0.015  0.0206  0.0115  
LL   
-55695.46
5    
 
  
 In general, the models, shown in Table 4.27, describing lung cancer terminal 
expenditures are relatively weak.  The yearly averages confirm the positive association 
between prior and terminal expenditures as well as the strong negative age at death impact. 
Blacks are confirmed to have lower costs and men are found to be particularly expensive. 
Men make up roughly 60% of decedents in the sample.  Treatment counts continue to exhibit 
a negative impact. This may well argue against the efficacy of the hospice program in 
reducing expenditures. The reason for this is that hospice expenditures are not itemized 
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under Medicare as are other treatments. A high number of treatments indicates that the 
patient is likely not in the hospice program for much of the time prior to death. While crude, 
the evidence from the coefficient on treatments suggests hospice may not be a low cost 
alternative. 
  
TABLE 4.28-LUNG CANCER: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.107 0.029 0.052 0.03 
Total Spending t-2 0.0084 0.04 -0.043 0.041 
Total Spending t-3 -0.06 0.045 -0.047 3.037 
Total Spending t-4 0.027 0.052 -0.022 0.041 
Total Spending t-5 0.045 0.054 -0.061 0.051 
Total Spending t-6 0.075 0.049 -0.64 0.056 
Total Spending t-7 -0.108 0.058 -0.12 0.057 
Age Death -85.62 12.38 -31.63 15.09 
Black 1197.6 417.55 457.68 444.5 
Male 384.94 229.93 442.96 244.3 
Cons 10443.9 1025.43 6632.23 1194.3 
     
Observations 2786  2040  
Uncensored Obs 
(Tobit) 2738    
R^2 0.0019  0.0124  
LL -27737.49    
 
  
 The path of total spending for lung cancer, as shown in Table 4.28, suggests no clear 
picture about the determinates of terminal period expenditures.  In disagreement with the 
other specification, total spending indicates that blacks experience higher costs than whites 
even among lung cancer decedents. Little else is clear from looking at total spending. The 
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hospice impact on total spending may be stronger than the expenditure specifically related to 
lung cancer. The result would be a significant hospice bill for lung cancer, but almost no 
other spending as per hospice program procedures.  
 
Colorectal Cancer 
 
TABLE 4.29-COLORECTAL CANCER: IN DISEASE EXPENDITURES IN  
YEAR OF DEATH 
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err.  Coeff Std. Err. Coeff Std. Err. 
t-1 0.118 0.005 1.104 0.021 -0.070 0.030
t-2 0.105 0.009 1.495 0.077 -0.168 0.049
t-3 0.068 0.010 1.112 0.087 -0.140 0.056
t-4 0.120 0.013 1.621 0.103 -0.163 0.067
Age -0.292 0.380 -1.395 7.624 -8.343 12.855
Black -4.987 14.136 -296.286 283.764 40.595 430.977
Male 1.830 8.578 263.478 167.288 73.020 246.917
Cons 87.780 31.042 -15453.19 685.800 3406.870 1037.954
       
Observations 60214  60214  1904  
Uncensored Obs (Tobit)  2035    
R^2 0.0167  0.038  0.0171  
LL   -26134.76    
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 Colorectal cancers present a puzzle. With roughly 2000 decedents in the sample, 
they represent a single cause of death ripe for analysis. The models above in Table 4.29 yield 
an inconsistent picture. The contradiction between the Tobit model and the OLS model on 
decedents is striking.  The characteristics of the sample which support the models are 
essentially identical. It may well be the case that significant levels of diagnostic testing for 
colorectal cancer among Medicare beneficiaries generate many observations with small 
positive claims for colorectal cancer treatment. This remains to be investigated. Among 
decedents, higher levels of claims during the year prior to death are associated with high 
terminal period claims in the Tobit specification and lower levels of claims in the OLS on 
decedents. The fact that the OLS on the total sample agrees with the Tobit lends credence to 
the explanation posited, though in no way proves the conjecture.   The models demonstrate 
no significance of race, sex, or age in terminal period expenditures.   
 The unusual contradiction between the OLS and the Tobit models continues even at 
the yearly level, as shown in Table 4.30. Decedents appear to have lower terminal period 
costs than do the general population who have some positive treatment for colorectal cancer. 
A comparison of the intercept terms of the OLS models further suggests there may be 
something to the colorectal screening hypothesis. Age at death has a negative impact in the 
OLS and Tobit models, though not in an otherwise strong OLS on decedents model. 
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TABLE 4.30-COLORECTAL CANCER: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff Std. Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.06 0.003 1.05 0.03 -0.13 0.02
Count Mean -2.47 0.51 -116.97 10.27 -1.37 15.21
Age Death -1.10 0.41 -36.49 8.17 -13.60 14.22
Black -6.46 14.21 380.84 286.14 82.48 430.52
Male -4.28 8.65 -72.21 169.03 122.37 247.04
Cons 196.37 37.28 -11068.82 755.24 3983.14 1233.77
       
Observations 60265  60265  1904  
Uncensored Obs (Tobit)  2035    
R^2 0.0052  0.0252  0.0156  
LL   -26482.75    
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TABLE 4.31-COLORECTALCANCER: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err
Total Spending t-1 0.23 0.053 0.038 0.042
Total Spending t-2 -0.12 0.068 -0.044 0.055
Total Spending t-3 0.076 0.077 -0.088 0.069
Total Spending t-4 0.054 0.075 -0.056 0.068
Total Spending t-5 0.07 0.099 -0.14 0.093
Total Spending t-6 -0.104 0.094 -0.07 0.058
Total Spending t-7 0.103 0.096 0.057 0.078
Age Death -88.11 20.19 -67.53 24.29
Black 185.2 701.4 -363.1 809.3
Male 82.8 403.7 22.9 441.12
Cons 11019.06 1746.4 10742.5 2043.3
     
Observations 1525  1179  
Uncensored Obs 
(Tobit) 1477    
R^2 0.002  0.0138  
LL -15358.66    
 
  
 The expenditure paths exhibited by colorectal cancer in the Tobit models and OLS 
on decedents above in Table 4.31 continue in the analysis of history of total spending. 
However, neither of these models is strong enough to make any significant claims. Age at 
death is confirmed as lowering expected terminal expenditures.  
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Leukemia 
 
TABLE 4.32-LEUKEMIA: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit OLS on Decedents
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.348 0.0073 2.189 0.139 0.027 0.081
t-2 0.284 0.009 1.201 0.157 0.088 0.094
t-3 0.0235 0.015 1.738 0.264 -0.398 0.176
t-4 0.421 0.027 2.911 0.467 0.052 0.292
Age -0.881 0.246 -28.35 16.05 -108.3 31.92
Black 0.258 9.09 -1189.7 654.4 1829.7 1270.2
Male 9 5.15 1783.5 369.6 -21.34 690.3
Cons 89.9 19.95 -24943.4 1604 12676.28 2551.97
       
Observations 60214  60214  417  
Uncensored Obs (Tobit)  573    
R^2 0.0781  0.0416  0.0456  
LL   -8195.752    
 
  
 As shown in Table 4.32, leukemia presents an expenditure pattern similar to that of 
the other cancers.  A significant positive slope to terminal period costs is clear. Age at death 
is strongly negative.  Sex and race appear to have little impact on the path of expenditures. 
Decedents seem to be representative of the general sample, equally likely to be male and 
black and of a similar age.  All the specifications prove to be rather weak at explaining 
variation in terminal period expenditures.   
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TABLE 4.33-LEUKEMIA: AVERAGE IN DISEASE SPENDING AND  TREATMENT 
COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff Std. Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.1222 0.0054 1.353 0.108 -0.0171 0.0594
Count Mean -1.62 0.337 -96.66 22.93 -96.72 40.27
Age Death -1.58 0.275 -71.7 18.16 -137.5 34.5
Black -2.99 9.42 -1343 696 1819.1 1259.6
Male 9.36 5.74 2015.5 398.5 -243.67 687.23
Cons 174.5 24.72 -22647.5 1834.8 16354 2993.22
       
Observations 60265  60265  417  
Uncensored Obs (Tobit)  573    
R^2 0.0078  0.0148  0.0493  
LL   -8425.034    
      
      
 
  
 In the OLS and Tobit models shown in Table 4.33, Leukemia exhibits significant 
positive persistence in in-disease expenditures. Among decedents the relationship is 
ambiguous.  It is clear that treatment counts are strongly associated with lower levels of 
terminal period expenditures. Age at death is negative, and blacks appear to have lower 
terminal period costs.  Sex appears to be a weal predictor.  
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TABLE 4.34-LEUKEMIA: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err
Total Spending t-1 0.278 0.077 0.008 0.091
Total Spending t-2 0.117 0.107 0.099 0.13
Total Spending t-3 0.073 0.0121 -0.018 0.14
Total Spending t-4 0.52 0.142 0.39 0.19
Total Spending t-5 -0.099 0.115 -0.05 0.14
Total Spending t-6 -0.29 0.167 -0.25 0.3
Total Spending t-7 0.381 0.14 -0.014 0.18
Age Death -133.6 25.05 -122.19 52.84
Black 651.2 960.04 -431.3 2049.6
Male -703.41 550.8 -1680.6 1000.2
Cons 1469.8 2218.7 17863.1 4289.9
     
Observations 829  290  
Uncensored Obs 
(Tobit) 781    
R^2 0.0072  0.0559  
LL -8125.31    
 
  
 
 The Tobit model as shown in Table 4.34 finds a significant relationship between 
higher costs in the first and fourth quarters prior to the terminal period and terminal period 
expenditures. Advanced age at death is correlated with lower levels of terminal period 
expenditures in both the Tobit and OLS specifications.   
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Non-Hodgkin’s Lymphoma 
 
TABLE 4.35-NON-HOGKIN’S LYMPHOMA: IN DISEASE EXPENDITURES IN YEAR 
OF DEATH 
202       
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff Std. Err. 
t-1 0.188 0.005 1.298 0.074 -0.014 0.046
t-2 0.361 0.007 1.508 0.106 0.158 0.067
t-3 0.209 0.011 1.324 0.147 0.022 0.095
t-4 0.031 0.013 1.311 0.175 -0.207 0.114
Age -0.448 0.154 -26.938 7.186 -25.426 13.851
Black 0.555 5.707 -1143.587 320.516 603.785 628.181
Male 3.923 3.463 350.945 162.166 346.604 289.029
Cons 51.143 12.536 -10615.910 662.150 3926.562 1103.916
       
Observations 60214  60214  625  
Uncensored Obs 
(Tobit)   820    
R^2 0.1079  0.0612  0.0258  
LL   -10748.021    
 
  
 Non-Hodgkin’s Lymphoma demonstrates above in Table 4.35 an expenditure profile 
that appears much the same as the other cancers. It exhibits high levels of expenditure at 
least three quarters prior to the terminal period. Men appear to have higher levels of 
expenditures, while blacks seem to incur lower costs. Age at death is significantly negative. 
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TABLE 4.36- NON-HOGKIN’S LYMPHOMA: AVERAGE IN DISEASE SPENDING 
AND TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit OLS on Decedents 
 Coeff Std. Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.089 0.003 0.977 0.050 -0.031 0.027
Count Mean -1.561 0.214 -84.467 10.630 -69.076 16.354
Age Death -1.204 0.175 -66.414 8.245 -48.425 14.301
Black -11.763 5.987 -1537.628
354.50
5 475.151 620.405
Male 3.342 3.645 408.118
177.32
3 299.386 285.854
Cons 
140.17
3 15.707 -7754.456
753.87
7 6762.04 
1210.99
0
       
Observations 60265  60265  625  
Uncensored Obs 
(Tobit)   820    
R^2 0.0171  0.0276  0.04553  
LL   
-11133.90
1    
 
  
 Higher level of yearly average expenditures predict increased terminal period 
expenditures. An increased number of treatments per quarter have a significant reducing 
effect on costs incurred at time of death.  The findings on demographic variables in Table 
4.36 are consistent with the models above and with those of the other cancers.   
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TABLE 4.37- NON-HOGKIN’S LYMPHOMA: HISTORY OF TOTAL SPENDING  
 
 
  
 As shown in Table 4.37, except for the period immediately preceding death, history 
of total spending gives no clear indication about the level of terminal period expenditures. 
Among decedents, the OLS finds an anomalous negative relationship three quarters prior to 
the terminal period.  In all other aspects the findings are similar or at least not contradictory 
to the more detailed models.  
 
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.25 0.055 0.084 0.05
Total Spending t-2 0.23 0.081 0.045 0.07
Total Spending t-3 -0.09 0.101 -0.21 0.092
Total Spending t-4 0.101 0.13 -0.103 0.113
Total Spending t-5 0.092 0.143 -0.087 0.118
Total Spending t-6 0.15 0.148 0.036 0.115
Total Spending t-7 0.14 0.11 0.103 0.85
Age Death -78.4 23.14 -89.23 28.94
Black 2257.75 900.4 2292.8 1302
Male 291.1 496.9 802.8 554.8
Cons 9213.1 2039.8 12126.8 2363.7
     
Observations 953  418  
Uncensored Obs 
(Tobit) 905    
R^2 0.0054  0.0682  
LL -9380.919    
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Cerebrovascular Disease 
 
TABLE 4.38-CEREBROVASCULAR DISEASE: IN DISEASE EXPENDITURES IN 
YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.175 0.0044 0.492 0.0139 0.081 0.017
t-2 0.0007 0.004 0.083 0.0144 -0.041 0.016
t-3 0.025 0.007 0.215 0.024 -0.06 0.029
t-4 0.017 0.007 0.186 0.022 -0.072 0.026
Age 1.38 0.217 14.9 1.037 7.08 3.25
Black 36.6 8.01 318.05 34.48 235.88 98.4
Male -3.63 4.87 -66.49 22.27 80.4 64.8
Cons -44.14 17.66 -3167.79 88.65 105.52 272.19
       
Observations 58603  58603  3910  
Uncensored Obs 
(Tobit)   9170    
R^2 0.0302  0.011  0.0144  
LL   -94902    
 
  
 The models, as shown in Table 4.38, are relatively weak in explaining variation in 
terminal period expenditures for cerebrovascular disease. While the variables in the model 
are mostly significant, they together explain little. Interestingly, age at death has a large 
positive impact on terminal period expenditures. Cerebrovascular disease affects women 
more commonly than it does men, and men seem to have lower costs associated with dying 
of the disease. Race is a significant factor with blacks having increased terminal period 
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costs.  
 
TABLE 4.39- CEREBROVASCULAR DISEASE: AVERAGE IN DISEASE SPENDING 
AND TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff 
Std 
Err Coeff Std. Err
Expenditure Mean 0.015 0.0014 0.122 0.0048 -0.037 0.0072
Count Mean -0.542 0.294 -5.23 1.37 -8.11 3.93
Age Death 1.41 0.237 14.83 1.16 2.76 3.64
Black 44.5 8.11 346.69 35.27 249.19 98.4
Male -5.38 4.9 -78.56 22.87 58.47 65.3
Cons -29.34 21.4 -3111.96 107.44 655.7 334.75
       
Observations 58676  58676  3910  
Uncensored Obs (Tobit)   9170    
R^2 0.0035  0.0053  0.0116  
LL   -95462.8    
 
  
 At the annual level, higher costs in the run up to the terminal period have a positive 
influence on terminal cerebrovascular disease expenditures, as shown in Table 4.39. 
Treatment counts are found to negatively influence the expense. The rest of the findings are 
consistent with the above model. 
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TABLE 4.40- CEREBROVASCULAR DISEASE: HISTORY OF TOTAL SPENDING  
History of total 
spending     
     
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err
Total Spending t-1 0.176 0.021 0.08 0.017
Total Spending t-2 -0.039 0.3 -0.02 0.023
Total Spending t-3 0.112 0.44 0.06 0.32
Total Spending t-4 0.052 0.041 0.08 0.033
Total Spending t-5 0.02 0.048 -0.08 0.038
Total Spending t-6 0.12 0.046 0.053 0.033
Total Spending t-7 0.08 0.045 -0.03 0.01
Age Death -88.7 11.85 -24.63 9.9
Black 1392.5 367.34 576.3 296.6
Male 627.3 232.61 601.5 193.9
Cons 11490.9 1023.23 4861.5 853.1
     
Observations 4282  2837  
Uncensored Obs 
(Tobit) 4218    
R^2 0.0034  0.0255  
LL -43659.8    
 
  
 It is evident from the results in Table 4.40 that costs one quarter out from the terminal 
period are strongly correlated with terminal period expenditures. There appears to be some 
significance for the time period a year prior to death, though not for the intervening two 
quarters.  Reflecting the sex distribution of patients of cerebrovascular disease, the sex 
variable is significant in both specifications. In contradiction to the other models however, 
the evidence suggest that men experience increased costs. Blacks have distinctly higher 
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terminal expenditures from cerebrovascular disease.   
 
Stroke 
 
 
TABLE 4.41-STROKE: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.161 0.011 1.33 0.107 -144 0.08
t-2 -0.012 0.017 0.376 0.224 -0.262 0.1232
t-3 -0.014 0.019 0.59 0.212 -0.233 0.146
t-4 0.059 0.014 0.277 0.167 -0.089 0.01
Age -0.311 0.32 -2.4 7.16 -26.38 17.8
Black 40.26 11.88 525.21 256.65 1408.7 599.63
Male 4.64 7.21 -16.36 161.86 273.04 383.29
Cons 75.92 26.07 -14564.99 657.65 5030.09 1465.74
       
Observations 60214  60214  988  
Uncensored Obs 
(Tobit)   1679    
R^2 0.0043  0.0039  0.0228  
LL   -22704.8    
 
  
 It is clear that people with positive levels of spending in stroke experience higher 
than normal terminal expenditure patterns. As shown in Table 4.41, the coefficients in the 
OLS and Tobit models are generally positive and strictly positive when found to be 
significant. Those individuals flagged as having died from a stroke however show a different 
picture. The coefficients in the OLS on decedents model are negative and approaching 
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significance at a casual level. Decedents are generally older than the sample in the Tobit and 
older than the general population, so it may be the case that it is the age at death effect that 
is pulling down terminal period expenditures for them.  Blacks appear to have significantly 
higher costs related to strokes.  Men seem to have no different expenditures than women.   
 
 
TABLE 4.42-STROKE: AVERAGE IN DISEASE SPENDING AND TREATMENT 
COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.011 0.006 0.286 0.0867 -0.1883 0.07
Count Mean -1.49 0.426 -56.68 9.66 -28.87 22.74
Age Death -0.78 0.347 -19.81 7.7 -37.84 19.86
Black 39.75 11.9 469.3 258.14 1522.41 601.97
Male 2.69 7.24 -72.16 162.73 351.1 382.9
Cons 137.09 31.19 -1240.7 736.77 6145.37 1773.24
       
Observations 60265  60265  988  
Uncensored Obs (Tobit)   1697    
R^2 0.0005  0.001  0.0191  
LL   -22771.4    
 
  
 As shown in Table 4.42, the pattern demonstrated on the quarterly model is 
reinforced by the yearly averages.  Individuals in the OLS and Tobit samples show positive 
persistence in stroke related expenditures while decedents show a reduction. Treatment 
counts are strongly negative but least so among decedents. Age at death is confirmed as 
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lowering terminal period expenditures. There is some evidence at the yearly level that 
women are more likely to have expenditures for stroke than are men. It is clear that blacks 
have higher levels of costs for stroke.  
 
TABLE 4.43-STROKE: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err
Total Spending t-1 0.24 0.056 0.165 0.06
Total Spending t-2 0.79 0.97 0.071 0.103
Total Spending t-3 0.049 0.066 -0.104 0.112
Total Spending t-4 0.22 0.103 0.07 0.11
Total Spending t-5 0.086 0.13 -0.133 0.16
Total Spending t-6 0.086 0.11 -0.092 0.12
Total Spending t-7 0.17 0.113 0.058 0.12
Age Death -65.16 18.74 -94.7 30.8
Black 1083.8 704.5 39.8 1045.6
Male -50.3 411.3 431.3 627.8
Cons 8804.3 1633.6 12538.8 2596.4
     
Observations 1252  584  
Uncensored Obs 
(Tobit) 1204    
R^2 0.0035  0.0415  
LL -12423.63    
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 Total spending in Table 4.43 shows a slightly different pattern than does in disease 
spending. The quarter prior to the terminal period is positive for the Tobit and OLS on 
decedents samples. This may indicate that many of the services stroke patients receive are 
coded under other diseases. To the extent that stroke effects the frail, it could likely occur in 
people with significant levels of co-morbidities. Thus total spending would be higher while 
in disease spending is lower. In general, the upward slope of expenditure is confirmed, while 
the findings on the demographic variables are consistent with the consensus of the literature. 
  
 
COPD 
 Chronic pulmonary obstruction disorder has a strong positive pattern of persistence 
both in the OLS and the Tobit specifications while the evidence that there is in the OLS on 
decedents specification is consistent. In Table 4.44, there appears to be rapidly-rising costs 
in the path of expenditures with costs in the final six months of life at a particularly high 
level. Men are over represented in decedents and seem to have higher expenditures. The 
evidence on the impact of race is inconclusive. 
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TABLE 4.44-COPD: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.233 0.009 0.768 0.024 0.105 0.031 
t-2 0.073 0.0104 0.363 0.028 -0.012 0.036 
t-3 0.126 0.0145 0.595 0.4 -0.013 0.052 
t-4 0.329 0.0153 0.813 0.42 0.221 0.055 
Age -2.41 0.544 -20.79 2.16 -15.99 6.67 
Black 29.03 20.07 -614.28 84.68 1439.88 283 
Male 8.1 12.2 499.21 47.65 -143.2 134.4 
Cons 278.77 44.47 -2926.44 176.12 2495.68 525.1 
       
Observations 58603  58603  5035  
Uncensored Obs 
(Tobit)   10400    
R^2 0.0411  0.017  0.0139  
LL   -113747    
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TABLE 4.45-COPD: AVERAGE IN DISEASE SPENDING AND TREATMENT 
COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff 
Std 
Err Coeff Std. Err
Expenditure Mean 0.096 0.0025 0.367 0.007 0.038 0.011
Count Mean -6.97 0.731 -55.76 2.92 -38.29 8.25
Age Death -4.56 0.593 -37.2 2.35 -30.83 7.458
Black 17.76 20.21 -677.17 85.79 1455.25 283.04
Male 3.55 12.32 466.78 48.38 -186.92 134.75
Cons 565.99 53.45 -830.64 209.17 4253.01 640.89
       
Observations 58676  58676  5035  
Uncensored Obs (Tobit)   10400    
R^2 0.0259  0.0142  0.0132  
LL   -114090    
 
  
 The general trend of positive persistence is also clear is the yearly averages, as 
shown in Table 4.45. The relative flatness of the slope implied by the coefficient on mean 
yearly expenditures may likely come from the fact that the periods prior to six months before 
death are not strongly significant indicators of terminal period expenditures. Treatment 
counts have a strong negative effect on expenditure at time of death related to chronic airway 
obstruction disease. Age at death is strongly negative. Blacks appear to have higher 
expenditures among decedents thought the Tobit sample (which is twice as large) finds a 
negative impact. Men are more likely to experience positive expenditures on the disease and 
having the disease seem to have higher costs.  
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TABLE 4.46-COPD: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
 Coeff 
Std 
Err Coeff Std. Err
Total Spending t-1 0.27 0.024 0.26 0.027
Total Spending t-2 0.043 0.03 0.06 0.034
Total Spending t-3 -0.014 0.044 0.022 0.043
Total Spending t-4 0.066 0.042 0.018 0.04
Total Spending t-5 0.017 0.047 -0.021 0.047
Total Spending t-6 0.06 0.043 0.079 0.051
Total Spending t-7 0.06 0.046 -0.016 0.051
Age Death -81.4 11.9 -62.24 13.5
Black 2370.9 500.2 2906.6 610.3
Male 108.07 239.9 -37.02 265.16
Cons 11205.9 993.1 8512.8 1080.9
     
Observations 5316  3804  
Uncensored Obs 
(Tobit) 5251    
R^2 0.0028  0.0501  
LL -55130.5    
 
 History of total spending, as shown in Table 4.46, agrees with the findings from in 
disease expenditures.  Persistence is present at least one quarter out and certainly not 
negative up to two years out. Age at death is confirmed to be negative, blacks appear to have 
higher costs, and the evidence about men’s expenditures related to chronic airway 
obstruction disease is inconclusive.  
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Pneumonia 
 
 
TABLE 4.47-PNEUMONIA: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.08 0.0073 0.34 0.02 -0.101 0.022
t-2 0.017 0.0099 0.14 0.028 -0.131 0.029
t-3 0.064 0.016 0.28 0.047 -0.195 0.049
t-4 0.07 0.017 0.31 0.048 -0.179 0.052
Age 3088 0.754 37.39 2.63 -12.31 5.53
Black 144.24 28.04 370.22 96.36 1580.578 230.6
Male 51.68 17.01 493.98 58.97 -159.63 134.27
Cons -5.5 61.58 -7893.02 223.21 3564.41 470.48
       
Observations 60214  60214  6806  
Uncensored Obs 
(Tobit)   13242    
R^2 0.0039  0.0023  0.0185  
LL   -148640    
 
  
 The presence of medical expenditures related to pneumonia, as shown in Table 4.47, 
clearly predicts higher terminal period expenditures for the general sample and for the 
individuals whose observations support the Tobit model. Decedents from pneumonia have 
the opposite pattern. This may well be because decedents from pneumonia are distinctly 
older than the general population and than a representative individual in the Tobit sample. 
Those individuals who have positive spending in pneumonia but that are classified as having 
died from a different disease incur significantly higher costs in their terminal period related 
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to their pneumonia-specific expenditures. Decedents from pneumonia show a decline in 
terminal period expenditures associated with increased pre-terminal period costs. Blacks 
show higher level of terminal period expenditures than do non-blacks.  Men are distinctly 
more costly from pneumonia.  In general, pneumonia is widespread, affecting at least one 
quarter of the sample and causing the death of more than 10%.   
 
 
TABLE 4.48-PNEUMONIA: AVERAGE IN DISEASE SPENDING AND TREATMENT 
COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.045 0.004 0.208 0.0135 -0.081 0.019 
Count Mean -8.86 1.01 -46.26 3.53 -37.74 7.96 
Age Death 1.37 0.818 24.05 2.85 -22.11 6.01 
Black 146.21 28.03 393.61 96.23 1435.46 230.87 
Male 44.14 17.06 460 59.12 -240.58 135.11 
Cons 324.71 73.53 -6155.5 261.24 4755.45 556.99 
       
Observations 60265  60265  6806  
Uncensored Obs 
(Tobit)   13242    
R^2 0.0036  0.0021  0.0137  
LL   -148679    
 
  
 The yearly averages, as shown in Table 4.48, confirm the quarterly observations. 
Treatment counts are a strongly negative predictor of terminal period expenditures. The 
decedents from pneumonia are clearly distinct from those who simply have positive 
expenditures. Demographic variables are confirmed in their pattern with the quarterly 
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averages and are similar to the consensus in the literature on the Medicare population.  
 
TABLE 4.49-PNEUMONIA: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err
Total Spending t-1 0.2 0.023 0.107 0.019
Total Spending t-2 0.023 0.031 -0.048 0.026
Total Spending t-3 0.12 0.042 0.025 0.034
Total Spending t-4 0.055 0.04 -0.018 0.035
Total Spending t-5 -0.015 0.05 0.019 0.042
Total Spending t-6 0.069 0.05 0.067 0.041
Total Spending t-7 0.037 0.05 0.097 0.041
Age Death -112.7 11.9 -53.23 9.8
Black 2136.12 446.5 3070.9 410.31
Male -378.43 257.3 -16.55 225.61
Cons 15712.9 1034.23 9045.23 856.54
     
Observations 5847  4915  
Uncensored Obs 
(Tobit) 5799    
R^2 0.0026  0.0333  
LL -61495    
 
  
 The pattern of total spending, in Table 4.49, reveals a positive though somewhat 
erratic expenditure path to the terminal period. Decedents from pneumonia experience 
higher terminal period costs though the strong age effect coupled with the high average age 
of decedents makes the expenditure path less distinct. In all other characteristics, pneumonia 
patients are revealed to be similar in their expenditures as the general population.  
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Diabetes Mellitus 
 
TABLE 4.50-DIABETES MELLITUS: IN DISEASE EXPENDITURES IN 
YEAR OF DEATH 
250       
 OLS Tobit OLS on Decedents
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.185 0.006 0.492 0.019 0.170 0.031
t-2 0.056 0.008 0.297 0.026 0.006 0.041
t-3 0.031 0.008 0.275 0.029 -0.026 0.047
t-4 0.174 0.009 0.462 0.032 0.169 0.051
Age -1.257 0.281 -24.403 1.452 -9.187 5.675
Black 20.033 10.397 350.339 50.150 -19.496 181.823
Male -6.975 6.312 -138.131 33.212 -83.789 135.790
Cons 130.656 22.970 -1268.324 116.300 1285.440 449.840
       
Observations 58603  58603  2592  
Uncensored Obs 
(Tobit)   7075    
R^2 0.0399  0.0165  0.0202  
LL   -76221.887    
 
  
 As shown in Table 4.50, diabetes mellitus is an expensive chronic disease that results 
in elevated terminal period expenditures. The expenditure path is strongly positive, though 
expenses seem to remain at a flat, high level throughout the terminal year. The more elderly 
an individual is, the lower a level of terminal period expenditures they tend to have 
associated with diabetes. Blacks are indicated as having higher costs, while there is some 
evidence that men experience lower expenditures. Diabetes is commonly co-morbid and 
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diabetes expenditures are present with a large number people who are flagged as having 
passed away from something else. The support for the Tobit model is toughly twice as large 
as that of the OLS on decedents model. Decedents are a bit younger than the general sample. 
 Age at death is strongly negative.  
 
 
TABLE 4.51-DIABETES MELLITUS: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff Std. Err Coeff Std Err Coeff 
Std. 
Err 
Expenditure Mean 0.03 0.0012 0.15 .004 0.02 0.01
Count Mean -1.958 0.3807 -14.69 2.04 -26.76 8.26
Age Death -2.074 0.309 -29.02 1.60 -16.36 6.11
Black 31.15 10.541 389.35 51.40 21.82 182.98
Male -9.867 6.42 -141.12 34.19 -92.94 136.74
Cons 233.84 27.83 -761.34 141.56 2405.46 542.75
       
Observations 58676  58676  2592  
Uncensored Obs (Tobit)   7075    
R^2 0.0118  0.0113  0.007  
LL   -76635.62    
 
 As shown in Table 4.51, yearly averages mirror the pattern suggested by the 
quarterly observations. A high stable level of expenditures is typical of a diabetes patient on 
Medicare. Men appear to have lower expenditures, though among decedents from diabetes 
the result is inconclusive.  
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TABLE 4.52-DIABETES MELLITUS: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.266 0.033 0.326 0.034 
Total Spending t-2 -0.06 0.043 -0.095 0.045 
Total Spending t-3 0.012 0.043 0.019 0.046 
Total Spending t-4 -.007 0.054 0.05 0.057 
Total Spending t-5 0.139 0.067 0.17 0.064 
Total Spending t-6 -0.052 0.064 0.022 0.057 
Total Spending t-7 0.008 0.057 -0.048 0.054 
Age Death -136.3 14.54 -56.45 14.65 
Black 1504.6 477.44 1449.52 450.9 
Male 275.82 324.03 126.36 338.8 
Cons 15880.4 1241.3 7419.25 1200.26 
     
Observations 3002  2058  
Uncensored Obs (Tobit) 2938    
R^2 0.0043  0.0838  
LL -30893.002    
 
  
 As shown in Table 4.52, total spending largely confirms the picture made by the 
prior two models. There is an anomalous finding nine months prior to death among the 
decedents from diabetes. It suggests that those people who spend less at that time experience 
a more costly death than those who spend more. All other results point to a significant 
persistence in diabetes related expenditures to the terminal period.  
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Alzheimer’s Disease 
 
TABLE 4.53-ALZHEIMER’S DISEASE: IN DISEASE EXPENDITURES IN  
YEAR OF DEATH 
331       
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff Std. Err. Coeff 
Std. 
Err.  
t-1 0.167 0.004 0.491 0.022 0.125 0.024
t-2 0.045 0.004 0.145 0.024 0.022 0.024
t-3 0.144 0.005 0.320 0.031 0.114 0.032
t-4 0.009 0.006 0.134 0.039 -0.028 0.038
Age 0.1512 0.0752 10.24 0.9302 -6.89 3.18
Black -4.404 2.796 -7.1881 32.59021 -119.05 125.54
Male -1.638 1.697 -49.2644 19.549 28.484 66.5
Cons -0.06145 6.14 -2655.9 84.8227 900.3 269.24
       
Observations 60214  60214  1414  
Uncensored Obs (Tobit)   3164    
R^2 0.0718  0.0172  0.0425  
LL   -34137.6    
 
  
 The models run on Alzheimer’s patients shown in Table 4.53 reveal a consistent 
upward sloping path of expenditures which is distinct in that all three models agree. It does 
not appear that decedents see a reduction in expenditure relative to the general population 
despite the fact that decedents are considerably older than the general sample. There appears 
to be an interesting stair step effect with sharp increases in expenditure nine months and 
three months out from the terminal period, with much more subtle increases at a year and six 
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months out. Age at death has conflicting indicators being significantly negative among 
decedents while strongly positive for the rest of the population. Blacks experience lower 
expenditures relative to non-blacks from Alzheimer’s disease. Men have lower expenditures 
in the OLS and Tobit models, but among decedents the evidence is inconclusive.   
 
 
TABLE 4.54-ALZHEIMER’S DISEASE: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff 
Std 
Err Coeff 
Std. 
Err 
Expenditure Mean 0.019 0.001 0.122 0.008 -0.010 0.009
Count Mean 0.108 0.104 6.982 1.248 -4.425 3.800
Age Death 0.236 0.085 13.680 1.103 -10.293 3.527
Black -3.62 2.89 5.60 34.62 -56.20 127.30
Male -1.89 1.76 -47.50 20.91 25.55 67.96
Cons -4.76 7.60 -3147.86 108.50 1345.97 323.41
       
Observations 60265  60265  1414  
Uncensored Obs (Tobit)   3164    
R^2 0.004  0.0059  0.008  
LL   -34531.9    
 
  
  
 The yearly observations in Table 4.54 reveal a weak positive, though strongly 
significant association between high expenditures prior to the terminal period. Except for 
decedents, treatment counts are revealed to be predictors of increased terminal expenditures. 
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Decedents show no evidence that treatment counts matter. The positive influence of 
treatment counts is unusual among diseases for Medicare beneficiaries. Racial indicators are 
inconclusive, as is the measured impact of the sex of the patient.  
 
 
TABLE 4.55-ALZHEIMER’S DISEASE: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.35 0.061 0.311 0.042
Total Spending t-2 -0.0004 0.076 -0.048 0.051
Total Spending t-3 0.018 0.101 0.2 0.065
Total Spending t-4 0.133 0.1 -0.122 0.07
Total Spending t-5 0.202 0.119 -0.01 0.065
Total Spending t-6 -0.085 0.138 -0.127 0.09
Total Spending t-7 -0.05 0.092 0.222 0.074
Age Death -54.41 16.96 -15.84 13.08
Black 1451.67 589.1 -329.3 505.63
Male 490.1 344.15 787.04 257.74
Cons 6543.44 1495.9 2369.04 1123.74
     
Observations 1072  975  
Uncensored Obs (Tobit) 1025    
R^2 0.004  0.1005  
LL -10303.42    
 
  
 The history of total spending shown in Table 4.55 seems to bear little relation to the 
terminal expenditures for Alzheimer’s patients. Patients tend to be old relative to the sample 
and have a high level of outside of disease expenditures. The payments specifically 
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attributed to Alzheimer’s disease seem to decline as patients enter extreme old age, though 
total payments remain high.   
 
Kidney Failure 
 
 Models for kidney disease, as shown in Table 4.56, explain a significant part of the 
variation in terminal period expenditures. Models demonstrate a strong upward path in 
expenditures and a high terminal period cost. Diseases of the kidney have long been 
recognized as requiring very expensive treatments over a long period of time. It is for this 
reason that people under the normal age of Medicare eligibility are often granted benefits 
under the End-Stage Renal Disease Program. The fact that the persistence of cost for kidney 
disease is revealed to be so strong makes it clear that that program at least is well-targeted.  
Given that typical Medicare beneficiary suffering from kidney disease is distinctly younger 
than the normal pool, analysis on the expenditure path is a bit further a field than in other 
diseases covered. Decedents are seven years younger on average than a typical Medicare 
decedent. The findings indicate that older patients experience terminal period expenditures 
and that blacks have higher expenditures than non-blacks. 
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TABLE 4.56-KIDNEY FAILURE: IN DISEASE EXPENDITURES IN  
YEAR OF DEATH 
       
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.284 0.0051 0.791 0.024 0.171 0.03 
t-2 0.02 0.0058 0.157 0.027 -0.037 0.03 
t-3 0.11 0.0066 0.348 0.03 0.049 0.04 
t-4 0.04 0.0052 0.121 0.024 0.0054 0.26 
Age -0.67 0.152 -22.22 1.29 3.43 3.05 
Black 24.27 5.58 440.83 42.52 134.2 99.43 
Male 4.39 3.38 93.08 30.23 75.99 85.39 
Cons 69.04 12.44 -1371.15 102.69 489.52 235.31 
       
Observations 58603  58603  2024  
Uncensored Obs (Tobit)  4286    
R^2 0.2037  0.0739  0.0272  
LL   -45351.7    
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TABLE 4.57-KIDNEY FAILURE: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff Std. Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.033 0.00046 0.113 0.0025 0.009 0.0028 
Count Mean -1.92 0.214 -18.27 2.01 -16.82 5.18 
Age Death -2.11 0.175 -35.69 1.54 1.93 3.23 
Black 39.77 5.94 574.42 47.48 121.65 100.77 
Male 2.29 3.62 87.45 33.67 80.02 86.03 
Cons 226.75 15.78 -344.67 131.58 1092.46 273.11 
       
Observations 58676  58676  2024  
Uncensored Obs (Tobit)  4286    
R^2 0.0942  0.0408  0.0105  
LL   -46981.4    
 
  
 Yearly averages, as shown in Table 4.57, reflect the same strong pattern of 
persistence in kidney disease expenditures with high levels of maintenance expenses 
predicting high terminal costs. The number of treatment an individual receives seems to 
reduce terminal period expenditures. This is counter to an intuitive perception that 
individuals requiring dialysis for kidney disease would have both a high number of 
treatment counts and high expenditures. The finding that blacks have higher costs is 
confirmed in the yearly data. Evidence on the impact of the sex of the patient is inconclusive.  
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TABLE 4.58-KIDNEY FAILURE: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.25 0.028 0.099 0.035
Total Spending t-2 -0.061 0.036 -0.015 0.045
Total Spending t-3 0.067 0.043 0.041 0.052
Total Spending t-4 0.008 0.046 -0.06 0.053
Total Spending t-5 0.002 0.048 0.013 0.056
Total Spending t-6 0.027 0.048 0.003 0.057
Total Spending t-7 0.3 0.049 0.008 0.054
Age Death -118.6 13.68 -61.67 16.99
Black 1419.1 460.11 2009.4 534.6
Male -4.97 346.37 3.2 466.7
Cons 14760.61 1165.9 10773.86 1359.22
     
Observations 3416  1663  
Uncensored Obs 
(Tobit) 3352    
R^2 0.0043  0.0273  
LL -35695.2    
 
 
 The history of total spending among kidney disease patients shown in Table 4.58 
fails to show any significant long run relationship to terminal period expenditures. That is 
surprising given the generally high level of expenditures for these patients. It may be that the 
End Stage Renal Disease program results in most expenditures being coded as 
kidney-related, thus making other expenditures more random.  
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Septicemia 
 
TABLE 4.59-SEPTICEMIA: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.157 0.009 0.736 0.046 -0.167 0.043 
t-2 0.046 0.01 0.406 0.076 -0.258 0.066 
t-3 0.21 0.0176 0.796 0.092 -0.129 0.084 
t-4 0.3 0.013 0.253 0.06 -0.247 -0.079 
Age -3.18 0.588 -17.87 4.25 -61.1 9.54 
Black 171.16 21.86 1901 146 839 337 
Male -33.39 12.24 -375 99.25 -347 243 
Cons 439 48 -8149 359 8316 796 
       
Observations 60214  60214  2831  
Uncensored Obs 
(Tobit)   5685    
R^2 0.01  0.0046  0.03  
LL   -69537    
 
  
  
 As shown in Table 4.59, individuals who die because of septicemia tend to do so at 
an expense which is correlated with their prior spending. This combined with the advanced 
age of the affected population, may well indicate that frailty is an unnamed cause for many 
of these deaths. While the models find strong significance on most of the coefficients, they 
do little to explain the variation in terminal period expenditures. Blacks are found to incur 
significantly higher costs, while men generate lower expenditures. The older a patient with 
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septicemia is the less likely they are to receive high levels of medical interventions 
reimbursed under Medicare.   
 
 
TABLE 4.60-SEPTICEMIA: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
Average In Disease Spending in Final Yr     
38       
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.04 0.006 0.323 0.03 -0.206 0.0405 
Count Mean -5.16 0.785 -60.13 5.927 -24.84 14.21 
Age Death -4.93 0.639 -36.38 4.614 -66.16 10.32 
Black 180.3 21.9 1939 147 741.3 337.2 
Male -42.3 13.33 -469.6 100.2 -341.5 243.9 
Cons 666 57.47 -5813 420.6 8914 939.8 
       
Observations 60265  60265  2831  
Uncensored Obs (Tobit)   5685    
R^2 0.004  0.003  0.024  
LL   -69638    
 
  
 The impression given by the yearly models is consistent with that from the quarterly 
based models above in Table 4.60. The Tobit finds that individuals with significant levels of 
septicemia related expenditures in the year prior to death experience higher terminal period 
expenditures. Treatment counts for septicemia are strongly negative for terminal expenses 
which also supports the conjecture that frailty is playing a major part. The coefficients on 
demographic variables match the general trend in the Medicare beneficiary pool.  
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TABLE 4.61-SEPTICEMIA: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents
 Coeff 
Std 
Err Coeff Std. Err 
Total Spending t-1 0.21 0.028 0.107 0.032
Total Spending t-2 -0.094 0.039 -0.01 0.044
Total Spending t-3 0.036 0.045 -0.03 0.046
Total Spending t-4 0.074 0.049 0.02 0.063
Total Spending t-5 -0.041 0.06 -0.05 0.07
Total Spending t-6 0.076 0.062 0.072 0.072
Total Spending t-7 0.15 0.063 0.071 0.061
Age Death -141.74 16.7 -124.8 18.85
Black 1308.3 522.3 1587.08 634.9
Male -666.2 375.5 -33.1 447.57
Cons 18648.3 1354.6 16162.83 1627.83
     
Observations 3276  1992  
Uncensored Obs 
(Tobit) 3228    
R^2 0.0035  0.0465  
LL -34513.5    
 
  
 History of total spending in Table 4.61shows little relation to septicemia related 
terminal expenditures.  For the most part, septicemia is not a chronic condition but a 
complication that can arise often in healthcare settings. It is commonly fatal among the very 
old.  One would not expect to find a particularly long history of expenditures related to 
septicemia given the acuteness of the disease.  
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Parkinson’s Disease 
  
 
TABLE 4.62-PARKINSON’S DISEASE: IN DISEASE EXPENDITURES 
 IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.26 0.004 0.92 0.05 0.20 0.04
t-2 0.10 0.005 0.53 0.06 0.06 0.06
t-3 0.07 0.005 0.43 0.06 0.05 0.06
t-4 0.00 0.006 0.62 0.08 -0.10 0.07
Age 0.10 0.053 10.95 2.07 3.91 6.52
Black -0.41 1.96 -391.30 89.94 162.00 296.17
Male 3.82 1.19 352.10 43.37 192.67 114.81
Cons -6.00 4.32 -4357.60 205.10 -49.27 532.01
       
Observations 58603  58603  548  
Uncensored Obs 
(Tobit)   913    
R^2 0.1058  0.0507  0.0626  
LL   -10811.6    
 
  
  
 Looking at Table 4.62, Parkinson’s disease seems to affect a great number more 
people than it kills. Most people affected by it can expect a steadily increasing level of 
Medicare expenditures along with an increased number of treatments that motivate them. 
Parkinson’s decedents seem to older than average. The impact of age one their expenditures 
is surprisingly positive. This is contrary to most other diseases, though most similar to 
Alzheimer’s disease. The results on the models as regard race is inconclusive, though the 
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Tobit model suggests that black incur lower expenditures.  There is strong evidence that men 
have higher terminal period expenditures from Parkinson’s disease than do women.   
 
 
 
TABLE 4.63-PARKINSON’S DISEASE: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit OLS on Decedents
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.018 0.0009 0.300 0.015 -0.031 0.017
Count Mean -0.037 0.075 4.753 2.920 -18.861 7.822
Age Death 0.135 0.061 17.130 2.650 -8.248 7.815
Black -0.961 2.064 -402.830 99.660 264.757 300.541
Male 5.377 1.259 435.124 49.592 181.264 117.535
Cons -6.498 53.449 -5421.789 280.453 1413.297 710.685
       
Observations 58676  58676  548  
Uncensored Obs (Tobit)   913    
R^2 0.0065  0.03  0.0277  
LL   -11047.5    
 
  
 The yearly averages shown in Table 4.63 indicate a high level of persistence in 
expenditures for Parkinson’s.  An increased number of treatments yields higher terminal 
period expenditures in contrast to the relationship found in other diseases. The demographic 
variables are generally consistent with the above models. None of them do a very good job 
explaining variations in terminal period expenditures.    
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TABLE 4.64-PARKINSON’S DISEASE: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
     
Total Spending t-1 0.223 0.07 0.19 0.043
Total Spending t-2 -0.08 0.106 0.074 0.076
Total Spending t-3 0.11 0.14 -0.067 0.072
Total Spending t-4 0.069 0.14 -0.038 0.087
Total Spending t-5 0.09 0.13 0.072 0.075
Total Spending t-6 0.018 0.14 0.16 0.089
Total Spending t-7 0.21 0.13 0.026 0.087
Age Death -26.53 17.96 -18.5 20.4
Black 2606.65 712.96 14.7 1013.7
Male 984.54 371.12 1015.7 356.5
Cons 4166.96 1593.5 2739.04 1678.3
     
Observations 1498  436  
Uncensored Obs 
(Tobit) 1434    
R^2 0.0017  0.1044  
LL -14780.02    
 
  
 History of total spending for Parkinson’s patients shown in Table 4.64 is significant 
only in the last quarter prior to the terminal period. The whole series of total spending forms 
a reasonable model of terminal period expenditures for Parkinson’s decedents though yearly 
totals may be a stronger predictor than any particular quarter other than the last. Parkinson’s 
patients have a high level of medical expenditures but they are spread randomly through out 
the terminal year. Given the fact that twice as many individuals are affected by Parkinson’s 
as have been flagged as having died from it, it is likely commonly co-morbid with other 
diseases. It is probable that frailty is a significant issue for Parkinson’s patients. 
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Multiple Sclerosis 
 
TABLE 4.65-MULTIPLE SCLEROSIS: IN DISEASE EXPENDITURES 
 IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff Std. Err. Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.254 0.017 3.642 0.472 -0.062 0.496
t-2 0.108 0.029 1.755 0.738 0.401 0.790
t-3 0.060 0.021 1.145 0.519 -0.234 0.538
t-4 0.06 0.018 2.517 0.4884 -0.2835 0.5105
Age -0.14 0.0781 -129.7 13.54 41.39 38.13
Black 7.12 2.884 -345.5 494.1 9822 2322
Male -2.36 1.754 -824.7 319.45 -732.6 1104.5
Cons 12.55 6.37 -4558 843.1 -1596 2598.4
       
Observations 58603  58603  91  
Uncensored Obs 
(Tobit)   152    
R^2 0.0099  0.1073  0.193  
LL   -2049.86    
  
  
 Multiple sclerosis generally affects much younger individuals than the Medicare 
population. The average age of decedents from Multiple Sclerosis on Medicare is lower than 
the total population average. As shown in Table 4.65, the progression of expenditures 
leading up to death is particularly strong for patients with Multiple Sclerosis. The pattern of 
costs for decedents however is unclear and in fact generally negative. It appears that 
individuals that have Multiple Sclerosis having reached the age of Medicare eligibility are 
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a diverse lot.  There is strong evidence that those individuals have a high level of 
expenditures both in Multiple Sclerosis and for other disorders.  The impression made by the 
pattern of expenditures is that of beneficiaries and a long term period of chronic disease and 
high costs. Decedents from Multiple Sclerosis show no distinct pattern in expenditures 
likely due to the frailty associated with their condition.   
 The impression given by the yearly model shown in Table 4.66 is consistent with that 
discussed above. There is a significant level of persistence demonstrated in the yearly model. 
Age at death is found to be strongly negative in the Tobit model though positive among 
decedents. Treatment counts continue to be a clear predictor of lower levels of expenditures. 
Men with Multiple Sclerosis incur lower costs than do women and blacks seem to have 
dramatically higher expenditures when stricken with Multiple Sclerosis at an age of 
Medicare eligibility.   
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TABLE 4.66- MULTIPLE SCLEROSIS: AVERAGE IN DISEASE SPENDING AND 
TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.025 0.001 0.387 0.039 0.012 0.037
Count Mean -0.141 0.104 -40.343 17.978 -36.281 65.948
Age Death -0.191 0.085 -140.055 13.913 32.771 403.360
Black 6.721 2.885 -659.044 503.684 9724.529 2288.783
Male -2.582 1.760 -881.163 310.721 -549.070 1085.727
Cons 19.068 7.623 -3196.411 930.407 -740.531 3563.435
       
Observations 58676  58676  91  
Uncensored Obs (Tobit)   152    
R^2 0.0071  0.0744  0.1897  
LL   -2125.49    
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 TABLE 4.67- MULTIPLE SCLEROSIS: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
     
Total Spending t-1 0.16 0.089 0.37 0.29
Total Spending t-2 -0.06 0.14 0.19 0.25
Total Spending t-3 0.026 0.223 0.044 0.31
Total Spending t-4 0.006 0.234 -0.26 0.38
Total Spending t-5 0.044 0.242 0.89 0.23
Total Spending t-6 -0.16 0.275 1.07 0.52
Total Spending t-7 -0.21 0.236 -1.4 0.513
Age Death -38.14 18.89 -5.5 48.3
Black 2485.6 785.37 232.3 3558.1
Male 565.82 416.65 -835.5 1553.3
Cons 5221.7 1688.3 976.64 3439.9
     
Observations 1249  73  
Uncensored Obs 
(Tobit) 1185    
R^2 0.0013  0.5114  
LL -12245.938    
 
  
 Total spending among Multiple Sclerosis patients shown in Table 4.67 provides little 
indication as to what level of expenditures one could expect to be associated with their 
terminal period. The results form the models on history of total spending are inconclusive on 
any matter of substance though they confirm the perception that the group of people living 
with Multiple Sclerosis in their late 60s and 70s face medical challenges distinctly different 
than non-sufferers.  
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Muscular Dystrophy 
 
TABLE 4.68-MUSCULAR DYSTROPHY: IN DISEASE EXPENDITURES  
IN YEAR OF DEATH 
       
 OLS Tobit OLS on Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.15 0.0008 0.27 0.04 0.14 0.02
t-2 0.08 0.0038 0.91 0.24 0.08 0.12
t-3 0.07 0.0092 2.27 0.70 0.06 0.40
t-4 0.07 0.0088 2.26 0.54 -0.12 0.28
Age -0.03 0.0119 -23.68 4.83 -4.92 9.57
Black 0.19 0.44 183.94 200.53 -403.94 827.61
Male 0.38 0.27 97.55 114.58 441.27 313.96
Cons 2.29 0.97 -2947.42 440.88 279.03 593.32
       
Observations 58603  58603  36  
Uncensored 
Obs (Tobit)   77    
R^2 0.3727  0.0589  0.6331  
LL   -1080.7421    
      
  
 
 Muscular Dystrophy, shown in Table 4.68, presents a picture similar to that of 
Multiple Sclerosis. Individuals among the Medicare population stricken with Muscular 
Dystrophy have high levels of costs throughout the year leading up to their terminals period. 
The costs ramp up considerably in the last six months of life.  Decedents from Muscular 
Dystrophy are significantly younger than the general sample. There are very few of either 
decedents or people in this sample with positive expenditures on Muscular Dystrophy but 
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who are flagged as having died from something else. The fact that strong results can come 
from such a small sample indicates the dramatic difference in expenditure paths that the 
elderly suffering from Muscular Dystrophy go through.  
 
TABLE 4.69- MUSCULAR DYSTROPHY: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff Std. Err 
Expenditure Mean 0.03 0.0016 0.74 0.12 -0.03 0.08
Count Mean -0.07 0.02 -15.68 8.37 -55.28 30.11
Age Death -0.05 0.02 -29.02 6.19 -17.24 15.81
Black 0.04 0.55 -257.37 254.27 144.53 1273.08
Male 0.41 0.34 133.79 142.33 376.32 424.62
Cons 5.24 1.46 -3477.30 603.41 2170.36 1311.17
       
Observations 58676  58676  36  
Uncensored Obs (Tobit)   77    
R^2 0.0064  0.0371  0.1531  
LL   -1105.853    
  
 
 The yearly model shown in Table 4.69 concurs with the results form the quarterly 
models in demonstrating that Muscular Dystrophy patients among the Medicare population 
exhibit high and increasing levels of expenditures. The sample sizes are too small to 
establish very much about the demographic distribution of Muscular Dystrophy, but it is 
clear that advanced age at death is associated with lower terminal period expenditures. The 
number of treatment counts appears to be associated with a reduction in terminal period 
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expenditures, though the effect is unclear and the evidence is inconclusive.   
 
TABLE 4.70- MUSCULAR DYSTROPHY: HISTORY OF TOTAL SPENDING  
 Tobit OLS on Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.3 0.093 0.24 0.216
Total Spending t-2 -0.12 0.118 -0.769 1.73
Total Spending t-3 0.063 0.253 1.32 1.2
Total Spending t-4 0.022 0.302 2.11 1.17
Total Spending t-5 -0.13 0.641 2.38 3.4
Total Spending t-6 0.17 0.37 -5.8 2.72
Total Spending t-7 -0.18 0.31 -6.3 3
Age Death -47.7 21.4 -530.62 272.38
Black 2350.7 863.3 19898.03 15298.07
Male 321.43 465.3 -13365.6 5903.7
Cons 6239.8 1920.8 51780.5 18758.09
     
Observations 1228  20  
Uncensored Obs 
(Tobit) 1164    
R^2 0.0012  0.5413  
LL -12145.5    
 
  
 History of total spending shown in Table 4.70 has little power to predict terminal 
period expenditures among Medicare beneficiaries stricken with Muscular Dystrophy. It is 
likely that, similar to the case of Multiple Sclerosis, seniors living with Muscular Dystrophy 
form a unique group whose experiences are not easily comparable to the general sample. 
The OLS model finds that men incur considerably lower cost in their terminal period than do 
women and the Tobit finds that blacks generate a higher level of total expenditure.  
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Hip Fracture 
 
TABLE 4.71-HIP FRACTURE: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.115 0.005 1.497 0.056 -0.14 0.02
t-2 -0.0167 0.006 0.5498 0.0801 -0.23 0.03
t-3 0.007 0.007 0.6138 0.1016 -0.22 0.04
t-4 -0.0019 0.007 0.384 0.1143 -0.25 0.03
Age 2.34 0.2864 118.7 8.165 -4.19 7.47
Black -42.17 10.58 -2207.663 340.31 -210.41 334.24
Male -16.24 6.44 -961.2 161.26 523.45 145.32
Cons -100.5 23.35 -22865.9 804.26 2416.00 636.46
       
Observations 58603  58603  2335  
Uncensored Obs 
(Tobit)   1802    
R^2 0.012  0.0317  0.0751  
LL   -23338.88    
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 Hip fracture by its nature is of a different character in expenditures, as shown in 
Table 4.71, than the diseases both chronic and acute that have been considered. The 
occurrence of a hip fracture indicates a singular event in a patient’s medical history, and 
often causes a change in the course of medical expenditures. The OLS model finds a strong 
positive impact of expenditures in the quarter prior to the terminal period on terminal period 
expenditures and a significant negative impact of expenditures six months before the 
terminal period. The Tobit model demonstrates, in contrast, a consistent high positive slope 
on the expenditure path. In further contract the OLS on decedents model shows a strong 
downward trend in expenditures.  It may well be the case that the factor which explains the 
inconsistencies is age at death.  Individuals who die of a hip fracture (or who die in a time 
when hip fracture treatments make up the majority of their expenditures) are the oldest 
group of decedents among the conditions considered.  Younger individuals who experience 
hip fractures often enter a period of poor health with higher costs and thus generate the 
upward sloping expenditure profile.   
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TABLE 4.72-HIP FRACTURE: AVERAGE IN DISEASE SPENDING AND 
 TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff 
Std 
Err Coeff Std. Err 
Expenditure Mean -0.004 0.002 0.218 0.031 -0.190 0.015
Count Mean 0.54 0.39 23.77 9.53 -19.93 8.67
Age Death 2.74 0.31 134.82 9.06 -12.47 8.40
Black -45.84 10.62 -2371.14 339.06 -175.76 333.50
Male -19.95 6.49 -1083.09 161.13 545.24 145.11
Cons -129.16 28.13 -24332.12 934.21 3276.40 777.26
       
Observations 58676  58676  2335  
Uncensored Obs (Tobit)   1802    
R^2 0.0023  0.0113  0.0763  
LL   -23832.71    
 
  
 The yearly expenditure model with treatment counts shown in Table 4.72 presents 
the same contradictory impression that the quarterly models do, but without the level of 
detail to make sense of them independently. The results from the OLS model on the entire 
sample show a negative relationship between hip fracture expenditures and terminal period 
expenditures attributed to hip fracture. The impression is consistent with a common story 
that many seniors do not survive a hip fracture, but that those who do are not likely to 
experience another one. The results from the Tobit model seem to demonstrate a story more 
related to a hip fracture pushing a senior into a declining period of poor health with high 
costs continuing to be attributed to the fracture.   
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TABLE 4.73-HIP FRACTURE: HISTORY OF TOTAL SPENDING  
 Tobit 
OLS on 
Decedents 
 Coeff Std Err Coeff Std. Err 
Total Spending t-1 0.161 0.044 0.091 0.031
Total Spending t-2 -0.074 0.075 -0.024 0.04
Total Spending t-3 0.35 0.089 0.026 0.045
Total Spending t-4 0.03 0.096 0.026 0.047
Total Spending t-5 0.13 0.99 0.0006 0.053
Total Spending t-6 0.232 0.091 0.024 0.051
Total Spending t-7 0.14 0.097 -0.12 0.05
Age Death -55.74 15.63 -27.44 17.5
Black 1086.95 669.24 267.9 726.1
Male 11.76 315.84 1159.9 338.8
Cons 8500.55 1381.2 6070.9 1526.6
     
Observations 2110  1733  
Uncensored Obs 
(Tobit) 2046    
R^2 0.0029  0.019  
LL -21080.08    
 
  
 The history of total spending for hip fracture patients, shown in Table 4.73, matches 
the mix of stories proposed above. The very elderly often die from complications brought on 
by the hip fracture. Many individuals change course in their medical spending after a hip 
fracture even if they survive it.  Age at death seems to predict the survivability of the 
accident and thus the pattern of spending for hip fracture patients.   
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Other 
 
 
TABLE 4.74-OTHER: IN DISEASE EXPENDITURES IN YEAR OF DEATH 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  Coeff 
Std. 
Err.  
t-1 0.011 0.005 0.315 0.011 0.089 0.016
t-2 0.066 0.006 0.149 0.0149 0.033 0.02
t-3 0.038 0.0073 0.157 0.0186 -0.0024 0.026
t-4 0.012 0.0082 0.119 0.021 -0.058 0.029
Age -0.0068 0.313 0.245 0.982 -2.26 2.85
Black 61.79 11.58 208.85 35.4 474.46 114.16
Male -7.54 7.04 -148.276 22.3 117.35 72.16
Cons 70.24 25.56 -1786.13 81.08 649.06 236.68
       
Observations 58603  58603  5544  
Uncensored Obs 
(Tobit)   13417    
R^2 0.0225  0.0055  0.0126  
LL   -136018.34    
 
  
 The “Other” category of disease combines all those diseases not otherwise itemized 
in this work. In general, the results on the “Other” category, shown in Tables 4.74, 4.75, and 
4.76, are consistent with a model run without distinguishing diseases. The general pattern of 
an increasing profile of disease expenditures leading to the terminal period is again 
confirmed and the demographic regularities found in this and other literature are again 
demonstrated.  
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TABLE 4.75-OTHER: AVERAGE IN DISEASE SPENDING AND  
TREATMENT COUNTS IN FINAL YEAR 
 OLS Tobit 
OLS on 
Decedents 
 Coeff 
Std. 
Err Coeff Std Err Coeff 
Std. 
Err 
Expenditure Mean 0.0115 0.0013 0.06 0.0036 -0.01 0.0063
Count Mean -1.8 0.43 -5.95 1.37 -20.88 4.1
Age Death -0.47 0.343 -0.632 1.08 -7.74 3.03
Black 78.58 11.68 272.62 35.85 536.91 112.87
Male -12.93 7.13 -159.72 22.77 73.99 71.97
Cons 148.45 30.84 -1631.99 98.43 1499.87 280.74
       
Observations 58676  58676  5595  
Uncensored Obs (Tobit)   13417    
R^2 0.0024  0.0015  0.0103  
LL   -136578.21    
 
   
  
 
 
 
 
 
 To the extent that the “other” category serves as a proxy for the entire Medicare 
population without considering specific disease categories, the results of the yearly count 
models are fairly interesting. While the persistence in expenditures is an empirical fact 
demonstrated in the literature, the demonstration of the negative impact of counts is fairly 
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novel. Decedents of “other” diseases form an interesting group in that the relationship 
between their maintenance expenditures and their terminal period expenditures is not clear 
but a negative coefficient is suggested.  This coupled with the strong age at death effect may 
again demonstrate that frailty is playing a part. History of total spending distinct from 
spending in other diseases is not imagined to be a fruitful distinction.   The corresponding 
table on total spending is therefore suppressed.  
 
Summary Findings 
 The tables below provide a condensed illustration of the findings of the models 
above.  Their focus is the qualitative aspects of the models and the quantitative elements are 
not included. They provide a simple means of identifying those diseases and variables that 
have suggested relationships and what those relationships are.  For each disease the 
following information is provided: a number of past expenditure quarters that prove 
significant in terminal year expenditures (as well as the direction) the direction of impact, if 
any, of black and male indicator variables, expenditure mean, count mean, total spending, 
and age at death.  The OLS model does not have total spending analysis, because in total 
spending OLS and OLS on decedents are identical. 
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TABLE 4.76-SUMMARY FINDINGS OF OLS  
 In-Disease  Age at   Expenditure Count 
 Expenditure Death Black Male Mean Mean 
 Heart Disease 3 -   + - 
Heart Failure 4    + - 
Breast Cancer 3 -  - + - 
Skin Cancer 4    + - 
Cancer of the Larynx 3   + + - 
Cervical Cancer 4   - +  
Prostate Cancer 4 + + + + - 
Bladder Cancer 4   + + - 
Lung Cancer 4 -  + + - 
Colorectal Cancer 4    + - 
Leukemia 3    + - 
Non-Hodgkin's Lymphoma 4 -   + - 
Cerebrovascular Disease  3 +   +  
Stroke 2  +   - 
COPD 4 -   + - 
Pneumonia 3 + + + + - 
Diabetes Mellitus 4 -   + - 
Alzheimer’s Disease 3    +  
Kidney Failure 4 - +  + - 
Septicemia 4 - + - + - 
Parkinson’s Disease 3   + +  
Multiple Sclerosis 4  +  + - 
Muscular Dystrophy 4 -   + - 
Hip Fracture 2 + - -   
Other  3  +  + - 
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TABLE 4.77-SUMMARY FINDINGS OF TOBIT  
 In-Disease  
Age 
at   Expenditure Count Total  
 Expenditure Death Black 
Mal
e Mean Mean Spending
 Heart Disease 4  +  + - 2 
Heart Failure 4 + -  + - 1 
Breast Cancer 4 -  - + - 1 
Skin Cancer 4    + - 1 
Cancer of the 
Larynx 4 -  + + - 1 
Cervical Cancer 3 -  - + - 1 
Prostate Cancer 4 + + + + - 2 
Bladder Cancer 4 + - + + - 2 
Lung Cancer 4 - - + + - 1 
Colorectal Cancer 4    + - 1 
Leukemia 4    + - 3 
Non-Hodgkin's 
Lymphoma 4 - - + + - 4 
Cerebrovascular 
Disease  4 + + - + - 2 
Stroke 2  +  + - 2 
COPD 4 - - + + - 1 
Pneumonia 4 + + + + - 2 
Diabetes Mellitus 4 - + - + - 2 
Alzheimer’s 
Disease 4 +   + + 1 
Kidney Failure 4 - + + + - 1 
Septicemia 4 - + - + - -1 
Parkinson’s Disease 4 + - + +  1 
Multiple Sclerosis 4 -  - + -  
Muscular Dystrophy 4 -   +  1 
Hip Fracture 4 + - - + + 4 
Other  4  + - + - n/a 
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TABLE 4.78-SUMMARY FINDINGS OF OLS ON DECEDENTS 
 In-Disease  
Age 
at   Expenditure Count Total  
 Expenditure Death Black Male Mean Mean Spending
 Heart Disease -4 -   - - 1,-2 
Heart Failure -3    - - 3 
Breast Cancer 1     -  
Skin Cancer 1 +      
Cancer of the Larynx        
Cervical Cancer 1       
Prostate Cancer 1  +   - 1 
Bladder Cancer 1      3 
Lung Cancer -3    - - -1 
Colorectal Cancer -4    -   
Leukemia -1 -    - 1 
Non-Hodgkin's 
Lymphoma 1     - -1 
Cerebrovascular Disease  -3 + +  - - 2 
Stroke -1  +  -  1 
COPD 2 - +  + - 1 
Pneumonia -4 - +  - - 2 
Diabetes Mellitus 2    + - 2 
Alzheimer’s Disease 2 -     3 
Kidney Failure 1    + - 1 
Septicemia -3 - +  -  1 
Parkinson’s Disease 1     - 1 
Multiple Sclerosis   +  + - -1 
Muscular Dystrophy 1      -2 
Hip Fracture -4   + - - 1,-1 
Other  1  +   - n/a 
  
  
  
 
181
 
 The most notable feature of Table 4.77 is the consistency across disease of the 
impact of expenditure and count means on total terminal period expenditure.  Also 
interesting is the variance in the number of periods that have predictive power.   
 The Tobit models in Table 4.78 prove to be far stronger than the OLS model as is 
demonstrated by comparing the table above to the one immediately before it.  There are no 
obvious important contradictions between the two tables, other than those noted in the more 
detailed analysis.   
 The models run only on decedents of specific diseases shown in Table 4.79 are 
uniformly weak.  In many cases the predictive power of prior spending is directly contrary 
to the model preceding it.  Positive expenditures leading up to the terminal period in many 
cases are associated with lower terminal period expenditures. It is likely the case this is 
evidence of accumulated frailty and the resulting withholding of invasive medical 
procedures.   
 In sum, the preceding three tables may well serve as an index for the findings that 
make up the bulk of this chapter. Given the coarseness of analysis undertaken, there are but 
a handful of compelling results and the summary tables make them more accessible.   
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Directed Analysis: Age at Death 
 The following tables, starting with aggregate results in Figure 4.1 and Table 4.80, 
analyze the history of the impact of age on the cost of dying within the sample.  The intent 
is to demonstrate the observed fact that the age expenditure profile for Medicare recipients 
has become steeper over time.  This means that the older a person is the less likely they are 
to receive expensive and/or invasive medical procedures in a given state of health and that 
that differential has been increasing.  The graph immediately below illustrates that while 
inflation-adjusted (or possibly inflation-over adjusted) terms the cost of dying has been 
relatively stable across the time period over which data is available.  It also demonstrates 
that individuals who pass away at an age one standard deviation above the mean have a 
distinctly different expenditure profile. Beginning in 1995, according to the data, those 
individuals who die at an advanced age spend less than mean aged individuals and the 
differential increases throughout the period.  By 2001, beneficiaries passing away at an age 
of 88 spend fully 40% less than those in their death cohort who are aged at the mean of 77.  
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Aggregate: Cost of Dying at Mean Age and at 
Mean Age + 1 S.D.
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FIGURE 4.1. AGGREGATE: COST OF DYING AT MEAN AGE AND AT  
MEAN AGE + 1 S.D. 
 
 
 
 
TABLE 4.79-AGGREGATE RESULTS: COST OF DYING AT MEAN AGE AND AT 
 MEAN AGE + 1 S.D. 
Aggreg.     
 Coeff 
Std 
Err Cons Mean 
1994 -99.53 10.88 13649 4620.56
1995 -80.62 8.97 11684 4510.18
1996 -105.73 8.71 13634 4695.14
1997 -116.84 8.67 14486 4861.81
1998 -114.19 9.06 14083 4917.04
1999 -108.43 7.88 13062 4627.97
2000 -108.25 8.14 12877 4694.59
2001 -132.48 7.53 14453 4740.39
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 The following graphs and charts replicate what is done above but now taking 
advantage of the level of detail available in the data.  The patterns of terminal expenditure 
impacts from age at death differ across diseases to a considerable degree. From the 
abstraction of looking simply at expenditure profiles, the reasons behind significant 
differences across diseases have to remain ambiguous. It could likely be that changes in the 
standards of treatment or the adoption of alternative means of treatment at any point could 
cause a significant shift in disease-specific expenditures. It could also well be the case that 
those changes would differentially affect people at advanced ages.   
 The graphs below, Figures 4.2 -4.11 with corresponding Tables 4.81-4.91, consist of 
measures of mean terminal period expenditures for individuals dying of specific diseases as 
well as an estimate of expenditures for the same individuals if they were one standard 
deviation older than the typical decedent. In effect, this demonstrates the total effect of age 
at death at a level that is relevant to diseases individually.  The mean ages and the standard 
deviation of the age are calculated with a pooled sample across all the years in the window 
of observation. Thus, the impact of the progression of medical science and any improved 
success of extending the lives of patients with these conditions is minimized though not 
likely entirely cleaned from the estimation. 
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Heart Disease: Cost of Dying at Mean Age and at 
Mean Age + 1 S.D.
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FIGURE 4.2. HEART DISEASE: COST OF DYING AT MEAN AGE AND AT MEAN 
 AGE + 1 S.D. 
 
 
 
 
 
TABLE 4.80-HEART DISEASE: COST OF DYING AT MEAN AGE AND AT  MEAN 
AGE + 1 S.D. 
Heart      
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -102.37 35.58 14826 6317.08 781
1996 -177.18 32.04 20365 5884.38 836
1997 -154.92 28.08 17912 5451.91 951
1998 -135.65 33.65 16466 5982.86 992
1999 -156.44 31.28 17693 5810 1020
2000 -146.14 31.08 16695 5793 1087
2001 -139.49 26.99 15705 5580 1198
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Heart Failure: Cost of Dying at Mean Age and at 
Mean Age + 1 S.D.
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FIGURE 4.3. HEART FAILURE: COST OF DYING AT MEAN AGE AND AT MEAN 
 AGE  + 1 S.D. 
 
 
 
 
 
TABLE 4.81-HEART FAILURE: COST OF DYING AT MEAN AGE AND AT  MEAN 
AGE + 1 S.D. 
 
428      
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -125.54 29.24 15716 4224 651
1996 -142.98 22.96 16822 4592 733
1997 -125.88 27.35 15903 4914 784
1998 -186.49 32.04 20052 4771 844
1999 -144.95 21.36 16013 4445 901
2000 -158.53 20.98 16896 4619 935
2001 -156.91 20.5 16388 4589 991
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Cancer: Cost of Dying at Mean Age and at Mean 
Age + 1 S.D.
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FIGURE 4.4. CANCER: COST OF DYING AT MEAN AGE AND AT MEAN  
AGE + 1 S.D. 
 
 
 
 
 
TABLE 4.82-CANCER: COST OF DYING AT MEAN AGE AND AT MEAN  
AGE + 1 S.D. 
Cancer      
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -74.34 24.88 10580 4608 1007
1996 -53.72 18.44 8808.47 4591 1083
1997 -52.84 23.57 8778.77 4754 1065
1998 -71.21 19.07 9866 4510 1007
1999 -78.15 21.14 9816.55 4102 1008
2000 -40.87 18.37 6937 4015 1081
2001 -82.97 25.51 10379 4621 1074
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Cerebrovascular Disease: Cost of Dying at Mean 
Age and at Mean Age + 1 S.D.
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FIGURE 4.5. CEREBROVASCULAR DISEASE: COST OF DYING AT MEAN AGE 
 AND AT MEAN AGE + 1 S.D. 
 
 
 
 
 
 
TABLE 4.83-CEREBROVASCULAR DISEASE: COST OF DYING AT MEAN AGE 
 AND AT MEAN AGE + 1 S.D. 
      
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -120.34 40.78 14965 3737 426
1996 -148.93 35.12 16542 3585 406
1997 -140.22 34.4 15834 3812 495
1998 -153.99 33.41 16642 3819 515
1999 -67.73 20.82 8727 3148 544
2000 -85.02 24.89 10040 3389 624
2001 -123.75 24.98 13146 3747 617
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FIGURE 4.6. COPD: COST OF DYING AT MEAN AGE AND AT MEAN AGE + 1 S.D. 
 
 
 
 
 
 
TABLE 4.84- COPD: COST OF DYING AT MEAN AGE AND AT MEAN  
AGE + 1 S.D. 
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -102.37 40.35 12889 4604 502
1996 -110.63 42.55 14251 5527 544
1997 -1.37 28.97 4882 4826 521
1998 -171.84 40.54 18286 5458 579
1999 -111.2 41.18 13284 5126 632
2000 -133.68 42.86 15039 5510 704
2001 -132.21 29.98 14007 4916 689
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Pneumonia: Cost of Dying at Mean Age and at 
Mean Age + 1 S.D.
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FIGURE 4.7. PNEUMONIA: COST OF DYING AT MEAN AGE AND AT MEAN  
AGE + 1 S.D. 
 
 
 
 
 
 
 
TABLE 4.85-PNEUMONIA: COST OF DYING AT MEAN AGE AND AT 
MEAN AGE + 1 S.D. 
 
Pneu      
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -97.7 22.12 13906 5569 752
1996 -95.47 26.48 13485 5465 765
1997 -154.5 27.39 18848 6177 769
1998 -99.35 28.45 13944 6009 833
1999 -84.33 23.43 12095 5629 875
2000 -113.17 24.02 14196 5676 908
2001 -123.88 21.24 14714 5607 870
 
  
 
191
 
Diabetes Mellitus: Cost of Dying at Mean Age and 
at Mean Age + 1 S.D.
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FIGURE 4.8. DIABETES MELLITUS: COST OF DYING AT MEAN AGE AND AT 
 MEAN AGE  + 1 S.D. 
 
 
 
 
 
TABLE 4.86-DIABETES MELLITUS: COST OF DYING AT MEAN AGE AND AT 
 MEAN AGE + 1 S.D. 
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -37.81 42.29 7684 4072 209
1996 -97.05 36.58 12496 3990 240
1997 -163.64 40.01 18533 5240 321
1998 -113.67 39.08 14005 4808 341
1999 -112.02 25.72 12257 3722 319
2000 -136.36 49.48 15332 5191 382
2001 -91.69 28.01 10753 3953 379
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Alzheimer's Disease: Cost of Dying at Mean Age 
and at Mean Age + 1 S.D.
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FIGURE 4.9.ALZHEIMER’S DISEASE: COST OF DYING AT MEAN AGE AND AT 
 MEAN AGE  + 1 S.D. 
 
 
 
 
 
 
 
TABLE 4.87-ALZHEIMER’S DISEASE: COST OF DYING AT MEAN AGE AND AT 
 MEAN AGE + 1 S.D. 
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -117.31 23.71 11845 1844 114
1996 -76.01 27.18 8452 2026 134
1997 -93.37 40.76 10248 2409 181
1998 -28.4 35.72 4268 2006 143
1999 -63.8 27.9 7215 2108 180
2000 -87.11 23.19 8878 2149 188
2001 -54.37 34.54 6287 2200 219
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Kidney Failure: Cost of Dying at Mean Age and at 
Mean Age + 1 S.D.
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FIGURE 4.10. KIDNEY FAILURE: COST OF DYING AT MEAN AGE AND AT 
 MEAN AGE + 1 S.D. 
 
 
 
 
 
TABLE 4.88-KIDNEY FAILURE: COST OF DYING AT MEAN AGE AND AT 
 MEAN AGE + 1 S.D. 
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -58.17 53.18 11895 7602 184
1996 -88.46 54.06 14780 8352 188
1997 -183.58 49.05 21041 7968 217
1998 29.2 54.19 6691 8780 259
1999 -30.76 33.57 9616 7563 308
2000 -104.17 32.82 14018 7234 317
2001 -159.68 41.02 18201 7856 331
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Hip Fracture: Cost of Dying at Mean Age and at 
Mean Age + 1 S.D.
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FIGURE 4.11. HIP FRACTURE: COST OF DYING AT MEAN AGE AND AT MEAN 
 AGE + 1 S.D. 
 
 
 
 
 
 
 
TABLE 4.89- HIP FRACTURE: COST OF DYING AT MEAN AGE AND AT MEAN 
AGE + 1 S.D. 
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -48.82 44.71 9176 4287 240
1996 -55.08 73.98 10309 4947 256
1997 -143.59 35.94 16464 3930 293
1998 -125.03 43.86 14798 4193 303
1999 -119.69 37.81 14443 4542 339
2000 -93.07 47.43 12123 4463 332
2001 -97.34 39.38 11953 4290 342
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Other: Cost of Dying at Mean Age and at Mean 
Age + 1 S.D.
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FIGURE 4.12. OTHER: COST OF DYING AT MEAN AGE AND AT MEAN  
AGE + 1 S.D. 
 
 
 
 
 
TABLE 4.90-OTHER: COST OF DYING AT MEAN AGE AND AT MEAN  
AGE + 1 S.D. 
 Age_Death 
Stand 
Err. Cons Mean Obs 
1995 -16.46 21.84 4759 3139 1032
1996 -37.18 18.34 6523 3244 1002
1997 -98.99 23.39 11956 3754 938
1998 -61.26 21.01 8681 3512 1051
1999 -70.22 20.53 9463 3863 1016
2000 -66.7 19.72 8798 3646 1108
2001 -113.27 18.86 12158 3730 1175
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 Age at death is a strong determinant of total terminal period expenditure though its 
influence is consistent neither across diseases nor across time.  As suggested above, the 
change in the impact of age at death in a specific disease could come from any number of 
causes, so it is beyond the scope of this work to explain the path in any particular disease. 
That said it is evident that in general the influence of age at death has become more strongly 
negative and is among the most significant determinants of terminal period expenditure.  
This is among the most striking findings of this work.  
 
Conclusion 
 Taken together, the relationships revealed between expenditures in the terminal 
period and the demographic variables and in disease expenditures prove to be quite 
consistent across diseases. While this is evidence of an empirical irregularity that may well 
be exploited to gain further insight into these diseases, it makes the recitation of the fact in 
each disease rather tedious. In a few cases, the models performed well in explaining the 
variation in terminal period expenditures.  In most cases however the models proved too 
weak.  This should not be a surprise.  The natural variation in death experiences and the 
expenditures they generate make a tighter model a goal that is likely unreachable. The 
models serve as a “first cut” of the data and the problem and open the door for future work. 
The hopes and goal of that future work will be outlined in the next chapter.  
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CHAPTER V 
 
CONCLUSIONS, DISCUSSIONS, AND PLANS FOR FUTURE WORK 
 
 The progression of expenditures in terminal disease reimbursed by the Medicare 
program is highly dependent on the characteristics of the individual beneficiary. The work in 
the preceding chapters has attempted to illuminate commonalities between groups of people 
and diseases that drive expenditures for which the Medicare program is by design liable. The 
method adopted was designed to refine the understanding of expenditure paths, to make use 
of new data, to expose existing relationships and to provide a structure to motivate future 
research.   
 The detail provided by the data used allows the models to identify the sources of 
many of the empirical irregularities previously established in the literature which have 
predominantly used more coarse aggregated data. While not terribly useful for the pressing 
funding problems that the Medicare programs faces, the approach is ideally geared to 
identify those disease particularly impacted by the structure of the Medicare program’s 
reimbursement policies. The diseases are all treated by the same modeling procedure. The 
results themselves present interesting commonalities sand differences among diseases and 
among demographic groups.  They do not serve to answer many questions of import, but 
further the literature by passing the diseases and groups of beneficiaries through a finer sieve 
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than has been done before. The method allows for a clear distinction between those diseases 
who pass through it easily and those who are different enough to generate mixed signals 
under the adopted procedure. To a large degree, it is the disorders which fail to “fall open” 
for the models in the previous chapters which draw attention for further research.  
 The contribution made by this work is in some sense, through presenting the 
challenges and difficulties and monotony, made possible by a much finer level of detail now 
available to researchers. The method adopted made use of quarterly level observations. The 
data in its raw form actually exists in daily observations. It is an open question whether a 
finer level of detail can offer any additional level of insight without clouding the issue by 
necessitating extravagant econometric techniques. It is certainly the case that the models 
presented have not pushed the envelope in econometric detail. One reason for this, and a 
primary contribution of this work, is the fact that the adopted procedure serves to “test the 
waters” both of disease specific expenditure profiles and of quarterly data on medical 
expenditures.   
 The net result of the findings presented is that there are vast differences in the way in 
which people die in the modern era and the expenses they incur in doing so. The procedure 
adopted, while crude and arbitrary, has served to illuminate many potential avenues of future 
research. The Medicare program has in the past adopted special programs focused on 
specific disease categories to augment and streamline financing solutions for individuals 
suffering from them. A prime example is the End-Stage Renal Disease Program. The results 
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of the present work serve to bring to light specific diseases whose sufferers may well benefit 
from a tailored Medicare funding program. None of the results are conclusive enough to be 
the basis of such a policy, but the work serves as a reference to motivate the research that 
would.   
 The promise embodied in the previous chapters comes from the refinement in 
modeling technique and the focus on important areas made possible by this first pass 
through the problem and through the data. It now remains to follow the research herein 
presented with targeted investigations of specific diseases and the expenditure relationships 
that will impact the efficacy of any changes in Medicare funding to do better by the 
Medicare program and its beneficiaries.  
 While the research accomplished is less than penetrating and largely descriptive in 
nature, it represents a necessary and distinct step in a useful understanding of the matter at 
hand. A deeper and more expansive investigation of all the diseases considered would 
certainly have been possible though would likely have strained attention and focus even 
more so than the present work has done. A finer and more targeted approach to a smaller set 
of diseases may well have been more entertaining and directly useful, but without the 
contribution made by this general and comprehensive treatment the selection of those 
diseases would be arbitrary and fail to give confidence that the important issues had been 
addressed.  
 The next step in the research made possible by the present work will be to identify 
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classes of diseases and tailor modeling techniques useful and appropriate to each class. For 
example, it may well be important to distinguish between chronic and acute conditions and 
model their expenditure profiles with different tools. Another intriguing avenue of research 
would be to begin by stacking individuals, not on death, but on the first instance of 
expenditure for the disease that ultimately causes that persons death. That avenue would 
allow consideration of the efficacy of treatments in extending a persons life and evaluate the 
impact on expenditure paths from any specific intervention, as well as evaluate the 
importance of the timing of that intervention. These and countless other potential 
investigations are brought to mind and made possible through this initial work and the 
investment in data organization required for it.   
 It is hoped that the efforts presented herein have served to further the literature and 
refine the understanding of disease expenditures under the Medicare program. The intended 
contribution is imagined to be important though almost by necessity rather modest. A goal 
and intention of the work has been to present the complex and intricate world of Medicare, 
Medicare beneficiaries, their health and the diseases which threaten it in a way that serves to 
organize and promote further research into the important problems faced by the program. As 
morbid, various, and analytically challenging as the death experience on Medicare is, it is an 
area of prime importance for the individuals affected and for the Medicare program in total. 
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